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Presentation
Healthcare practice is becoming more and more complicated due to many different factors. One 
of the most relevant factors is the increase of scientifi c information available to us.
For the clinical decisions to be adequate, effi cient and safe, professionals need to perma-
nently update their knowledge, to which end a great deal of effort has been invested.
In 2003, the Interterritorial Council of the Spanish National Health Service (SNS) created 
the GuiaSalud Project whose ultimate aim is to improve clinical decision-making based on scien-
tifi c evidence, via training activities and the confi guration of a registry of clinical practice guide-
lines (CPG).Since then, the GuiaSalud project has assessed dozens of CPGs in agreement with 
explicit criteria generated by its scientifi c committee, it has registered them and has disseminated 
them over the Internet.
At the beginning of 2006, the Directorate General of the Quality Agency of the SNS pre-
pared the Quality Plan for the National Health System, which was divided into 12 strategies.The 
purpose of this Plan is to increase the cohesion of the SNS and help guarantee maximum qual-
ity healthcare for all citizens regardless of their place of residence. As part of the Plan, different 
agencies and expert groups in prevalent pathologies related to the health strategies were asked to 
prepare eight CPG.Furthermore, the defi nition of a common CPG preparation methodology was 
requested for the SNS, which has been prepared among the expert groups in CPGs in our country, 
combining their efforts and coordination.This methodology has been the basis to prepare this 
CPG on ADHD.
In 2007, the GuiaSalud Project was renewed, creating the Clinical Practice Guideline Library.
This project goes deeper into the preparation of CPGs and includes other evidence-based medi-
cine products and services.Furthermore, its aim is to favour the implementation and assessment 
of the use of CPGs in the National Health System.Later, another fourteen guidelines have been 
addressed, with the collaboration of the same institutions and participation of the scientifi c socie-
ties involved.This Clinical Practice Guideline on attention defi cit hyperactivity disorder (ADHD) 
in Children and Adolescentsis the fruit of this request.
ADHD is a disorder that has a neurobiological origin, starting in childhood and whose symp-
toms can last until adult age.It is one of the psychiatric disorders with greatest prevalence and 
the one that records the largest number of consultations due to the enormous consequences in the 
different aspects of the patient’s life.Over the last few years, it has been one of the most highly-
researched disorders, due to the potential repercussions that it has on the personal and family 
development of the person affected.
The aim of this CPG is to give citizens, health and education professionals, a useful instru-
ment that will provide answers to the basic questions about the disorder, especially those related 
to the diagnostic assessment and the different types of treatment of ADHD in children and ado-
lescents.
This guideline is the result of a group of professionals associated with ADHD and experts 
in the methodology of CPGs and its aim is to detect and become aware of the disorder, assessing 
it correctly as well as proposing therapeutic objectives and strategies for the family and teachers.
This CPG has been reviewed by Spanish experts in ADHD and has the backing of associa-
tions of patients and Spanish scientifi c societies involved in its care.
We trust that this work will undoubtedly result in higher quality care of children and adoles-
cents with ADHD and the carers.
PABLO RIVERO CORTE
D. G. of the Quality Agency of the SNS
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Questions to be answered
ADHD
1. How is ADHD defi ned? What clinical manifestations does the disorder have?
2. Etiopathogeny of ADHD. What are the main risk factors?
3. In ADHD: Are there neuropsychological dysfunctions?
4. What is the natural course of ADHD?
5. In ADHD: What is the long-term prognosis? What factors have an infl uence on a good or 
bad prognosis? To what extent does early diagnosis and intervention improve the prognosis 
of ADHD?
6. In ADHD: What are the most frequent comorbid disorders?
DIAGNOSIS
7. What are the diagnostic criteria for ADHD in children and adolescents?
8. How is ADHD diagnosed in children and adolescents? Who must diagnose it?
9. Which evaluation areas must be included in the diagnosis of ADHD?
10. In the diagnosis of ADHD in children and adolescents? Is the neuropsychological assess-
ment necessary?
11. In the diagnosis of ADHD in children and adolescents? Is the psychopedagogical assess-
ment necessary?
12. In the diagnosis of ADHD in children and adolescents? Are supplementary examinations 
necessary?
13. In the diagnosis of ADHD in children and adolescents? Which entities would the differen-
tial diagnosis have to be carried out with?
ASSESSMENT INSTRUMENTS
14. Which screening instruments and specifi c scales of ADHD in children and adolescents are use-
ful/recommendable for the diagnosis? Which have been validated in the Spanish population?
15. In ADHD in children and adolescents? Which general or broad spectrum pyschopathology 
scales are useful/recommendable? Which have been validated in the Spanish population?
16. In ADHD in children and adolescents? Which interviews are useful/recommendable for the 
diagnosis? Which have been validated in the Spanish population?
17. In ADHD in children and adolescents? Which neuropsychological and intelligence tests are 
useful/recommendable? Which have been validated in the Spanish population?
18. In ADHD in children and adolescents? Which psychopedagogical assessment tools are use-
ful/recommendable? Which have been validated in the Spanish population?
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TREATMENT
Psychological treatment
19. Psychological treatment: What does it consist of? What must it include?
20. Which psychological treatment is effectiveto treat ADHD in children and adolescents?
21. Psychological treatment of children and adolescents: Has it proved to be effi cient/effective 
in the short and long term?
22. How effective is psychological treatment of ADHD in children and adolescents?
23. In ADHD in children and adolescents? What clinical variables and standardised instru-
ments exist to evaluate the effi cacy of psychological treatment?At what moment of the 
treatment should its effi cacy be evaluated?
Psychopedagogical Treatment
24. Psychopedagogical intervention: What does it consist of? What must it include?
25. Which psychopedagogical interventions are effi cient/effective to treat ADHD?
26. Psychopedagogical re-education: What does it consist of? What must it include?
27. In ADHD in children and adolescents? What adaptations are useful/recommendable in the 
school context?
28. Is the training given to teachers effi cient/effective? What must it include?
29. In ADHD in children and adolescents? What clinical variables and standardised instru-
ments exist to evaluate the effi cacy of psychopedagogical treatment? At what moment of 
the psychopedagogical treatment should its effi cacy be evaluated?
Pharmacological Treatment
30. What drugs are available for ADHD in Spain?
31. In ADHD: What pharmacological treatments are effi cient/effective? How safe are the phar-
macological treatments?
32. In ADHD: How effective are pharmacological treatments in the short and long term?
33. In ADHD: When and with what criteria must pharmacological treatment be started?
34. In ADHD: What criteria are used to choose the drug? What are the start, suppression and 
maximum dose guidelines?Which are the fi rst and second choice drugs?
35. What are the most frequent (short term) side effects? How must the side effects be ad-
dressed?
36. In ADHD: How long should the pharmacological treatment last?
37. In ADHD: Are supplementary examinations required before starting the pharmacological 
treatment in children and adolescents?
38. What is the pharmacological strategy when there is a partial response, side effects or 
contraindication?How are the different methylphenidate presentations combined? How to 
make the transition from stimulants to atomoxetine?
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39. In which ADHD subtypes is pharmacological treatment more effi cient?
40. Are there differences in response depending on the gender or age?
41. Which physical parameters must be controlled before starting the pharmacological treat-
ment and during it?
42. What scientifi c evidence exists about the long-term effects in pharmacological treatment? 
Is it associated with growth retardation?
43. Pharmacological treatment of ADHD: Does it cause addiction? Does it increase the risk of 
consumption of substances?
44. Does the effi cacy of pharmacological treatment decrease with time?
45. Do the effects remain after the pharmacological treatment has been withdrawn?
46. Is it recommendable to leave stimulant-free periods during the pharmacological treatment 
(“therapeutic holidays”)?
47. What clinical variables and standardised instruments exist to evaluate the effi cacy of phar-
macological treatment?At what moment of the treatment should its effi cacy be evaluated?
Combined Treatment
48. Combined treatment: What does it consist of? What must it include?
49. In ADHD in children and adolescents? Which intervention or combination of interventions 
has proved to be more effi cient in the short and long term?
Comorbidity Treatment
50. In children and adolescents with ADHD: What must be done with comorbid epilepsy?
51. In children and adolescents with ADHD: What must be done with comorbid autism spec-
trum disorders?
52. In children and adolescents with ADHD: What must be done with comorbid mood disorders?
53. In children and adolescents with ADHD: What must be done with comorbid bipolar disorder?
54. In children and adolescents with ADHD: What must be done with comorbid substance 
abuse disorder?
Complementary and alternative medicine
55. Complementary and alternative medicine: What does it consist of?
56. To treat ADHD in children and adolescents:Are complementary and alternative therapies 
effi cient?
ETHICAL AND LEGAL ASPECTS
57. Which ethical principles must be taken into account in relationship with minors or adoles-
cents with ADHD?
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58. What precautions must be taken, from the ethical viewpoint, in the fi eld of ADHD diagnosis?
59. What are the correct ethical standards for the start of therapeutic intervention in ADHD?
60. How involved must the minor be in the decision-making in the context of the diagnosis and 
treatment of ADHD?
61. What are the minor’s rights in the fi eld of information and confi dentiality related to the 
diagnosis and treatment of ADHD?
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Recommendations of the CPG
The CPGs are a series of systematically developed recommendations to help professionals and 
patients take decisions about the most appropriate healthcare and select the most adequate diag-
nostic or therapeutic options to address a specifi c clinical condition or health problem.
This Clinical Practice Guideline on Attention Defi cit Hyperactivity Disorder (ADHD) in 
Children and Adolescents is a healthcare decision aid in the fi eld of the Spanish SNS.It is not 
mandatory and it is not a substitute for the clinical judgement of healthcare personnel.
The CPG has detection, diagnosis and treatment algorithms, which must be followed when 
the successive clinical situations that arise are recognised.
When making out the prescriptions, the costs must also be taken into account by the clinician 
given their impact on the sustainability of the system.
The recommendations are presented in this section, following the structure of the guideline. 
Chapters 1, 2 and 3 of the CPG include the Introduction, Scope and Objective, and Methodology, 
respectively. Chapter 4 deals with ADHD. All these chapters are descriptive and, consequently, no 
recommendations for clinical practice have been formulated. Chapter 5, Diagnosis, is the fi rst to 
contain recommendations. The clinical questions that do not present recommendations have been 
omitted from this section.
The letters corresponding to the degrees of recommendations and quality of the scientifi c 
evidence are listed below:
Degree of recommendation: A, B, C or D, depending on whether the quality of the scientifi c 
evidence is very good, good, moderate or low (Appendix 1).
 Good clinical practice: Recommendation by consensus of the development group.
5. Diagnosis
5.1. What are the diagnostic criteria for ADHD in children and adolescents?
D 5.1.1.
To diagnose ADHD in children and adolescents the use of the 
diagnostic criteria of DSM-IV-TR or ICD-10 is recommended.
5.2. How is ADHD diagnosed in children and adolescents? Who must diagnose it?
Recommendations
D 5.2.1.
The diagnosis of ADHD in children and adolescents is exclusively 
clinical.
D 5.2.2.
The diagnosis of ADHD in children and adolescents must be carried 
out by a health professional with training and experience in the 
diagnosis of ADHD and its most frequent comorbidities.
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5.3. Which evaluation areas must be included in the diagnosis of ADHD?
Recommendations
D 5.3.1.
The diagnosis of ADHD in children and adolescents must be done via 
clinical interviews with parents and the patient, obtaining information 
from the school, reviewing family and personal background as well 
as the physical and psychopathological examination of the patient.




The neuropsychological assessment is not essential for the diagnosis 
of ADHD in children and adolescents.
 5.4.2.
The neuropsychological examination of ADHD in children and 
adolescents is useful to get to know the profi le of skills and 
diffi culties in cognitive functioning and comorbidity with specifi c 
learning disorders.
C 5.4.3.
To diagnose ADHD it is not necessary for there to be an alteration 
in the results of the neuropsychological tests that assess executive 
functions.




The psychopedagogical assessment is useful to evaluate the learning 
style and diffi culties and to establish the re-education intervention 
objectives.




To diagnose ADHD in children and adolescents supplementary 
laboratory, neuroimage or neurophysiological tests are not indicated 
unless the clinical evaluation justifi es this.
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6. Assessment instruments
6.1. Which screening instruments and specifi c scales of ADHD in children and 
adolescents are useful/recommendable for the diagnosis?Which have been 
validated in the Spanish population?
Recommendations
C 6.1.1.
The specifi c scales for ADHD in children and adolescents can be 
used in a complementary manner but never as substitutes for the 
clinical interview, to detect the presence and assess the intensity of 
the nuclear symptoms.
 6.1.2.
The information provided by parents and teachers, via the assessment 
scales, is useful to diagnose ADHD in children and adolescents and 
to assess the evolution of the symptoms and the response to the 
treatment.
6.2. In ADHD in children and adolescents:Which general or broad spectrum 
psychopathology scales are useful/recommendable?Which have been validated 
in the Spanish population?
Recommendations
 6.2.1. The general psychopathology questionnaires can be used to screen 
comorbidity.
6.3. In ADHD in children and adolescents:Which interviews are useful/
recommendable for the diagnosis? Which have been validated in the Spanish 
population?
Recommendations
 6.3.1. Structured and semi-structured interviews are useful to establish the 
diagnosis of ADHD and its comorbidities in children and adolescents.
7. Treatment
7.1. Psychological treatmen
7.1.2. Which psychological treatment is effective to treat ADHD in children and adolescents?
Recommendations
B 7.1.2.1.
The application of a behavioural training programme is recommended 
for parents of children and adolescents diagnosed with ADHD, with 
or without comorbidity.
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D 7.1.2.2.
Cognitive behavioural therapy is recommended as an initial treatment 
for ADHD in children and adolescents in any of the following 
situations:
 • The ADHD symptoms are mild
 • The impact of ADHD is minimal
 • There is considerable discrepancy about the frequency and in-
tensity of symptoms between parents, or between these and the 
teachers
 • The diagnosis of ADHD is uncertain
 • Parents reject the use of medication
 • Children under 5 (although this age group is outside the scope of 
this guide).
7.1.5. In ADHD in children and adolescents:What clinical variables and standardised instruments 
exist to evaluate the effi cacy of psychological treatment? At what moment of the treatment 
should its effi cacy be evaluated?
Recommendations
 7.1.5.1.
The effi cacy, possible adverse effects and therapeutic compliance 
must be assessed in the psychological treatment programmes 
of children and adolescents with ADHD. The assessment of the 
treatment will be carried out 3 months after the start, at the end (in 
case of having a defi ned time limit), or when the clinician deems this 
appropriate.
7.2. Psychopedagogical Treatment
7.2.2. Which psychopedagogical interventions are effi cient/effective to treat ADHD?
Recommendations
B 7.2.2.1.
Children and adolescents with ADHD require a personalised 
intervention programme at school that will include academic, social 
and behavioural aspects (adapted from SIGN 4.1.2)1.
 7.2.2.2. The school programmes for ADHD must involve the majority of the 
teaching staff to facilitate its effi cacy.
 7.2.2.3.
School programmes for ADHD may include: Adaptations in the 
classroom, training for teachers, behaviour modifi cation techniques 
and other strategies to manage ADHD in the classroom (application 
of rules and limits, presentation of tasks, student assessment systems 
for students with ADHD, etc.).
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7.2.3. Pyschopedagogical re-education: What does it consist of? What must it include?
Recommendations
 7.2.3.1.
Personalised and specifi c treatment of teaching in academic 
competences and skills is recommended for children and adolescents 
with ADHD and repercussion on academic performance.




When ADHD has a signifi cant impact on the child’s or adolescent’s 
academic competence, the schools should make adaptations to help 
them in the classroom.
7.2.5. Is the training given to teachers effi cient/effective? What must it include?
Recommendations
 7.2.5.1.
It is recommendable for teachers to receive training that enables 
them to detect ADHD alert signals and to manage ADHD in children 
and adolescents at school.
7.2.6. In ADHD in children and adolescents:What clinical variables and standardised instruments 
exist to evaluate the effi cacy of psychopedagogical treatment? At what moment of the psy-
chopedagogical treatment should its effi cacy be evaluated?
Recommendations
 7.2.6.1.
The effi cacy and possible adverse effects of the psychopedagogical 
intervention that is being carried out must be assessed in the 
psychopedagogical treatment programmes of children and 
adolescents with ADHD at least once every school year whilst the 
treatment lasts.
7.3. Pharmacological Treatment




Methylphenidate and atomoxetine are the recommended drugs today 
to treat ADHD in children and adolescents based on their effi cacy 
and safety at recommended doses (adapted from NICE 10.18.5.1)2.
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7.3.3. In ADHD: How effective are pharmacological treatments in the short and long term?
Recommendations
A 7.3.3.1. Long-term treatment with methylphenidate and atomoxetine can be 
recommended as its effectiveness is not reduced.
7.3.4. In ADHD: When and with what criteria must pharmacological treatment be started?
Recommendations
D 7.3.4.1.
Pharmacological and/or behavioural treatment must be considered as 
fi rst choice for ADHD in children and adolescents bearing in mind the 
age of the patient, the seriousness of the symptoms, their functional 
repercussion and the family’s characteristics and preferences.
D 7.3.4.2.
Pharmacological treatment must be started by a properly qualifi ed 
physician who is an expert in treating ADHD and its most frequent 
comorbidities.
7.3.5. In ADHD: What criteria are used to choose the drug? What are the start, suppression and 
maximum dose guidelines?Which are the fi rst and second choice drugs?
Recommendations
D 7.3.5.1.
The decision about which drug to choose must be based on (adapted 
from NICE 10.18.5.2)2:
 • The presence of comorbid conditions (for example, tic disorders, 
Tourette’s syndrome, epilepsy and anxiety).
 • The different adverse effects of the drugs
 • Previous experiences of lack of effi cacy
 • Issues regarding compliance, for example, problems created by 
the need to administer a treatment dose at school
 • Potential misuse
 • The preferences of the child/adolescentand his or her family
7.3.6. What are the most frequent (short term) side effects? How must the side effects be ad-
dressed?
Recommendations
D 7.3.6.1. Periodic follow-ups and monitoring of the possible adverse effects 
of methylphenidate and atomoxetine are recommended.
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7.3.7. In ADHD: How long should the pharmacological treatment last?
Recommendations
 7.3.7.1.
The duration of the treatment must be established on a personal basis 
depending on the symptoms and functional repercussion.In some 
cases the treatment can last for several years.
 7.3.7.2.
It is advisable to periodically evaluate the persistence or remission of 
the symptoms.An accepted practice is to suspend the pharmacological 
treatment for short periods of 1 or 2 weeks a year, obtaining 
information about the functioning of the child or adolescent by the 
family and from the school.
7.3.8. In ADHD: Are supplementary examinations required before starting the pharmacological 
treatment in children and adolescents?
Recommendations
D 7.3.8.1.
The systematic execution of supplementary examinations is not 
recommended, unless indicated by the physical exploration or 
anamnesis.
7.3.9. What is the pharmacological strategy when there is a partial response, side effects or con-
traindication? How are the different methylphenidate presentations combined? How to 
make the transition from stimulants to atomoxetine?
Recommendations
 7.3.9.1.
If there is a partial response to the drug, increase the dose until 
the maximum indicated or tolerated. If there is no response with 
maximum doses, consider the alternative drug that has not been used 
with this child or adolescent (another methylphenidate presentation 
or atomoxetine).
 7.3.9.2. If side effects appear, address them adequately. If they persist or are 
not tolerated, evaluate a change in medication.
 7.3.9.3. In the case of contraindication, evaluate the use of the alternative 
drug.
 7.3.9.4.
If extended release methylphenidate is used with osmotic technology 
and an adequate adjustment of the dose is not achieved, a dose of 
immediate release methylphenidate can be added to the treatment 
at breakfast and/or mid-afternoon, to thus adjust the total dose of 
methylphenidate in agreement with the weight of the child or 
adolescent with ADHD and with the clinical response.If a 12-hour 
therapeutic action is required and the child or adolescent with ADHD 
is not able to swallow tablets, extended release methylphenidate can 
be administered with pellet technology in the morning (opening 
the capsule) and in the afternoon, after school, a dose of immediate 
release methylphenidate can be administered.This latter pattern can 
also be followed if there is a rebound effect in the afternoon with 
extended release methylphenidate with pellet technology.
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7.3.10. In which ADHD subtypes is pharmacological treatment more effi cient?
Recommendations
C 7.3.10.1.
Methylphenidate and atomoxetine are recommended as 
pharmacological treatments of choice for ADHD in children and 
adolescents regardless of the ADHD subtype.
7.3.11. Are there differences in response depending on the gender or age?
Recommendations
B 7.3.11.1.
Methylphenidate and atomoxetine are recommended as 
pharmacological treatments of choice for ADHD in children and 
adolescents regardless of the age and gender.




A physical examination must be performed before starting the 
pharmacological treatment, which will include taking the blood 
pressure, measuring heart rate, height and weight.Personal and 
family history of cardiac diseases must be sought, as well as history 
of exercise syncope or other cardiovascular symptoms (adapted from 
NICE, 10.18.4.1)2.
D 7.3.12.2.
A preliminary cardiovascular study must be carried out at the start 
of the pharmacological treatment if there is a personal and/or family 
history of cardiac diseases, a history of serious cardiac problems, of 
sudden death in the family or abnormal fi ndings in the initial physical 
examination (adapted from NICE, 10.18.4.1.)2.
 7.3.12.3.
In children and adolescents with ADHDreceiving treatment with 
methylphenidate or atomoxetine:The height must be measured 
every 6 months, the weight must be controlled 3 and 6 months after 
starting the pharmacological treatment, and every 6 months during 
the administration of the treatment.
 7.3.12.4.
The height and weight in children and adolescents with ADHD 
receiving pharmacological treatment must be plotted on a growth 
chart and reviewed by the physician responsible for the treatment.
 7.3.12.5.
The heart rate and blood pressure must be monitored in children 
and adolescents with ADHD receiving pharmacological treatment, 
plotting them before and after every change in dose, and systematically 
every 3 months.
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7.3.13. What scientifi c evidence exists about the long-term effects in pharmacological treatment? 
Is it associated with growth retardation?
Recommendations
C 7.3.13.1.
Regular monitoring of the growth of children and adolescents with 
ADHD is recommended during the pharmacological treatment with 
methylphenidate and atomoxetine.
 7.3.13.2.
The assurance of an adequate nutritional intake is recommended in 
children and adolescents receiving pharmacological treatment for 
ADHD with secondary anorexia to the treatment.
7.3.14. Pharmacological treatment of ADHD: Does it cause addiction? Does it increase the risk 
of consumption of substances?
Recommendations
B 7.3.14.1.
The use of methylphenidate and atomoxetine is recommended to 
treat ADHD in children and adolescents, at the right doses, as it does 
not cause addiction or increase the risk of substance abuse.
7.3.15. Does the effi cacy of pharmacological treatment decrease with time?
Recommendations
B 7.3.15.1.
Pharmacological treatment with methylphenidate and atomoxetine 
for ADHD in children and adolescents should be continued in time 
whilst the clinical effectiveness is demonstrated.
7.3.17. Is it recommendable to leave stimulant-free periods during the pharmacological treatment 
(“therapeutic holidays”)?
Recommendations
 7.3.17.1. Pharmacological treatment rest periods (“therapeutic holidays”) are 
not systematically recommended during treatment of ADHD.
 7.3.17.2.
In some cases, periods without pharmacological treatment or with 
a lower dose can be included, when agreed between the family, the 
physician and child or adolescent, with the specifi c objective of:
 • Assessing the need to maintain the treatment or not.
 • Reduce adverse effects (lack of appetite, slowing-down in height 
growth, etc.).
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7.3.18. What clinical variables and standardised instruments exist to evaluate the effi cacy of phar-
macological treatment?At what moment of the treatment should its effi cacy be evaluated?
Recommendations
 7.3.18.1.
The assessment of the effi cacy and tolerability of the intervention 
will be carried out in the pharmacological treatment of children and 
adolescents with ADHD at least 1, 3 and 6 months after the start 
of the treatment, and then, every 6 months whilst it lasts, or else 
whenever adjustments are made in the dose or changes are made in 
the drug.
7.4. Combined Treatment
7.4.2. In ADHD in children and adolescents? Which intervention or combination of interventions 
has proved to be more effi cient in the short and long term?
Recommendations
B 7.4.2.1.
In children and adolescents with moderate or serious ADHD, 
combined treatment is recommended, which includes behavioural 
psychological treatment, pharmacological treatment and 
psychopedagogical intervention at school.
7.5. Comorbidity Treatment
7.5.1. In children and adolescents with ADHD: What must be done with comorbid epilepsy?
Recommendations
C 7.5.1.1. The use of methylphenidate is not contraindicated in children and 
adolescents with ADHD and comorbid epilepsy.




The use of methylphenidate and atomoxetine is not contraindicated in 
children and adolescents with ADHD and comorbid autism spectrum 
disorders. However, they must be used with caution.




In children and adolescents with ADHD and comorbid mood 
disorders, it is advisable to fi rstly treat the more intense disorder and 
that might have greater repercussion on the patient.
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B 7.5.3.2.
In children and adolescents with ADHD and associated anxiety, the 
use of atomoxetine is recommended as treatment of fi rst choice, as it 
has proved to be effi cient to treat both disorders.




In the cases of clear comorbidity of bipolar disorder and ADHD in 
children and adolescents, stimulant medication may be useful to treat 
ADHD once the mood symptoms have been adequately controlled 
with other drugs.




In the case of comorbidity of ADHD and substance use disorder in 
children and adolescents, treatment with non-stimulants or with long 
acting stimulants is indicated.
7.6. Complementary and alternative medicine




The elimination of artifi cial colouring agents and additives from the 
diet is not recommended as general treatment applicable in children 
and adolescents with ADHD.
D 7.6.2.2. A supplementary diet of fatty acids is not recommended as general 
treatment applicable in children and adolescents with ADHD.
 7.6.2.3.
Treatment with optometry, auditory stimulation, osteopathy and 
psychomotricity is not recommended to treat ADHD in children and 
adolescents.
B 7.6.2.4.
Treatment with homeopathy, herbal medicine and 
encephalogrambiofeedbackis not recommended to treat ADHD in 
children and adolescents.
 7.6.2.5.
Health professionals must place emphasis, as with any other child 
and adolescent, on the importance of a balanced diet and regular 
exercise for children and adolescents with ADHD.
 7.6.2.6.
Health professionals must ask the families about the use of 
complementary and alternative therapies to identify and informabout 
their possible risks or side effects to treat ADHD in children and 
adolescents.




It is advisable to pay special attention to the risk populations:
 • Family history of ADHD
 • Preterm infants
 • Low birthweight
 • Toxic consumption during pregnancy.
 • Serious craniocerebral (CCT) trauma.
9. Ethical and legal aspects
9.1. Which ethical principles must be taken into account in relationships with 
minors or adolescents with ADHD?
Recommendations
 9.1.1.
In the specifi c context of this guide, the ethical principles of 
nonmalefi cence, benefi cence, autonomy and justice are worth 
taking into account, in connection with aspects associated with the 
diagnosis and treatment of ADHD, distinguishing the area that refers 
to very young children, when it is the parents or guardians who 
must necessarily assume an essential and almost exclusive leading 
role, from the area of young adolescents or pre-adolescents, where 
patients must be involved much more, insofar as they are developing 
individuals, with certain rights that must be preserved.




In the diagnosis of ADHD, the professional must be cautious, 
always respecting the criterion of nonmalefi cence, in order to avoid 
pernicious effects for the child or adolescent in his or her school, 
social and family environment.




The professional who assumes responsibility for the diagnosis and 
treatment of ADHD must act in agreement with criteria of suitability, 
necessityand proportionality, restricting those more restrictive 
interventions of the minor’s rights to what is strictly necessary.
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9.4. How involved must the minor be in the decision-making in the context of the 
diagnosis and treatment of ADHD?
Recommendations
 9.4.1.
When the parents’ consent must be given, if there is clear 
discrepancy between the two, consensus and mediation must be 
sought for the greater benefi t of the minor, after informing the two 
about the risks derived from taking or not taking actions for the 
diagnosis and treatment of ADHD.If it is not possible to conciliate 
positions, the professionals responsible for the diagnosis and 
treatment will second the decision of the progenitor that adapts 
to criteria of greater benefi t for the minor.Faced with a situation 
of doubt or special confl ict, it is recommended to resort to the 





In all the cases, even in situations of subrogated decision of 
parents or guardians due to immaturity or incompetence of the 
minor, the latter must be informed of the situation and possible 
alternatives, in the appropriate language and understandable by 
him or her, clarifying any doubts that might arise, in order for 
him or her to form a valid criterion and cooperate in this situation.
9.5. What are the minor’s rights in the fi eld of information and confi dentiality 






Minors with ADHD must always be listened to and they must 
always be informed in the most complete way possible in 
agreement with their level of comprehension, comparing with 
them the different options and doubts they may have, and sharing 
the information with the parents or guardians in agreement 
with the degree of maturity and the need to complement the 





In the care of minors with ADHD, the professionals must respect 
professional secrecy and confi dentiality in all those data referring 
to the context of the therapeutic relationship, except in the case 





Between the ages of 12 and 16, confi dentiality of the information 
and health data about the ADHD of the mature minor and with 
suffi cient judgement must be respected, insofar as possible, 
especially when explicitly demanded by them.In this process 
the risks and benefi ts of transferring or communicating that 
information to parents or guardians will be considered, as well 
as its possible transcendence in other areas of the minor, and 
the minor will be advised on the advisability of dialogue and 
communication with parents or guardians about their health, 
avoiding presenting the clinical documentation to third parties 
without their consent, with the exception of properly justifi ed 
serious risk situations.





From 16 years up, the minor’s confi dentiality must be preserved, 
as if he or she were of full legal age, leaving to their personal 
criterion, the decision about communicating the information to 
parents or guardians, unless there is a situation of serious risk or 
clear incompetence.
List of abbreviations of the recommendations
ICD10 International Classifi cation of Diseases, tenth version
DSM –IV-TR
Diagnostic and Statistical Manual of Mental Disorders, 4th version, 
revised text
CPG Clinical Practice Guideline
NICE National Institute for Health and Clinical Excellence
SIGN Scottish Intercollegiate Guidelines Network
SNS National Health System
ADHD Attention defi cit hyperactivity disorder
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1. Introduction
Background
The “Evidence-based Clinical Practice Guideline (CPG) Development Programme for the entire 
National Health System” is being carried out within the framework of the preparation of the 
Quality Plan of the Ministry of Health and Consumer Affairs, through the Quality Agency of the 
National Health System.
The guidelines must address the main public health and healthcare problems, focusing on 
those disorders where there is considerable variability in the clinical practice.Their main objec-
tive is to help take clinical decisions and they are aimed at the different professionals involved in 
healthcare, patients and their family members.
The majority of the guidelines available for ADHD in Spain come from the Anglo-Saxon 
world and do not adapt very well to our social and healthcare reality.
This CPG on Attention Defi cit Hyperactivity Disorder (ADHD) in children and adolescents, 
written by experts who work in Spain and who are aware of the idiosyncrasy of our health sys-
tem and of its professionals, aims to cover that vacuum, giving valid recommendations for our 
environment, based on the best scientifi c evidence available to date, and systematically developed 
to help professionals and carers intervene in the management of these patients and the decision-
making about the most appropriate care.It is the fi rst CPG on ADHD in children and adolescents 
carried out with this methodology in Spain.
The Sant Joan de Déu Foundation (FSJD), together with the Agencia d’Informacio, Avaluacio 
I Qualitat (AIAQS) of Catalonia are responsible for the development of this guideline.
Justifi cation
G. Still3 gave the fi rst defi nition of ADHD in 1902, describing 43 children who had serious prob-
lems with sustained attention and self-regulation, to whom a defect in moral behavioural control 
was attributed.In 1914, Dr. Tredgold4 argued that the causes were due to brain dysfunction, lethar-
gic encephalitis that affects the area of behaviour, hence the subsequent compensatory hyperkine-
sis, explosivity in voluntary activity and impulsivity.In 1937, Bradley5 discovered by chance the 
therapeutic effects of amphetamines in hyperactive children.The term “minimal brain dysfunc-
tion” was coined by Strauss and Lehtinen in 1947, applied to those children with behavioural dis-
orders in whom there was not suffi cient scientifi c evidence of brain pathology (Barkely, 2006)6. 
Lauferr and Denhoff (1957)7 referred for the fi rst time to hyperkinetic syndrome.In 1968, the 
Diagnostic and Statistical Manual of Mental Disorders, known by its English initials as DSM-II8 
included it as a hyperkinetic reaction ofchildhood and, later, the DMS-III (1980)9 used the term 
of attention defi cit disorder. Finally, the DMS-IV.TR (2001)10 reached the term of attention defi cit 
hyperactivity disorder.
ADHD is a disorder that starts in childhood and is characterised by a persistent pattern of 
inattention, hyperactivity and impulsivity.The disorder is considered to be present when this be-
haviour occurs more often than normal in agreement with the age and development of the person, 
and these manifestations signifi cantly interfere with school or work performance and their daily 
activities (DSM-IV-TR, 2001)10.
32  CLINICAL PRACTICE GUIDELINE ON ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) IN CHILDREN AND ADOLESCENTS
ADHD represents a public health problem due to its high prevalence, which is estimated, ac-
cording to epidemiological sources, at between 3 and 7% of the school population (DMS-IV-TR, 
2001)10. Children with this disorder are at a greater risk of school failure, behavioural problems 
and diffi culties in social and family relations, as a result of the symptoms of ADHD.The course of 
the disorder is chronic and requires long-term treatment, with the relative social cost.
Over the last few years, it has been one of the most highly researched disorders, due to the 
potential repercussions that it has on the child’s personal and family development. Given the 
enormous number of bibliographic references that exist on the topic, the professionals who work 
in the fi elds of paediatrics, neurology, psychology and psychiatry in children and adolescents 
must have a practical guideline on the assessment and treatment of ADHD. This guideline must 
include the best scientifi c evidence and must be helpful to select the best option in the diagnosis 
and treatment of this disorder.
There is no agreement in our medium about which instruments must be used to assess chil-
dren with possible ADHD. There is also controversy about the criteria that must be used to diag-
nose it.These diffi culties in the detection, the diagnostic process and methodology, give rise to 
considerable variations (geographic and demographic), which lead an underdiagnosis or over-
diagnosis of ADHD. There are no biological markers that enable us to diagnose ADHD, so the 
diagnosis is clinical. The instruments that are normally used to assess children, in whom the 
disorder is suspected, have not always been validated in the Spanish population.With reference 
to therapeutic options with drugs, there is controversy about whether to use stimulants or non-
stimulants as a fi rst choice, if the effi cacy persists in treatments lasting for longer than 12 weeks, if 
it is recommendable to suspend the medication during holiday periods or at weekends, as well as 
the duration of the pharmacological treatment.Insofar as psychosocial treatment is concerned, the 
data are contradictory with respect to effi cacy, duration and the generalisation of the results.There 
is no consensus, either, about measuring the therapeutic response, the side effects of the treatment 
or about the frequency of follow-up visits.The great variability in the treatment and controversy 
in the areas mentioned justify the preparation of a CPG that includes the best scientifi c evidence 
available to date.
Magnitude of the problem
ADHD is one of the most frequent reasons for children being referred to the paediatrician, neuro-
paediatrician, or to the mental health team, because they present behavioural problems.In fact, 
ADHD is one of the most prevalent psychiatric (neurobiological) disorders in children and ado-
lescents (Barkley, 2006)6.
The prevalence rates are markedly different depending on the diagnostic criteria used, the 
origin of the samples (clinical or population), the methodology and the ages and gender chosen 
(Benjumea, 2006)11. The prevalence ranges from 1.9 to 14.4% (DuPaul et al., 2001)12. The DSM-
IV-TR refers to an estimated prevalence of 3 to 7% of the school-aged population10. Polanczyk 
et al. (2007)13 informed of a world prevalence of 5.29%. In Spain, as in other European studies, 
the prevalence rates are similar (see Table 1).
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Table 1. ADHD prevalence studies in Spain
Authors and year Age (years) Prevalence (%)
Cardo et al., 200714 (Mallorca) 6-11 4.57
Andrés et al., 199915 (Valencia) 10 3.6







Benjumea & Mojarro, 199317 (Seville) 6-15 4-6
Farré & Narbona, 198918 (Navarre) 5-10 1-2
An isolated presentation of the disorder is not very common. In one clinical sample, Jensen 
et al. (2001)19 found that more than 85% of the patients presented at least one comorbidity, and 
about 60% had at least two comorbidities, the most frequent being oppositional defi ant disorder, 
anxiety disorder and conductdisorder.
In non-clinical community samples, Szatmari et al.(1989)20 indicated that around 44% of 
the patients presented at least one comorbidity, 32% two comorbidities, and 11% three or more 
comorbidities.
It is commonly accepted that the disorder occurs more frequently in males than in females, 
with ranges that vary from 2.5:1 to 5.6:1 (Criado et al., 2003)21. In both sexes, the combined sub-
type is the most frequent, but in the inattentive subtype there appears to be a greater percentage of 
girls, in whom the impulsivity and hyperactivity symptoms can appear with less intensity.The dif-
ferences with respect to gender have more to do with the psychopathological and/or behavioural 
evaluation scales, which do not include specifi c items for girls, than with a specifi city depending 
on the gender (Knellwolf et al., 2008)22.
The average age of onset of the symptoms is between 4 and 5 years old; the children present 
impulsivity, hyperactivity, disobedience and are more prone to having accidents (Bonati et al., 
2005)23. Diagnosis in preschool age can be more diffi cult as the symptoms are typical of the age; 
in this case it will be the intensity, frequency and repercussion on the environment which would 
orientate about an ADHD.Beitchman et al.,(1987)24 found that preschool patients diagnosed with 
ADHD were more likely to receive the same diagnosis 5 years later or even for the same hyper-
activity and disobedience symptoms to persist.
The diagnosis is usually made when they start primary education, when problems appear in 
school performance (incomplete and badly organised homework, as well as with mistakes), the 
child is easily distracted, talks impulsively, answers before the question ends, and social dysfunc-
tion is observed (disadaptive behaviour in the classroom, diffi culties to accept rules, aggressive-
ness, interrupting and meddling with everything, etc.) (Johnston et al., 2001)25.
Not all patients who have ADHD are correctly identifi ed and treated. This fact will have 
important personal and family repercussions as well as an infl uence on public health.The North 
American Centers for Disease Control and Prevention (CDC) analysed the data of a national 
health survey on children and found that only 56.3% of them within the age group of 4 to 17, 
diagnosed with ADHD, received correct pharmacological treatment. No differences were found 
respect to gender (Goldman et al., 1998)26.
In a study conducted by Jensen et al.(1999)27 whose aim was to evaluate the possibility of 
overdiagnosis and overtreatment with stimulants, 5.1% prevalence of ADHD was found. Only 
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12.5% of the children diagnosed with ADHD received treatment with stimulants.On the contrary, 
some of the prescriptions of stimulants were administered to children that did not satisfy all the 
ADHD criteria although they had high symptom levels, so they conclude that overdiagnosis does 
not exist.
Over the last few years, we have observed an increase in the number of patients treated with 
stimulants.Prescriptions for the treatment of ADHD have multiplied by fi ve in the United States 
since 1991, which would mean that one out of every eight North American children takes meth-
ylphenidate (Dopfner et al., 2004)28. A similar situation occurs in Spain, between the years 1992 
and 2001, the use of methylphenidate multiplied by six (Criado et al., 2003)21, a lower increase 
than that experienced in the United States.
It is estimated that the increase in the use of methylphenidate is partly due to the larger num-
ber of ADHD consultations, to the extension of the pharmacological treatment and to the current 
use of stimulants in girls, in adolescents and in young adults, too, and to the case of predominantly 
inattentive ADHD (Pomerleau et al, 1995)29.
Variability in clinical practice
Patients with ADHD represent quite a heterogeneous group, presenting considerable variations in 
the intensity of the symptoms, the onset age and the presence of symptoms in different situations. 
ADHD symptoms can be affected by situational factors, such as the time of day or tiredness, and 
motivational factors, the possibility of supervision, etc. (Barkley et al., 2006)30.
This situation has led some professionals to question its existence and to wonder why more 
and more people present ADHD symptoms, suggesting that this may be a passing fashion in psy-
chiatric diagnosis. Social critics and some professionals, who are not experts in the topic, say that 
ADHD is a myth or, more specifi cally, that children diagnosed with ADHD are normal but that 
they are “labelled” as suffering a mental disorder due to the intolerance of parents and teachers, 
due to the cultural and parental anxiety about the education of children and due to an unspecifi c 
or undocumented conspiracy between the medical community and pharmaceutical companies 
(Barkley et al, 2006)30.
More specifi cally, in the United States, lobby groups have taken advantage of this situation 
to promote important media campaigns, which have managed to generate considerable alarm 
among parents of children and adolescents with ADHD due to the use of psychotropic drugs. 
Focusing on infrequent reactions of methylphenidate, they label it as a hazardous and addictive 
drug, used by intolerant parents and educators and “physicians without scruples”, which can 
cause death or violent acts, suicide, Tourette’s syndrome, permanent brain injury, epileptic crises, 
increase in blood pressure, confusion, agitation and depression (Barkley et al., 2006)6.
The American Medical Association (AMA) ordered a study to be carried out, which con-
cludes that “ADHD is one of the best studied disorders in medicine and the general data about 
its validity are more convincing that in the majority of mental disorders and even in many other 
diseases” (Goldman et al., 1998)26.
Based on the clinical experience in the assessment of people diagnosed with ADHD, it has 
been observed that the symptoms of the disorder have a great impact on the development of the 
individual and interfere in his or her social, emotion and cognitive functioning. They also cause 
important morbidity and dysfunctionality in children, in the group of companions and in their 
families (Cardo & Servera, 2008)31.
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Health Repercussions
The repercussions of ADHD not only affect patients, but also their families. If ADHD is not 
treated or it is undertreated, in the long term it is associated with a wide range of adverse results, 
such as lower academic performance, an increase in school expulsions or school drop-out, lower 
professional category, more car accidents, an increase in visits to emergency services due to ac-
cidents, a greater incidence of divorce and even an increase in delinquency (Barkley et al., 2006; 
Mannuzza et al., 1993; 1998; 1997; 1991; 1991)32-37. Comorbidity with other psychiatric disorders 
is frequent, such asoppositional defi antdisorder and learning disorders, tic disorders and anxiety 
disorders (Jensen et al., 199738; MTA, 199939). Problems of low self-esteem and lack of social 
skills are frequent both in adolescents and in adult age (Wilens et al., 199540; Pomerleau et al, 
199529, Biederman et al., 199741).The consumption of substances starts earlier on, too, in these 
patients, and abstinence in adult age is less likely.The risk of presenting an antisocial personality 
disorder is fi ve times greater in patients with a history of ADHD, a risk that is associated with 
comorbidity with previous conductdisorders (Faraone et al, 1998)42.
In a study prepared by Escobar et al.(2005)43 that compared the quality of life between pa-
tients with ADHD and asthmatic patients, the authors concluded that ADHD interferes in the daily 
lives of children, parents and families more than asthma, mainly in those aspects related to psy-
chosocial functioning. It also involves a subsequent impairment in physical functioning. Delays 
in the recognition, evaluation and treatment of ADHD can have a negative effect on the quality of 
life of these children.This same study observed that, on average, almost 6 years passed between 
the onset of symptoms and the diagnosis of ADHD.
In families, we fi nd ideas of self-blame, social isolation, marriage confl icts, affective and 
anxiety symptoms, and less productivity as well as an increase in occupational absenteeism 
(Johnston et al., 200125; Mash et al., 198344).
Economic Repercussions
On the other hand, the impact of the disease on public health and its cost for the health system are 
considerable. The health costs of children with ADHD are almost double that of children without 
this disorder, so, in general, the cost of the disease is estimated to be more than 40 billion dollars 
a year in the United States (Schlander et al., 2007)45.
The costs in that country have risen due to the increase in diagnosis and treatment of ADHD.
The annual economic expenditure in children and adolescents amounted to approximately 14,000 
dollars per person in 2005 prices (ranging from 12,000 to 17,500 dollars). This expenditure can 
be broken down into health costs (18%), education costs (34%) and costs associated with crime 
and delinquency (48%) (NICE, 2009)2.
It can be deduced from this information that ADHD is signifi cantly associated with fi nancial 
costs and emotional overload that are refl ected in the health system, education services, carers, 
families and society in general.An adequate treatment could improve the quality of life of people 
with ADHD, of their carers and family members, and at the same time, would reduce their psy-
chological wear, as well as the fi nancial implications and overload of ADHD for society.
The impact of ADHD and the associated costs in our medium are an unknown factor, but it 
is estimated that they are different to those of other societies due to the differences in the attention 
and treatment pattern, so they cannot be pervasive or compared. The costs to be studied in our me-
dium should include:Accidents, health service costs, comorbidity with other disorders, substance 
abuse, antisocial behaviour, school failure, dysfunctions in the family and society, among others.
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2. Scope and objectives
Target population
This CPG focuses on the following groups:
a) Children and adolescents aged between 6 and 18 years old.
b) With main diagnosis of ADHD (any of the subtypes) according to DSM-IV-TR criteria or 
comparable criteria, with and without psychiatric and learning comorbidity.
This CPG has been limited to ADHD in school-aged children and does not deal with children 
in pre-school age (from 3 to 5), or adults (over 18). These age groups can be addressed in future 
reviews of the guide.
Scope and healthcare process
The guideline describes the healthcare that primary care and specialised care health professionals 
of the SNS provide children and adolescents with ADHD, as well as the clinical decision-making 
in its diagnosis and treatment.Although the assessment of scientifi c evidence includes questions 
related to the organisation of the disorder, planning the health services of the autonomous com-
munities is not the aim of this guideline.
This CPG does not aim to be a substitute for clinical judgement.
The guideline examines the following aspects of the management of ADHD in children 
and adolescents:prevention, detection and screening, diagnosis, assessment instruments, types of 
treatment and their assessment (psychological, psychopedagogical, pharmacological, combined, 
comorbidity and special situations, complementary and alternative medicine), as well as ethical 
and legal aspects.
Psychiatric and non-psychiatric comorbidities that may require another type of care have 
been included in the CPG:epilepsy, autism spectrum disorders, mood disorders, bipolar disorder 
and substance use disorder.It does not include specifi c interventions for psychiatric and non-
psychiatric comorbid disorders of ADHD.
Main Objective
To develop a scientifi c evidence-based CPG about ADHD in children and adolescentsthat 
will provide the professionals responsible for caring for patients, parents and educators, with a 
tool that will enable them to take the best decisions about the problems posed by their care.
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Secondary objectives
a) To generate recommendations about the diagnosis, treatment and evaluation of the thera-
peutic response of the patient with ADHD.
b) To generate recommendations about the detection and screening instruments of ADHD.
c) To generate recommendations about the diagnostic assessment instruments of ADHD.
d) To generate recommendations on the optimal use of the health resources in ADHD 
healthcare.
e) To give useful information to professionals from the clinical area to help them detect and 
take decisions about the management of ADHD.
f) To give information and clinical counselling to parents and educators that will enable 
them to learn, collaborate and take decisions regarding the treatment of ADHD.
g) To establish recommendations for future research in ADHD that will permit making pro-
gress in its knowledge.
h) To develop indicators that can be used to assess the recommendations.
Main users
This CPG is aimed at professionals from the clinical and education areas, and others, and at par-
ents who intervene in the management of ADHD in children and adolescents.
The CPG provides information for patients, family members and educators that can also be 
used by the general population.
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3. Methodology
The methodology used is contained within the CPG Development Manual46 of the Ministry of 
Health and Consumer Affairs.
The steps below have been followed:
 • Formation of the CPG development group, comprised of specialists in neuropaedi-
atrics, psychiatry, psychology and psychopedagogy, involved in the study and care of 
ADHD in children and adolescents.There have been two coordinators in the develop-
ment group, one clinician, Jose Angel Alda, and one technician, Monica Fernandez, 
who, together with a member of the development group, Anna Torres, have carried out 
the systematic review of the bibliography.The development group has received advice 
on the methodology from a member of the AIAQS with experience in preparing sci-
entifi c evidence-based CPGs and critical reading, and support from a documentation 
offi cer from the AIAQS.
Collaborators have participated with the development group to prepare the chapter on 
ethical and legal aspects.
With respect to the collaboration of experts, a group of Spanish professionals selected 
for their prestige in the area have also participated.External reviewers have also col-
laborated in preparing the guideline, including patients’ representatives, who have been 
incorporated into the external review.
All the members of the development group, collaborators, experts and external review-
ers presented a declaration of interest (Appendix 6).
Table 2 describes the different phases in the preparation of the guideline and the distri-
bution of functions among the group of authors and collaborators.
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Clinical questions +++ ++ +++ + - - ++ -
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 • Formulation of clinical questions following the format, Patient/Intervention/
Comparison/Outcome (PICO).
 • The search and selection of scientifi c evidence for this guideline has given priority to 
identifying CPGs, SRs, MAs and other critical synthesis documents from quality scien-
tifi c literature.
The search was organised as follows:
1. The following generic databases, metasearch engines and guideline preparation and 
compilation organisations were consulted: US National Guidelines Clearinghouse, US 
National Library ofMedicine (NLM), Tripdatabase, CMA Infobase, Natio nal Institute 
for Clinical Excellence (NICE), Scottish Intercollegiate Guidelines Network (SIGN), 
Institute for Clinical System Improvement (ICSI), New Zealand Guidelines Group 
(NZGG), Centre for Reviews and Dissemination (CRD), Cochrane Library, ISI web of 
knowledge, Psycinfo and PubMed.
2. A main systematic search was carried out, based on a strategy that combined the main 
terms related to ADHD, with CPG, SR and MA in the title, or else the MeSH /Medical 
Subject Headings) terms were used.The strategy depended in each case on whether the 
information source accepted a simple syntax or not.Studies published for children and 
adolescents in the age groups from 6 to 18 years old were sought.
3. The time window to search for the databases that permitted this was restricted from 1993 
to February 2008. Later, to answer the questions not solved by the available referenc-
es, or to update them if necessary, additional and supplementary searches were made in 
Pubmed/Medline and Psycinfo until March 2009.
4. To complete the search, sources suggested by members of the development group were 
used, as well as a manual investigation of secondary information sources.
5. The most relevant documents were selected by applying inclusion and exclusion criteria.
Inclusion criteria:
 • Studies from journals published in Spanish, English or French.
 • CPG, SR, MA, RCT, diagnostic test assessment studies, cohort studies, case-control 
studies and non-systematic (or narrative) reviews were selected.
 • Studies were selected that dealt with the assessment and/or treatment of ADHD in chil-
dren and adolescents.
 • Guidelines prepared no more than 3 years ago or updated and valid ones to date.
 • Guidelines classifi ed as highly recommended or recommended according to the AGREE 
instrument (Appraisal of Guidelines for Research and Evaluation) with a score of more 
than 60 in the respective area in the rigour of development.
 • Age range of participants included went from 6 to 18 years (average age).
 • Availability of search strategies, scientifi c evident classifi cation scales used, the recom-
mendation formulation process and the scientifi c evidence tables.
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Exclusion criteria:
 • Studies on description of cases, summaries, lectures, papers at congresses or case de-
signs without control group.
 • Studies that did not include results.
 • Studies where the majority of the individuals in the sample were outside the inclusion age.
 • Unavailable documents/guidelines (erroneous electronic address or reference).
 • References not directly related to the objectives set out.
Two reviewers independently examined the titles and/or summaries of the documents identi-
fi ed by the search strategy. If any of the inclusion criteria were not satisfi ed, the document was 
excluded. Otherwise, the full document was requested and assessed to decide on its inclusion or 
exclusion.Discrepancies or doubts that occurred during the process were solved by consensus of 
the reviewers.
 • Scientifi c evidence quality assessment. The quality assessment of the CPGs was done 
through the AGREE instrument by three assessors from the development group.The 
guidelines classifi ed as recommended in the respective section in the rigour of develop-
ment were considered as quality guidelines (Appendix 7).
For the SR. MA and RCT, critical SIGN (Scottish Intercollegiate Guidelines 
Network) reading templates were used by the two assessors following the recommen-
dations established in the CPG Preparation Manual of theMinistry of Health and 
Consumer Affairs46. The scientifi c evidence has been classifi ed with the SIGN system 
(Appendix 1).
Synthesis documents have been included with quality 1++, 1+, 2++ and 2+, considering 
those with quality 1- only in the cases where there was no scientifi c evidence of a better 
quality.
The quality of the individual studies considered in the CPGs and SRs has been assumed 
by the development group on considering them quality studies.When the evaluation 
scale used by the CPGs or SRs differed from SIGN (followed in this guideline), the 
equivalent was sought.
 • Synthesis and analysis of the scientifi c evidence. Information was taken from the main 
characteristics of the studies, which was summed up in scientifi c evidence tables for 
later qualitative analysis and weighting of the recommendations. When the CPGs in-
formed about the results of individual studies, these were described in the “Scientifi c 
Evidence” section.
With reference to the CPGs, apart from using the guidelines selected for their methodol-
ogy quality, specifi c sections have been used from other guidelines to inspire specifi c 
aspects of this CPG, or scientifi c evidence has been compiled from them (Appendix 7).
Observational studies were used for those questions where no quality scientifi c evidence 
was found.
 • Formulation of recommendations based on the “formal assessment” or “consid-
ered judgement” of SIGN.The recommendations have been ranked according to the 
SIGN system (Appendix 1).The recommendations have been made during meetings of 
the development group.Any controversial recommendations or with a lack of scientifi c 
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evidence have been solved by consensus of the development group.On some occasions, 
and for greater transparency, those recommendations that have been adapted from other 
guidelines and contextualised in our medium are explicitly established, so that the user 
can easily identify in which cases this has occurred. A total of 28 meetings of the devel-
opment group have been held during the entire guideline preparation process.
 • Collaborators in the chapter on ethical and legal aspects.They have participated with 
their experience in reviewing the legislation in force in our medium for children and 
adolescents with ADHD.
 • Expert collaborators:They have participated in the preparation process of the scope 
and clinical questions to be answered, as well as in the review of the guideline.
 • External reviewers:Different relevant professionals in the subject have participated in 
the review of the draft guideline, as well as scientifi c societies and representatives of 
patients and family members involved in ADHD in children and adolescents.
 • To prepare the information for patients, family members and educators (Appendix 
3), the development group agreed upon an index based on the complete guideline, which 
includes the most relevant aspects that might be of interest to patients, family members 
and educators.A summary of the sections of the guideline and of its main recommenda-
tions was prepared based on that index, adapting the information provided, the style and 
the language for this section.Although this information forms part of the CPG and must 
be presented and explained by the physicians, personalised leafl ets to facilitate its dis-
semination are hoped to be published.
 • The CPG is organised into chapters, where answers are given to the questions that ap-
pear at the beginning.Following each question, the documents and quality on which 
the answer is based are described.Afterwards, the results of the scientifi c evidence are 
presented in two blocks:scientifi c evidence and summary of the scientifi c evidence. The 
scientifi c evidence section presents the results of the individual studies described in the 
CPGs, SRs and MAs included. The results/conclusions of the CPGs, SRs, and MAs are 
included in the scientifi c evidence summary section. In some questions, to avoid repeti-
tions, only one of these two sections is presented. Finally, the recommendations of the 
development group of this CPG are presented.Although the fi rst author and the year of 
the individual publications are described in the scientifi c evidence tables, the results that 
appear correspond to the reviewed CPGs, SRs or MAs, except when RCTs have been 
identifi ed in the update.The type of study and the quality of the reviewed literature is 
given in the right-hand margin, throughout the text.In the case of the CPGs, this is not 
indicated as they are all quality ones.
 • The expression “children and adolescents” is constantly repeated throughout this CPG, 
referring to both sexes.
 • This CPG is available on the portal of GuiaSalud (www.guiasalud.es). As well as on the 
web page of the AIAQS (www.aiaqs.net) and of the Sant Joan de Deu Hospital (www.
hsjdbcn.org).
 • This CPG, published in 2009, will be updated after evaluating any new scientifi c evi-
dence that might appear over the next 3 years.Any modifi cation during that time will be 
refl ected in electronic format, which can be consulted on the portal of GuiaSalud and 
on the web page of the AIAQS.The methodology proposed in the Manual, Update of 
Clinical Practice Guidelines in the National Health System will be applied to carry out 
this update. Methodology Manual47 of the Ministry of Health and Consumer Affairs. 
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4. ADHD
Questions to be answered:
4.1. How is ADHD defi ned? What clinical manifestations does the disorder have?
4.2. Etiopathogeny of ADHD. What are the main risk factors?
4.3. In ADHD: Are there neuropsychological dysfunctions?
4.4. What is the natural course of ADHD?
4.5. In ADHD: What is the long-term prognosis? What factors have an infl uence on a good or 
bad prognosis?To what extent does early diagnosis and intervention improve the progno-
sis of ADHD?
4.6. In ADHD: What are the most frequent comorbid disorders?
4.1. How is ADHD defi ned? What clinical manifestations 
does the disorder have?
Attention defi cit hyperactivity disorder (ADHD) is a neurobiological disorder that starts during 
childhood and affects between 3 and 7% of school-aged children.It is characterised by a level of 
impulsivity, activity and attention that are not adequate for the development age.Many children 
and adolescents with ADHD fi nd it diffi cult to regulate their behaviour and adjust to the rules 
expected for their age and, consequently, they fi nd it diffi cult to adapt in their family and school 
environment, and in their relationships with their peers.They often perform below their capabili-
ties and may present emotional and behavioural disorders (APA, 2001)10.
What are the nuclear symptoms and how are they clinically 
manifested?
The data or behaviours that are taken into consideration to evaluate ADHD are dimensional. They 
are distributed continuously going from normality to pathology.The nuclear symptoms are: inat-
tention, hyperactivity and impulsivity, to which comorbidity side effects are often added.
According to the DSM-IV-TR (APA, 2001)10, the clinical manifestations of the nuclear 
symptoms refer to:
Hyperactivity
This is manifested by excess movement, motor and/or cognitive activity, in situations in which it 
is inappropriate to do so. These children show a high motor activity in different areas. They have 
diffi culty keeping quiet when situations require this, both in structured contexts (the classroom or 
table at mealtime), and in non-structured contexts (playtime).
The developmental moment has a signifi cant infl uence on the manifestation of the hyperac-
tivity.Thus, the pervasive hyperkinesis of pre-school children is less dependent on the environ-
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ment.At school age, the hyperactive behaviour of the child may be limited to certain situations, 
especially when these are not very structured. They talk too much and make too much noise 
during quiet activities. Hyperactivity in adolescents is usually less obvious, an internal feeling of 
restlessness prevailing, trying to do several things at the same time and going from one activity to 
another without fi nishing any.
Inattention
This refers to the diffi culties to pay attention during a period of time, both in academic and in 
family tasks, as well as social tasks. Children fi nd it diffi cult to give priority to the tasks, persist 
until they are fi nished and they avoid activities that represent sustained mental effort. They often 
tend to change tasks without fi nishing any of them. They often appear not to be listening.They do 
not follow orders or instructions and they have diffi culties in organising tasks and activities, often 
tending to forget things and lose things.They are usually easily distracted by irrelevant stimuli.
In social situations, inattention is usually manifested by frequent changes in conversation, 
with diffi culties to follow the rules or details in activities and/or games.
On a developmental level, inattention usually appears more frequently during the school 
stage, when a more complex cognitive activity is required, and it signifi cantly persists during the 
teens and adult age.
Impulsivity
This is manifested by impatience, diffi cult to postpone answers and to await their turn, often in-
terrupting others.The children often blurt out answers before the questions have been completed, 
letting themselves be taken away by the high-handed answer (spontaneous and dominant).
During the fi rst years, impulsivity makes children appear “to be controlled by stimuli” so 
they have a tendency to touch everything.During school age, they constantly interrupt others and 
have diffi culties awaiting their turn.
Impulsivity in adolescents leads to a greater confl ict with adults and a tendency towards 
more risky behaviour (toxic substance abuse, early sexual activity and car accidents).
The behavioural manifestations described above usually take place in multiple contexts 
(home, school, work and social situations). As they grow older, the apparent hyperactivity usually 
decreases, but the impulsivity and inattention persist.
Are there any differences between the clinical manifestations of boys 
and girls?
With reference to nuclear symptoms, boys and girls with ADHD present different behav-
ioural patterns.Girls tend to present greater inattention and the boys a greater hyperactivity-im-
pulsivity component.
According to Lahey et al. (1994)48, the proportion of boys/girls is greater for the combined 
type (7.3:1), followed by the hyperactive-impulsive type (4:1) and less so for the inattentive type 
(2.7:1).
More recently, Biederman et al.(2002)49 presented the frequency, in percentage terms, of the 
ADHD subtypes according to sexes, determining that:
 • ADHD-C: The combined subtype appeared more often in boys than in girls (80% com-
pared with 65%, respectively).
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 • ADHD-I: The inattentive subtype was more frequent in girls than in boys (30% com-
pared with 16%, respectively).
 • ADHD-HI: The hyperactive-impulsive subtype is the least frequent of the three and is 
found both in girls (5%) and in boys (4%).
There are studies, such as the Quinn study (2004)50, that point out that teachers detect girls 
with ADHD less than boys with ADHD.
How do the clinical manifestations affect the school performance?
It is worthwhile bearing in mind, too, that school children with ADHD fi nd learning more 
diffi cult than the rest of the child population. This fact is one of the main reasons for consultation 
and school failure (Spencer J, 2007)51.
The low academic performance is partly due to the actual organisational, planning, prioriti-
sation and attention diffi culties, as well as hastiness in providing answers, that are due to the al-
terations of the executive functions (working memory and response inhibition) typical of ADHD, 
and to the specifi c diffi culties entailed by the specifi c learning disorders that are often associated 
such as dyslexia.
In general, girls with ADHD have less associated learning disorders and better reading skills, 
which often lead to underdiagnosis.
How do the clinical manifestations affect the comorbid disorders?
There are different clinical manifestations of psychiatric comorbidity in boys and girls with 
ADHD (Spencer, J, 2007)51.
 • Boys are diagnosed more often with oppositional defi ant disorders, behavioural disor-
ders and major depression.In the classroom, they present a higher percentage of disrup-
tive behaviour and hyperactivity.
 • Girls with ADHD are less aggressive and impulsive and present less behavioural disor-
der symptoms.They have a greater risk of suffering anxiety disorders.At school level, 
they have fewer problems and participate in more out-of-school activities.
These sex differences disappear after puberty (Seidman L.J, 2006)52.
4.2. Etiopathogeny of ADHD.
What are the main risk factors? Which etiopathogenic model is 
proposed in ADHD?
The etiopathogeny of ADHD entails the interrelationship of multiple genetic and environmental 
factors. ADHD is considered as a heterogeneous disorder with different subtypes resulting from 
different combinations of the risk factors that act at the same time.
It has been suggested that ADHD originates in a dysfunction of the prefrontal crust and of 
its fronto-striatal connections.
Different data support this etiopathogenic model, including the benefi cial effect of stimu-
lants and animal models that involve the dopaminergic pathways,which are very important in the 
functioning of the prefrontal lobe (Shaywitz et al., 1978; Arnsten, 2006)53;54.
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Volumetric brain studies have shown deviations in the development of the cortical structures 
in individuals with ADHD with respect to the controls.These studies suggest that ADHD is a cor-
tical maturation disorder more than a deviation in the development (Shaw et al., 2007)55.
What structures and brain circuits are involved in ADHD?
On a structural level, in the paediatric population with ADHD, signifi cantly lower volumes have 
been found at dorsolateral prefrontal cortex level and in regions connected to this, such as the 
caudate nucleus, pale nucleus, anterior cingulated gyrus and cerebellum (Castellanos, 200256; 
Seidman et al., 200557). The functional neuroimage studies, especially in adults, also consist-
ently involve the prefrontal cortex and the anterior cingulate (Bush et al., 200558; Pliszka et al., 
200659).
Is there a genetic component in ADHD?
There is scientifi c evidence of the importance of genetic aspects in ADHD. In 20 independent 
studies performed on twins, it has been verifi ed that the inheritability of ADHD amounts to 76% 
(Faraone et al., 2005)60. Recent genomic studies show the genetic complexity of ADHD, which 
has been associated with markers in chromosome4, 5, 6, 8, 11, 16 and 17 (Faraone et al., 200560; 
Smalley et al., 200261). Faraone et al. (2005)60 have identifi ed 8 genes that have been investigated 
in at least three more studies; 7 of these genes have shown a statistically signifi cant association 
with ADHD. These genes are related to receptors DR4, DR5 and the dopamine transporter (DAT), 
the dopamine – hydroxylase enzyme, the transporter (DBH) and serotonin receptor 1B (HTR1B) 
and the synaptosomal-associated protein 25 gene (SNAP25).
In a study performed by Spanish researchers, the participation of the so-called neurotrophic 
factors (NTF) has been verifi ed in the genetic susceptibility of ADHD (Ribases et al., 2008)62.
Are there other neurobiological factors in the origin of ADHD?
The presence of non-genetic neurobiological factors in the genesis of ADHD has been referred to 
in different studies: prematurity, hypoxic-ischemic encephalopathy and low birthweight (Botting 
et al., 1997)63, consumption of tobacco and alcohol during pregnancy, basically (Linnet et al., 
2003)64. The consumption of other substances such as heroin and cocaine during pregnancy has 
also been associated with ADHD (Ornoy et al., 2001)65. Intrauterine exposure to substances such 
as lead and zinc has also been indicated as a risk factor to suffer from ADHD (Tuthill, 1996)66. 
Moderate and serious craniocerebral traumas (CCT) in early childhood, as well as infections of the 
central nervous system (CNS) have also been associated with a greater risk of ADHD (Millichap, 
2008)67. These non-genetic neurobiological factors are generically called environmental factors.
Are there non-neurobiological factors involved in the origin of ADHD?
Psychosocial risk factors, which would affect the development of the emotional and cognitive 
control capacity, have also been described. Problems in family relationships are more frequent in 
families with children with ADHD. This may be a consequence or a risk factor per se (Biederman 
et al., 2002)68.
Today, gene-environment interaction is accepted as possible, so the presence of certain 
genes would affect the individual sensitivity to certain environmental factors (Lehn et al., 200769; 
Thapar et al., 200770).
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Dietetic factors such as the type of food, the use of food additives, sugar and sweeteners have 
also given rise to controversy, but, for the moment, there are no conclusive studies that associate 
them with ADHD (Mc Ardle et al., 2004)71.
4.3. In ADHD: Are there neuropsychological dysfunctions?
Functional neuroimage and neuropsychological studies have shown that boys and girls with 
ADHD have a cognitive alteration in different components of the executive functions (AACAP, 
200772; Willcut et al., 200573).
Which are these dysfunctions?
More specifi cally, a MA of 83 studies with more than 6000 patients indicates that the population 
with ADHD has alterations in different executive function components, such as response inhibi-
tion, vigilance, working memory and planning.
Pennington (2005)74 performed a review of the explanatory neuropsychological models of 
cognitive dysfunctions of ADHD, which would refer to:
 • a defi cit in executive functions (Barkley, 199775; Nigg et al., 200576);
 • a motivational defi cit, also called imposition of delay/”delay aversion” (Sonuga-Barke 
et al., 2005)77, and
 • fi nally, the cognitive-energetic regulation model (Sergeant, 2005)78.
It is not known exactly if these three cognitive models form independent circuits and/or 
interrelated circuits.
Thomas Brown also developed a model on complex cognitive capacities that are affected 
in ADHD.Apart from the executive functions, already mentioned by Barkley, Brown adds two 
important aspects, motivation and emotion regulation. Brown places more emphasis on these 
cognitive capacities as a cognitive basis of the disorder (Soutullo, 2007)79.
Is there one single neuropsychological profi le present in all the 
individuals?
Doyle (2006)80 carried out a MA that reviews the knowledge about the relationship of ADHD 
and the problems in executive functions. On the one hand, he considered that there is scientifi c 
evidence about the alteration of executive functions (especially response inhibition and working 
memory), but, on the other hand, he fi nds considerable neuropsychological variability among the 
ADHD samples and within them, which makes it diffi cult to conceptualise the problem.
Along the same line, Seidman (2006)52 reviewed the effect of the executive functions on 
ADHD throughout the entire life cycle, bearing in mind variables such as comorbidity, sex, psy-
chopharmacology, etc. In this case, the conclusion was that “future research should clarify the 
multiple sources of ADHD impairments, continue to refi ne and optimise neuropsychological tools 
for their assessment and incorporate longitudinal, developmental designs to understand the disor-
der across the life cycle”.
By way of a conclusion, as Doyle says, “ADHD can be conceptualised as a neuropsycho-
logically heterogeneous condition”.
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4.4. What is the natural course of ADHD?
The assessment of the developmental changes in the symptoms of ADHD has been considerably 
complicated by the changes in diagnostic systems, so studies prior to 1994 and many published 
after that date are often based on the unitary model of the DSM-III-R. Barkley (1997)75 summed 
up the evidence that hyperactivity-impulsivity symptoms appear earlier on (at 3 to 4 years of age), 
inattention is obvious later on, when they start school (at 5 to 7 years of age), and the problems 
associated with inattention even later on.In fact, the predominantly hyperactive type is diagnosed 
more easily in younger children and the predominantly inattention type later on, as the ADHD 
develops. The hyperactivity-impulsivity symptoms decline more during childhood than the inat-
tention symptoms (Gjone et al., 199681; Hart et al., 199582; Hechtman, 199683; Levy et al., 199684). 
This reduction of the hyperactivity-impulsivity symptoms is not the consequence of medication 
or any other treatment, but it is possible that it is developmental (Hart et al., 1995)82. Inattention 
could also decrease in intensity, and attention would last for longer with age, but it tends to be 
lower than the attention of unaffected people, than the level expected at that age and that is needed 
for the demands of daily life (NICE, 2009)2.
4.5. In ADHD: What is the long-term prognosis? 
What factors have an infl uence on a good or bad 
prognosis?To what extent does early diagnosis and in-
tervention improve the prognosis of ADHD?
The long-term prognosis of ADHD
The best summary of the developmental perspective of ADHD is that there is not one single 
prognosis. Hetchman (1996)83 summed up the results, identifying three groups in adult age: 1) 
Those whose functioning is as good as that of those without a childhood history of ADHD; 2) 
those with important psychopathology; and 3) the largest group, those that have some diffi culties 
with concentration, impulse control and social functioning. The percentages mentioned vary con-
siderably among the different studies. Hetchman (1996)83 analysed many of the relevant methodo-
logical questions, and a key question is the way in which the adults have been identifi ed (by their 
own children, via follow-up studies based on their own behaviour in childhood, by self-referral, 
via clinical trials, etc.).
The risk of subsequent disadaptation also affects children who have not been referred to 
the practice clinic and to those not treated in any way. Longitudinal population studies (Moffi tt, 
199085; Taylor et al., 199686) have shown that hyperactive-impulsive behaviours are a risk for 
several types of dysfunctions inadolescents.It has been informed that the lack of friends, of work 
and of constructive leisure activities is prominent and affects the quality of life. Varying levels of 
hyperactivity and impulsivity also lead to a greater probability of children developing an antiso-
cial evolution and it also increases the probability of personality disorders, or substance abuse in 
late adolescence and in adult age (NICE, 2009)2.
In the Milwaukee study, Barkley et al. (2002)87 found that in young adults (average age of 
20) 42% of the patients continued to satisfyDSM-III-R criteria for ADHD, based on the interview 
with parents.
Mannuzza et al. (1998)34 found that ADHD in children predicted specifi c psychiatric disor-
ders in adults, an antisocial personality disorder and drug abuse. Lam bert (1988)88 informed that 
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hyperactive children had signifi cantly lower educational results and more behavioural disorders 
than their peers of the same age. Lie (1992)89 informed that criminality was related to school and 
behavioural problems in childhood more than ADHD per se, with a greater role for comorbid 
behavioural disorder in the fi nal prognosis.
The psychiatric comorbidity studies in adults with ADHD by Biederman et al. (1993)90 
found major depression, bipolar disorder, anxiety and personality disorders. They also informed 
of high rates of antisocial disorder and substance abuse, as well as lower scores in total intellec-
tual quotient (IQ), vocabulary and reading.
Although the symptoms of ADHD persist in the majority of the cases, it is important to recall 
that many adolescents with ADHD will also adapt well in adult age and will be free from mental 
problems.The prognosis will probably be better when inattention prevails more than hyperactivi-
ty-impulsivity, no antisocial behaviour is developed and relationships with family and with other 
children are correct.More studies must be carried out on the evolution of ADHD in children and 
adolescents until adult age, which should include the long-term prognosis together with possible 
benefi ts (and risks) of early diagnosis and treatment (NICE, 2009)2.
Good or bad prognosis factors
Age
In general, it can be stated that in many individuals, the excess of motor activity decreases sig-
nifi cantly the older the people get, whilst impulsivity and inattention tend to remain (Hart et al., 
1995)82. Longitudinal studies show very different prevalence rates regarding the persistence of 
ADHD symptoms in adolescence and in adult age, due to the methodology differences in inclu-
sion criteria and in the tools used to measure the symptoms. In general terms, we can say that the 
ADHD symptoms persist in adolescence in almost 80% of the people affected, where almost one 
third of the patients fully satisfy the disorder criteria (Klein & Mannuzza 199191; Mannuzza et 
al., 199834; Biederman et al., 199692, 199893). In adult age, between 30% and 65% of the patients 
will present the disorder or will maintain clinically signifi cant symptoms (Weiss et al., 198594; 
Biederman et al., 199692, 199893).
Gender
There is only one prospective study on the prognosis of ADHD depending on gender. A cohort 
of 17 girls with ADHD was compared with a cohort of 24 boys with ADHD and 24 control boys 
(Manuzza & Klein, 2000)95. The results indicated worse scores in academic, behaviour and social 
functioning measures in girls compared with boys. On the contrary, in adult age, the girls had bet-
ter results than the boys, especially regarding prevalence of antisocial personality and substance 
abuse (Manuzza y Klein, 2000)95. These results must be taken with caution, given the size of the 
sample studied.
Cognitive level
Loney et al. (1982)96 found that IQ was a predictive factor for antisocial personality and alcohol 
abuse disorder. Weiss & Hechtman (1993)97 indicated that the cognitive level in children, com-
bined with other factors, is a predictive factor of the prognosis of ADHD in adult age.
ADHD Subtype
According to several authors, factors of bad prognosis of ADHD exist if the symptoms are serious 
or predominantly hyperactive-impulsive (Moffi tt, 1990; Lynskey & Fergusson, 1995; Babinski et 
al., 1999; Merrell & Tymms, 2001)85; 98-100.
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Parents’ psychopathology
In the study by Biederman (2001)101 patients with ADHD whose parents have an antisocial 
personality disorder had more anxiety, major depressive disorder, antisocial behaviour and ag-
gressiveness in the follow-up.
The psychopathology of parents, especially the family history of ADHD, is associated with 
a greater risk of psychiatric and emotional problems of children in adolescence (August et al., 
1983102; Biederman et al., 199692; Fergusson et al., 1996103; Fischer et al., 1993104; Lambert et al., 
1987105; Paternite & Loney, 1980106; Taylor et al., 199686; Weiss & Hechtman, 199397). Families 
with a history of ADHD with comorbid behaviour problems, antisocial behaviour, and substance 
dependence and abuse, are also associated with a worse prognosis in children with ADHD in 
adolescence.
Parent-children relationship
The level of confl ict and/or hostility in the parent-child interaction is associated with aggres-
sive behaviour in adolescence (August et al., 1983102; Biederman et al., 199692; Fergusson et al., 
1996103; Fischer et al., 1993104; Lambert et al., 1987105; Paternite & Loney, 1980106; Taylor et al., 
199686; Weiss & Hechtman, 199397).
A confl ictive and/or hostile emotional climate in the home is associated with a bad prognosis 
of ADHD in adult age (Weiss y Hechtman, 1993)97.
Socio-economic status
The low academic level and the presence of antisocial behaviour in adult age are associated 
with a low social and economic status of the parents (Weiss & Hechtman, 1993)97.
Comorbidity
The conductdisorder increases the probability of substance use disorder (Au gust et al., 1983)102.
In the New York study, the perpetration of criminal acts was almost exclusively explained by 
the prevalence of antisocial and substance use disorder (Manuzza & Klein, 2008)107. Criminality 
in adult age is associated more with antisocial behaviour than just with ADHD (Satterfi eld et al., 
1997)108.
The persistence of ADHD is associated with comorbidity with behaviour disorder and an-
tisocial personality disorder (Biederman et al., 199692, 199893). A worse prognosis of ADHD is 
associated with comorbidity with behavioural disorder, bipolar disorder, oppositional defi ant dis-
order and substance abuse (Biederman et al., 2001)101.
Infl uence of early diagnosis and intervention in the prognosis of ADHD
Despite not having found scientifi c evidence about the extent to which early diagnosis and in-
tervention improve the prognosis of ADHD, the guideline development group considers that the 
prognosis is variable depending on how serious the symptoms are and on the problems and/or 
disorders that may co-exist with ADHD.In general, an early diagnosis and correct treatment will 
have a decisively positive infl uence on its development.
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4.6. In ADHD: What are the most frequent comorbid 
disorders?
The term, comorbidity, refers to the existence of two or more different disorders or illnesses in 
one same individual. ADHD is frequently associated with other psychiatric disorders (Pliszka 
et al., 1999)109. A study conducted in Sweden by the group of Kadesjo and Gillberg (2001)110, 
showed that 87% of children that satisfi ed all the ADHD criteria had at least one comorbid diag-
nosis and that 67% satisfi ed the criteria for at least two comorbid disorders.
Oppositional defi ant disorder and learning disorders, tic disorders and anxiety disorders are 
among the most frequent comorbidities(Jensen et al., 199738; MTA, 199939, Barkley, 200630).
A complete appraisal of ADHD in children and adolescents must include an evaluation of the 
associated learning and psychiatric disorders.The presence of comorbidity determines the clinical 
presentation, the prognosis, the therapeutic plan and the response to the treatment.
Table 3 shows the most frequent comorbidities in children and adolescents with ADHD.
Table 3. Comorbidity with ADHD
Disorder Approximate rate in children with ADHD
Learning disorders (reading disorder, 
arithmeticdisorder)
Between 8 and 39% reading disorder, 12 to 
30% arithmetic disorder 30
Developmental Coordination Disorder (DCD) 
/ motor coordination retardation
47% satisfy DCD criteria / 52% have motor 
coordination retardation 30
Speech development disorders, expressive 
disorders (pragmatic)
Up to 35% start to talk late / between 10-54% 
have expressive diffi culties, mainly pragmatic 
ones30
Pervasive developmental disorders*
UP to 26% of the children with pervasive 
developmental disorder (PDD) may have 
combined type ADHD 30
Oppositionaldefi ant disorder Between 40 and 60% 30, 39
Conductdisorder 14.3%39
Tics disorder / Tourette’s syndrome 10.9%39
Substance use disorder
In adolescence, the risk is 2 to 5 times greater 
than in normal controls, if there is comorbidity 
with conductdisorder 30
Mood disorder: Major depression / bipolar 
disorder
3.8%/2.2%39
Anxiety disorder (panic, phobia, compulsive 
obsessive, pervasive anxiety, separation 
anxiety)
Between 25 and 35%30, 39
Sleep disorder Between 30 and 35%30, 39
* Despite the fact that today’s diagnostic criteria do not permit the diagnosis of ADHD in children and adoles-
cents with pervasive developmental disorders, a signifi cant number of these patients also present compat-
ible symptoms with ADHD, which requires specifi c appraisal and treatment.
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5. Diagnosis
Questions to be answered:
5.1. What are the diagnostic criteria for ADHD in children and adolescents?
5.2. How is ADHD diagnosed in children and adolescents? Who must diagnose it?
5.3. Which evaluation areas must be included in the diagnosis of ADHD?
5.4. In the diagnosis of ADHD in children and people: Is the neuropsychological assessment 
necessary?
5.5. In the diagnosis of ADHD in children and adolescents: Is the psychopedagogical assess-
ment necessary?
5.6. In the diagnosis of ADHD in children and adolescents: Are supplementary examinations 
necessary?
5.7. In the diagnosis of ADHD in children and adolescents: Which entities would the differen-
tial diagnosis have to be carried out with?
5.1. What are the diagnostic criteria for ADHD in children 
and adolescents?
Summary of scientifi c evidence
There are two international classifi cation systems:
 – Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR) (APA, 
2001)110
 – International Classifi cation of Mental Disorders (ICD-10) (WHO, 1992)111.
The diagnostic criteria of DSM-IV-TR and ICD-10 are found in Appendix 2.
The specifi c criteria that are included in DSM-IV-TR and in ICD-10 include 
a similar list of 18 symptoms, referring to inattention, hyperactivity and 
impulsivity behaviour.
The codes of the attention defi cit hyperactivity disorder (314.xx), are:
 – F90.0. Combined type (314.01).
 – F98.8 Predominantly inattentive type (314.00).
 – F90.0 Predominantly hyperactive-impulsive type (314.01).
 – F90.0 Attention-Defi cit/Hyperactivity Disorder NOS (314.9).
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Both classifi cation systems coincide on several important points:
 – Onset of symptoms before the age of 6 (ICD-10) or 7 years (DMS-IV-TR).
The NICE guideline (2009)2 recommends that ADHD can be diagnosed in 
some cases when the onset of symptoms takes place between the age of 7 and 
12 years.
 – the symptoms must be maintained throughout time (persist for at least 6 
months).
 – must be present in different situations of the child’s life,
 – must cause a functional impairment, and
 – the symptoms cannot be explained any better by other disorders.
Despite the similarities described, there is not total agreement between the two 
classifi cations.
A specifi c characteristic of ICD-10 not shared by DSM-IV-TR is the requirement 
of the presence of three essential symptoms to make a diagnosis of ADHD 
referring to inattention, hyperactivity and impulsivity behaviours.
It requires at least six inattention, three hyperactivity and one impulsivity 
symptoms, establishing four diagnostic categories:
1. Activity and attention disorder.
2. Hyperkinetic conductdisorder, in this case, hyperkinetic disorder is accom-
panied by a behaviour disorder.
3. Other hyperkinetic disorders.
4. Hyperkinetic disorders NOS.
However, in agreement with DSM-IV-TR, both the attention diffi culties and 
the hyperactivity-impulsivity, can produce a positive diagnosis. Thus, the 
current phenotype classifi cation, according to DSM-IV-TR, poses the existence 
of three different subtypes of ADHD. It distinguishes a “combined subtype” 
(ADHD-C), when all the criteria for attention defi cit and hyperactivity-
impulsivity are satisfi ed; a “predominantly attention defi cit subtype” (ADHD-I) 
and a “hyperactive-impulsive subtype” (ADHD-HI), when six or more criteria 
of one type and less than six criteria of the opposite factor are satisfi ed.It also 
distinguishes a “NOS subtype”.
Another specifi c characteristic of ICD-10 and not shared by DSM-IV-TR is that 
the presence of anxiety or mood alterations is a diagnostic exclusion criterion.






CLINICAL PRACTICE GUIDELINES IN THE SPANISH NHS 55
A SR conducted by the NICE guideline (2009)2 identifi ed clinical, genetic, 
environmental and neurobiological factors associated with ADHD or that 
associate it with high levels of ADHD symptoms in the general population, 
which are suffi cient to validate the diagnostic construct of ADHD.The review 
concludes that ADHD is contextualised as the extreme of a continuous trait that 
is distributed through the population; the distinction from normality being made 
by the presence of high levels of ADHD symptoms when they are accompanied 
by signifi cant impairments in the functioning of the child, as defi ned by the 
diagnostic criteria of DMS-IV-TR and of ICD-10.
Among the limitations presented by the DSM-IV-TR and ICD-10 classifi cations, 
the non-inclusion of necessary modifi cations for different age groups and sexes 
must be mentioned.




Despite the fact that today’s diagnostic criteria do not permit the diagnosis of 
ADHD in children and adolescents with pervasive developmental disorders, a 
signifi cant number of these patients also present compatible symptoms with 
ADHD, which requires specifi c appraisal and treatment.
Currently, both the DSM-IV-TR criteria and the ICD-10 criteria are undergoing 





To diagnose ADHD in children and adolescents the use of the diagnostic 
criteria of DSM-IV-TR or CIE-10 are recommended.
5.2. How is ADHD diagnosed in children and adolescents? 
Who must diagnose it?
The answer is based on the AAP (2000)112, SIGN (2005)1, AACAP (2007)72 and NICE (2009)2 
guidelines.
Summary of scientifi c evidence
The diagnosis of ADHD is exclusively clinical, and must be based on the 
presence of the typical symptoms of the disorder, backed by a clear functional 
repercussion in the personal, family, academic and/or social areas, and after 
having excluded other disorders or problems that might be justifying the 
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Recommendations
D 5.2.1.
The diagnosis of ADHD in children and adolescents is exclusively
clinical.
D 5.2.2.
The diagnosis of ADHD in children and adolescents must be carried out 
by a health professional with training and experience in the diagnosis of 
ADHD and its most frequent comorbidities.
5.3. Which evaluation areas must be included in the diag-
nosis of ADHD?
The answer is based on the AAP (2000)112, SIGN (2005)1, AACAP (2007)72 and NICE (2009)2 
guidelines, the MA of Biederman et al.(2006)113 and the review of Linnet et al. (2003)64.
Summary of scientifi c evidence
The diagnosis must be made based on the information obtained through 
the clinical interview with the child or adolescent, and with the parents.
The information from the school must be evaluated as well as the physical 
examination of the child.
The family background must also be appraised (given the genetic infl uences of 
the disorder) and the family functioning.
Information must be obtained about the pregnancy, birth and perinatal period, 
about the psychomotor development, pathological background and mental 
health history of the child (especially previous psychiatric treatments).
Although the majority of children with ADHD do not have an outstanding 
medical history and the physical examination is normal, both the anamnesis 
and physical examination can help rule out associated neurological processes 
and other causes that might justify the symptoms (AAP, 2000112; SIGN, 20051; 
AACAP, 200772; NICE, 20092).
Experts’ 
opinion 4
History of the current disease
Summary of scientifi c evidence
Parents must be interviewed regarding the child’s current problems, the nature 
of the symptoms (frequency, duration, situational variation of the symptoms), 




The information obtained from the parents has proved, in general, to be validand 
reliable for the appraisal and diagnosis (SIGN, 2005)1. A recent MA of two 
RCTs has shown that the information obtained from the parents in the appraisal 
of ADHD symptoms during clinical trials is just as feasible as the information 
obtained from the teachers (Biederman et al., 2006)113.
MA of RCT
1+
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Family background
Summary of scientifi c evidence
Questions must be asked about the history of psychiatric and specifi c disorders 
of ADHD in the family.Scientifi c evidence has clearly been established with 





See chapter 4. ADHD, where the genetic factors of ADHD are described.
Personal background
Obstetric and perinatal history
Summary of scientifi c evidence
Previous guidelines recommend requesting information from the parents 
about the obstetric and perinatal history, as obstetric complications have been 
found that are associated with ADHD, such as intrauterine growth retardation, 
prematurity and toxic habits during pregnancy –alcohol and tobacco- (SIGN, 
20051; Linnet et al., 200365).
SR cohort and 
control case 
studies 2+
See chapter 4. ADHD, where the risk factors of ADHD are described.
Developmental history
Summary of scientifi c evidence
Apart from the patient’s perinatal history, the clinician must obtain information 
about the physical and motor development, the keydevelopmental milestones, 
the medical and mental health history (above all respect to any previous 




Summary of scientifi c evidence
In patients with ADHD, the aim of the physical examination is to appraise 
other medical diseases that may be the cause or contribute to the symptoms 
that give rise to the consultation, as well as potential contra-indications for 
pharmacological intervention.
Neurological signs and minor physical anomalies do not exclude or confi rm the 
diagnosis of ADHD (SIGN, 2005)1.
Experts’
opinion 4
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Psychopathological examination
Summary of scientifi c evidence
The clinician must perform a complete psychopathological examination, 





Summary of scientifi c evidence
Given that the majority of patients with ADHD have diffi culties at school, 
it is important to pose specifi c questions about this fi eld, examining the 
possible presence of learning disorders and reviewing the patient’s academic 
performance over time (SIGN, 2005)1.
Experts’
opinion 4
See chapter 6. Assessment tools, where the school learning assessment tools used in our medium for the 
diagnostic appraisal of ADHD in children and adolescents are reviewed.
Data collection tools
Summary of scientifi c evidence
The development group considers that there are specifi c tools to appraise the 
symptoms of ADHD and of general psychopathology that facilitate screening 
or detection, an appraisal by intensity of the disorder and the response to 
treatment.Questionnaires must not, under any circumstances, be used as the 
only method to establish the diagnosis, nor as a substitute for a correct clinical 
interview with parents and with the child or adolescent.
Experts’
opinion 4
See chapter 6. Assessment tools, where the school learning assessment tools used in our medium for the 
diagnostic appraisal of ADHD in children and adolescents are reviewed.
Recommendations
D 5.3.1.
The diagnosis of ADHD in children and adolescents must be done via 
clinical interviews with parents and the patient, obtaining information 
from the school, reviewing family and personal background as well as 
the physical and psychopathological examination of the patient.
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5.4. In the diagnosis of ADHD in children and adolescents: 
Is the neuropsychological assessment necessary?
The answer is based on the AACAP guideline (2007)72, the reviews of Nigg et al. (2005)76, 
Sergeant et al. (2005)78, Sonuga-Barke et al. (2005)77 and the studies of Jakobson et al. (2007)114 
and Geurts et al. (2005)115.
Summary of scientifi c evidence
The neuropsychological study is not essential to diagnose ADHD.The 
neuropsychological examination enables us to discover the detailed profi le of 
cognitive functioning, and it is also useful to carry it out when the presence of 




The neuropsychological profi les in ADHD are not homogeneous and the most 
frequent cognitive defi cits cover a broad spectrum of skills considered to be 
executive functions (Nigg et al., 200576; Sergeant et al., 200578; Sonuga-Barke 
et al., 200577).
The variability in the neuropsychological profi les in children with ADHD is 
probably due to a not very precise defi nition of these executive functions and 
the use of not very specifi c neuropsychological tests.
Narrative 
reviews 3
There are currently no well-defi ned neuropsychological profi les that permit 
distinguishing different subtypes of ADHD (Geurts et al., 2005)115.
Control case 
study 2+
See chapter 6. Assessment tools, where the neuropsychological tests used in our medium for the diagnostic 
appraisal of ADHD in children and adolescents are reviewed.
Recommendations
C 5.4.1.
The neuropsychological assessment is not essential for the diagnosis of 
ADHD in children and adolescents.
 5.4.1.
The neuropsychological examination of ADHD in children and 
adolescents is useful to get to know the profi le of skills and diffi culties in 
cognitive functioning and comorbidity with specifi c learning disorders.
C 5.4.1.
To diagnose ADHD it is not necessary for there to be an alteration in the 
results of the neuropsychological tests that assess executive functions.
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5.5. In the diagnosis of ADHD in children and adolescents: 
Is the psychopedagogical assessment necessary?
The answer is based on the AACAP (2007)72 and SIGN (20051 guidelines.
Summary of scientifi c evidence
Academic impairment is frequently due to ADHD per se. In other cases, 
learning problems are present and the reason for these cannot be explained by 
ADHD. In these cases, the examination will be necessary in order to rule out 
specifi c learning disorders (AACAP, 2007)72.
Experts’
opinion 4
An appraisal by academic performance is essential for the diagnostic evaluation 
of the child or adolescent with ADHD /SIGN, 2005)1.
Experts’
opinion 4
See chapter 6. Assessment tools, where the psychopedagogical tests used in our medium for the diagnostic 
appraisal of ADHD in children and adolescents are reviewed.
Recommendations
D 5.5.1.
The psychopedagogical assessment is useful to evaluate the learning 
style and diffi culties and to establish the re-education intervention 
objectives.
5.6. In the diagnosis of ADHD in children and 
adolescents:Are supplementary examinations necessary?
The answer is based on the AAP (2000)112, SIGN (2005)1 and AACAP (2007)72 guidelines.
Summary of scientifi c evidence
There is no specifi c biological marker to be able to diagnose ADHD (SIGN 
20051, AAP 2000)112.
Although differences have been found in some studies in neuroimage and 
neurophysiologic tests between ADHD cases and control cases, these tests do 
not permit identifying individual cases (AACAP, 200772; AAP 2000112).
Case and control 
studies 2++
Blood analyses, neuroimage studies (CT and brain MRI, SPECT or PET) or 
neurophysiologic studies (EEG, evoked potentials) are not indicated in the 
diagnostic assessment of ADHD (AAP 2000112, SIGN 20051; AACAP 200772). 
These examinations will only be used if justifi ed by the physical examination 





To diagnose ADHD in children and adolescents supplementary 
laboratory, neuroimage or neurophysiological tests are not indicated 
unless the clinical evaluation justifi es this.
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5.7. In the diagnosis of ADHD in children and adolescents: 
Which entities would the differential diagnosis have 
to be carried out with?
The answer is based on the AAP (2000)112, AACAP (2007)72, NICE (2009)2 guidelines, as well as 
on the reviews of Soutullo & Diez (2007)79 and Culpepper (2006)116.
Summary of scientifi c evidence
Within the clinical evaluation of children with ADHD it must be taken 
into account that not all lively and absent-minded children have ADHD; a 
differential diagnosis must be made with other entities that can be confused 
with the disorder (AAP, 2000112; Culpepper, 2006116; Soutullo y Diez, 200779; 
AACAP, 200772; NICE, 20092).
The fi rst step, however, will be to rule out that the child’s behaviour falls within 
normality. Thus, it is important to evaluate the quantity and intensity of the 
symptoms, the permanence in time and their functional impact on the different 
situations.
The symptoms of hyperactivity, impulsivity and attention defi cit may appear in 
a wide range of disorders:
 • mental retardation
 • learning disorders,
 • pervasive developmental disorders,
 • behavioural disorders,
 • anxiety disorders,
 • mood disorders,
 • substance abuse.
 • Environmental factors:
 • stress,
 • negligence/child abuse,
 • malnutrition,
 • inconsistency in education patterns.
 • Medical disorders:
 • Posttraumatic or postinfectious encephalopathies,
 • Epilepsy,
 • Sleep disorders (sleep apnoea, restlessleg syndrome, regular extremity 
movement syndrome,
 • Perceptualdisorders (signifi cant auditory and sight defi cits),
 • Side effect of drugs (bronchodilators, antiepileptics),
 • Thyroid dysfunction,
 • Lead intoxication,
 • Ferropenic anaemia.
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6. Assessment instruments
Questions to be answered:
6.1. Which screening instruments and specifi c scales of ADHD in children and adolescents 
are useful/recommendable for the diagnosis?Which have been validated in the Spanish 
population?
6.2. In ADHD in children and adolescents? Which general or broad spectrum psychopatholo-
gyscales are useful/recommendable?Which have been validated in the Spanish popula-
tion?
6.3. In ADHD in children and adolescents? Which interviews are useful/recommendable for 
the diagnosis? Which have been validated in the Spanish population?
6.4. In ADHD in children and adolescents? Which neuropsychological and intelligence tests 
are useful/recommendable?Which have been validated in the Spanish population?
6.5. In ADHD in children and adolescents? Which psychopedagogical assessment tools are 
useful/recommendable? Which have been validated in the Spanish population?
Assessing ADHD requires obtaining information from the child or adolescent, from parents 
and carers, as well as from teachers about the nuclear symptoms of ADHD in several areas, the 
duration of the symptoms and the degree of impactof this situation.The information about the 
behaviour symptoms can be obtained by several methods, which include: open-ended questions, 
specifi c questions, semistructured interviews, questionnaires and scales (AAP, 2000)112.
The ADHD assessment instruments are a means of obtaining standardised information about 
the parents’ and teachers’ perceptions of the child’s problems.The results should be interpreted 
with caution when the scales used derive from other different populations to the Spanish popula-
tion.
The aim of this section of the guideline is to review the detection and assessment tools avail-
able in the Spanish population (specifi c ADHD scales, broad spectrum scales and structured and 
semistructured interviews), as well as about the use of neuropsychological and psychopedagogi-
cal tests.
The lists presented include the main tools to assess ADHD in children and adolescents that 
are available in our medium.There are other types of questionnaires, scales and tests that have not 
been included as no translation or comparative scales have been found for the Spanish population.
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6.1. Which screening instruments and specifi c scales of ADHD in children and adolescents 
are useful/recommendable for the diagnosis?Which have been validated in the Spanish 
population?
6.2. In ADHD in children and adolescents? Which general or broad spectrum psychopatholo-
gyscales are useful/recommendable?Which have been validated in the Spanish popula-
tion?
6.3. In ADHD in children and adolescents? Which interviews are useful/recommendable for 
the diagnosis? Which have been validated in the Spanish population?
The answer is based on the technical review of the Agency for Health Care Po licy and 
Research (AHCPR) (Technical Review n.3, 1999)117, the AAP guideline (2000)112, and question-
naire validation studies.
Summary of scientifi c evidence
A technical review conducted by the Agency for Health Care Policy and 
Research (AHCPR) (Technical Review n.3, 1999)117 has reviewed the reliability 
and validity of the screening and assessment tools for the diagnosis of ADHD 
compared with the gold standard. It can be concluded from the report that broad 





Likewise, the specifi c ADHD scales, more specifi cally the Conners scales, 
1997 version, permit discriminating children with ADHD in community studies 
(sensitivity and specifi city of over 94%), although their discrimination capacity 





The development group considers that there are useful structured and 
semistructured interviews to compile information, both in clinical practice and 
in research.However, the considerable application time and the preliminary 




Table 4 presents the main specifi c scales, general psychopathology scales, and 
structured and semistructured interviews used in our medium to assess ADHD 
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Recommendations
C 6.1.1.
The specifi c scales for ADHD in children and adolescents can be used in 
addition but never as substitutes for the clinical interview, to detect the 
presence and assess the intensity of the nuclear symptoms.
 6.1.2.
The information provided by parents and teachers, via the assessment 
scales, is useful to diagnose ADHD in children and adolescents and to 
assess the evolution of the symptoms and the response to the treatment.
 6.2.1. The general psychopathology questionnaires can be used to screen 
comorbidity.
 6.3.1. Structured and semi-structured interviews are useful to establish the 
diagnosis of ADHD and its comorbidities in children and adolescents.
6.4. In ADHD in children and adolescents: 
Which neuropsychological and intelligence tests are 
useful/recommendable? 
Which have been validated in the Spanish population?
The answer is based on the AACAP (2007)72 ,SIGN (2005)1 and AAP (2000)112 guidelines.
Summary of scientifi c evidence
The neuropsychological examination is not essential as part of the normal 
assessment of ADHD, but it can be indicated to get to know the profi le of 
the cognitive functioning and comorbidity with specifi c learning disorders 
(AACAP, 200772; SIGN, 20051; AAP, 2000112).
Experts’ 
opinion 4
Children and adolescents with ADHD are no different from the general population 
in the majority of the traditional psychological tests.Neuropsychological 
attention and concentration measurements do not differentiate ADHD children 
from other disorders or controls (SIGN, 2005)1.
Case and control 
studies 2++
Table 5 presents the major intelligence and neuropsychological tests most frequently used 
and validated in our medium.
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Table 5. Intelligence and neuropsychological tests most frequently used and validated 
in our medium
Name Author / publishing house / year What does it assess? Ages
WISC-IV David Weschler / TEA Ediciones 
(2005)
Intelligence 6-16 years
WAIS-III David Weschler / TEA Ediciones 
(1999)
Intelligence 16-94 years
K ABC Kaufman / TEA Ediciones (1997) Intelligence 2.5-12.5 
years
K BIT Alan S. Kaufman, Nadeen L., 















Golden / TEA Ediciones (2001) Executive functions 7-80 years









Thurstone & Yela. Narbona (3 & 6 







Rey / TEA Ediciones (2003) Visospatial, 
visoconstructive 


























Toulouse y Pieron / TEA Ediciones 
(2007)
Attention >10 years
* There are no scales for the Spanish population.
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6.5. In ADHD in children and adolescents:
Which psychopedagogical assessment tools are 
useful/recommendable?
Which have been validated in the Spanish population?
The answer is based on the SIGN guideline (2005)1.
Summary of scientifi c evidence
The psychopedagogical assessment consists in evaluating the level of the 
child or adolescent in basic areas such as reading, writing and mathematics 
to determine if they are in agreement with their age, schooling and skills.




Table 6 presents the major psychopedagogical tests most frequently used and validated in 
our medium..
Table 5. Intelligence and neuropsychological tests most frequently used and validated 
in our medium
Name




and writing analysis 
test) and T.A.L.E.C. 
(Analysis test
On reading and 
writing in Catalan)
Cervera & Toro / TEA 
Ediciones Cervera y 
Toro / TEA Ediciones 
(1990)
Writing: Calligraphy, 
copy, dictation and 
drafting
Reading letters, 









tests). Version in 
Spanish and Catalan
Canals, Bosch, Mon- 
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7. Treatment
7.1. Psychological treatment
Questions to be answered:
7.1.1. Psychological treatment: What does it consist of? What must it include?
7.1.2. Which psychological treatment iseffective to treat ADHD in children and adolescents?
7.1.3. Psychological treatment of children and adolescents: Has it proved to be effi cient/effec-
tive in the short and long term?
7.1.4. How effective is psychological treatment of ADHD in children and adolescents?
7.1.5. In ADHD in children and adolescents? What clinical variables and standardised instru-
ments exist to evaluate the effi cacy of psychological treatment?At what moment of the 
treatment should its effi cacy be evaluated?
7.1.1. Psychological treatment: What does it consist of? What must it 
include?
The psychological interventions that have shown some scientifi c evidence of effi cacy for ADHD 
are based on the principles of cognitive behavioural therapy (CBT).The type of interventions that 
are applied are described briefl y below.
Behavioural therapy
The behaviours to be changed are defi ned based on a functional analysis of behaviour, which 
identifi es the factors that are maintaining the maladaptative behaviour. These are then observed 
and recorded, analysing the existing contingencies, and a new contingency system is construct-
ed in agreement with the objectives proposed; a reinforcement programme is planned and the 
programme is assessed during treatment.Positive reinforcements can include praise, positive at-
tention, rewards and privileges.The techniques to reduce undesired behaviours include response 
cost, isolation timeout, overcorrection, extinction and punishment.Other behaviour modifi cation 
techniques are token economy that combines positive reinforcement, response cost and contin-
gency contract.
Parent Training Programs
This is a behavioural treatment programme whose aim is to provide information about the dis-
order, to train parents in behaviour modifi cation techniques to help them manage their children 
better, to increase the parents’ competence, to improve the parent-child relationship via better 
communication and attention to the child’s development.The programmes are structured and de-
veloped in a specifi c number of sessions and are normally carried out in groups. Examples of 
programmes are: Triple P (Sanders, 2004)143; The Incredible Years (Webster-Stratton, 2004)144; 
Barkley, 199775; The Community Parent Education Program (Cunningham, 1998)145.
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Cognitive therapy with children
The aim of cognitive therapy is to identify and modify the maladaptivecognitions, emphasising 
the impact on behaviour and emotions to replace them with other, more adequate cognitions.These 
objectives are carried out through different procedures, highlighting training in self-instruction, 
self-control and problem-solving techniques.
Social Skills Training
Children and adolescents with ADHD often have relationship problems with the family; they 
have social skills diffi culties and relationship problems with peers.Social skills training uses CBT 
techniques and is normally carried out in group format.
7.1.2. Which psychological treatment is effectiveto treat ADHD in 
children and adolescents?
The answer is based on the NICE (2009)2 and SIGN (2005)1 guidelines, a Cochrane SR with 1++ 
quality by Bjornstad & Montgomery (2008)146, and a MA with 1+ quality by Van der Oord et al. 
(2008)147. The search has been updated with a RCT published in 2007 (Pfi ffner, 2007)148.
Practically all the scientifi c evidence shown studies the effi cacy of psychological interven-
tions based on behavioural therapy (BT) or cognitive behavioural therapy (CBT):
In the SR and MA conducted in the NICE CPG (2009)2 10 RCTs of studies published be-
tween 1997 and 2007 were included. The psychological interventions of all the studies included 
are based on cognitive behavioural therapy (CBT). Two RCTs only included preschool children 
and the intervention consisted in parenttraining(Bor, 2002149; Sonuga-Barke, 2001150), as in the 
two RCTs on children with ADHD with an average age of under 8 (Hoath, 2002151; Hoofdakker, 
2007152). Four RCTs included children with ADHD with an average age of over 8 and the psy-
chological intervention consisted in parenttraining and children (Bloomquist, 1991153; Fehlings, 
1991154; Pfi ffner, 1997155; Tutty, 2003156). Finally, 2 RCTs on children with an average age of over 
8 included psychological interventions with children (Antshel, 2003157; González, 2002158). The 
comparison groups included waiting list, control without treatment and normal treatment.
In the Cochrane MA and SR carried out by Bjornstad & Montgomery (2008)146 all those 
quality studies that included family therapy were included. Only 2 RCTs based on CBT satisfi ed 
the quality criteria: 1 RCT lasting for 14 months conducted by NIMH-MTA (Jensen, 1999)39, and 
1 RCT by Horn (1991)159. In the NIMH-MTA study (1999)39 a training condition was included 
for parents + social skills training for the child + intervention at school.In this study, the rel-
evant comparison condition for the MA was the attention group in the community.Horn’s study 
(1991)159 included the placebo medication alone and placebo medication + family BT intervention 
conditions in the MA.
Van der Oort, et al. (2008)147 performed a MA that included those quality RCTs that assessed 
the effi cacy of the psychological treatments published between 1985 and 2006, and in which the 
patients with ADHD has an average age of between 6 and 12. 12 RCTs satisfi ed the criteria, which 
included a psychological treatment condition based on CBT principles: Anastopoulos, 1993160; 
Antshel, 2003157; Brown, 1985161, 1986162; Fehlings, 1991154; Hom, 1990163; Hoath, 2002151; Klein, 
1997164; Miranda, 2000165, 2002166; NIMH-MTA, 199939; Pfi ffner, 1997155; Tutty, 2003156.
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Variable: ADHD symptoms 
Scientifi c evidence
There is not suffi cient scientifi c evidence to suggest that the psychological 
intervention has positive effects on the teachers’ scores in ADHD symptoms 
(4 RCTs, N=163, Tutty, 2003156; Fehlings, 1991154; Hoath, 2002151; Bloomquist, 
1991153) (SMD: -0.25 [95% CI: -0.56 to 0.07]).
RCT
1++
There is limited scientifi c evidence to suggest that the psychological 
intervention has positive effects on the parents’ scores in ADHD 
symptoms (5 RCT, N=288, Tutty, 2003156; Sonuga-Barke,2001150; 
Fehlings, 1991154; Hoath, 2002151; Hoofdaker, 2007152) (SMD: =0.57
[CI 95): -1.00 to -0.14])
RCT
1+
There is not suffi cient scientifi c evidence to suggest a positive effect of the 
psychological intervention compared with treatment in the community on 
the parents’ scores in ADHD inattention symptoms (1 RCT, N=259; Jensen, 
199939) (SMD: -0.09 [95% CI: -0.25 to 0.07]), nor hyperactivity/impulsivity 
(1 RCT, N=259; Jensen, 199939) (SMD: -0.11 [95% CI: -0.29 to 0.07]).
RCT
1++
There is not suffi cient scientifi c evidence to suggest a positive effect of the 
psychological intervention compared with treatment in the community on 
the teachers’ scores in ADHD inattention symptoms (1 RCT, N=247; Jensen, 
199939) (SMD: -001 [95% CI: -0.21 to 0.19]), nor hyperactivity/impulsivity (1 
RCT, N=247; Jensen, 199939) (SMD: -0.15 [95% CI: -0.35 to 0.05]).
RCT
1++
There is limited scientifi c evidence to suggest a positive effect of the 
psychological intervention compared with placebo treatment on the teachers’ 
scores in ADHD inattention symptoms (1 RCT, N=25; Horn, 1991159) (SMD: 
-1.98 [95% CI: -6.01 to 2.05]).
RCT
1++
In studies with ADHD in school age (6-12), there is limited scientifi c 
evidence to suggest a positive effect of the psychological intervention 
on the parents’ scores in ADHD symptoms (13 RCT,N=402; Anastopoulos, 
1993160; Antshel, 2003157; Brown, 1985161, 1986162; Fehlings, 1991154; Horn, 
1990163; Hoath, 2002151; Klein, 1997164; Miranda, 2000165, 2002166; NIMH-




In studies with ADHD in school age (6-12), there is limited scientifi c 
evidence to suggest a positive effect of the psychological intervention 
on the teachers’ scores in ADHD symptoms (12RCT, N=381; Anastopoulos, 
1993160; Antshel, 2003157; Brown, 1985161, 1986162; Fehlings, 1991154; Hoath, 
2002151; Klein, 1997164; Miranda, 2000165, 2002166; NIMH-MTA, 199939; 
Pfi ffner, 1997155; Tutty, 2003156) (SMD: 0.75 [95% CI: -0.49 to 1.01]).
RCT
1+
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Variable: Behavioural symptoms (ODD, CD) 
Scientifi c evidence
There is not suffi cient scientifi c evidence to suggest that the psychological 
intervention has positive effects on the teachers’ scores in behavioural problem 
symptoms (3 RCT, N=63,Pfi ffner, 1997155; Hoath, 2002151; Bloomquist, 1991153) 
(SMD: -012 [95% CI: -0.61 to 0.38]).
RCT
1+
There is limited scientifi c evidence to suggest that the psychological intervention 
has positive effects on the parents’ scores in behavioural problem symptoms 
(5 RCT, N=231, Bor, 2002149; Sonuga-Barke, 2001150; Hoofdaker, 2007152; 
Pfi ffner, 1997155; Hoath, 2002151) (SMD: -0.54 [95% CI: -1.05 to =0.04]).
RCT
1+
In studies with ADHD in school age (6-12), there is limited scientifi c evidence 
to suggest a positive effect of the psychological intervention on the parents’ 
scores in behavioural problem symptoms (7 RCT, N=381; Brown, 1986162; 
Horn, 1990163, 1987167; Klein, 1997164; Miranda, 2000165, 2002166; MTA, 199939) 
(SMD: 0.43 [95% CI: -0.26 to 0.60]).
RCT
1+
Variable: Social skills 
Scientifi c evidence
There is not suffi cient scientifi c evidence to suggest that the psychologica 
intervention has positive effects on the teachers’ scores in the child’s social 
skills (1 RCT, N=18, Pfi ffner, 1997155) (SMD: -0.40 [95% CI: -033 to 0.54]).
RCT
1+
There is not suffi cient scientifi c evidence to suggest that the psychological 
intervention has positive effects on the parents’ scores in the child’s social skills 




There is not suffi cient scientifi c evidence to suggest that the psychological  
intervention has positive effects on the children’s scores in social skills (1 RCT, 
N=120, Antshel, 2003157) (SMD: -0.23, (95% CI: -0.61 to 0.15]).
RCT
1++
In studies with ADHD in school age (6-12), there is limited scientifi c evidence 
to suggest a positive effect of the psychological intervention on the parents’ 
scores in the child’s social skills (5 RCT, N=292; Antshel, 2003157; Brown, 




In studies with ADHD in school age (6-12), there is limited scientifi c 
evidence to suggest a positive effect of the psychological intervention
on the teachers’ scores in the child’s social skills (5 RCT, N=203; Brown, 
1986162; Miranda, 2000165, 2002166; MTA, 199939; Pfi ffner, 1997155) (SMD: 0.71 
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Variable: Internalized symptoms 
Scientifi c evidence
There is not suffi cient scientifi c evidence to suggest that the 
psychological intervention has positive effects on the teachers’ scores 
ininternalizing symptoms (1 RCT, N=18, Pfi ffner, 1997155) (SMD: -0.20 [95% 
CI: -1.12 to 0.73]).
RCT
1+
There is not suffi cient scientifi c evidence to suggest that the psychological 
intervention has positive effects on the parents’ scores ininternalizingsymptoms 




Variable: self-effi cacy 
Scientifi c evidence
There is not suffi cient scientifi c evidence to suggest that the psychological 
intervention has positive effects on the children’s scores in self-effi cacy (3 
RCT, N=78, Bloomquist, 1991153; Fehlings, 1991154; González, 2002158) (SMD: 





There is limited scientifi c evidence to suggest that the psychological intervention 
has positive effects on the academic functioning in children at school age (6 
RCT, N=274, Brown, 1985161; Horn, 1990163, 1987167; Miranda, 2002166; MTA, 





One RCT that studies the effi cacy of the therapeutic programme “Child Life 
and Attention Skills Program” (mixed house/school implementation), by Linda 
Pfi ffner for inattention subtype ADHD, randomised a sample of 69 school 
children with ADHD-HI (recruited from school population, not clinical), 
showing that the treatment group, compared with the control group, presented 
an improvement in inattention symptoms, “sluggish cognitive tempo”, social 
and organisational skills (Pfi ffner, 2007)148.
RCT
1+
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In 2006, NICE168 published an assessment report on the effi cacy of parenttraining 
in children with behavioural disorders. Seven of the studies included patients 
with ADHD.It was concluded that the parents training programmes for of 
children with behavioural disorders, mainly oppositional defi ant disorder 
(ODD), were effi cient under the following conditions:
- Structured and based on social learning theory principles.
Including strategies to improve the parent-child relationship.
Optimal number of sessions: 8-12.
- In group or individual format.
- It would enable parents to identify their own objectives.
- Incorporated role-playing sessions and homework to improve the generalisation.
- Led by properlytrained professionals.
- Based on manual and standardised materials.
SR of RCT
1++
In the NICE Technology Assessment report (2006)168 scientifi c evidence was 
found of the effi cacy of training for parents in children with behavioural 
disorder based on the results of the SR of quality 1++ assessed: Barlow & 
Stewart-Brown, 2000169; Richardson & Joughin, 2002170; Serketich, 1996171. 
They also found scientifi c evidence of the medium and long-term effectiveness 
(Dimond y Hyde, 1999)172.
SR of RCT
1++,
In the studies included in the analysis of the scientifi c evidence of the 
psychological intervention on ADHD, both parenttraininand (social and self-
control) skills training for children appeared in a predominant way, it being 
diffi cult to determine which of the components has a greater impact on the 
effi cacy; if one of them or the combination of both NICE2.
MA of RCT
1++
In the MA by Van der Oord et al. (2008)147, in general, greater effi cacy effects 
on the ADHD symptoms have been found in those studies with a mainly 
behavioural treatment, compared with cognitive-behavioural type studies; 
these differences are not statistically signifi cant. Although there are statistically 
signifi cant differences in the effi cacy of the behavioural interventions compared 
with the behavioural cognitive interventions on the scores for ADHD symptoms 
or behavioural problems according to the teachers, they do fi nd differences in 




The cognitive-behavioural interventions for school-age children with ADHD 
must ideally last for 8 to12 sessions of 50-90 minutes of CBT/SK for children 
+ 8 sessions of 50 to 120 minutes for parents (NICE, 2009)2.
Experts 
opion 4
Summary of scientifi c evidence
There is scientifi c evidence from several RCTs of quality (1+) about the 
effi cacy of psychological interventions (CT/CBT) on ADHD and behavioural 
symptoms referred by parents (NICE-2009)2.
SR of RCT 1+
There is not suffi cient scientifi c evidence or there is only limited scientifi c 
evidence about the effi cacy of psychological interventions on ADHD and 
behavioural symptoms referred by teachers (NICE, 2009)2.
SR of RCT 1+
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The scientifi c evidence about the effi cacy of psychological interventions on 
social skills from studies of quality (1+) (NICE, 2009)2.
SR of RCT 1+
There is not suffi cient scientifi c evidence about the effi cacy of psychological 
therapy oninternalizedand self-effi cacy symptoms (NICE, 2009)2.
SR of RCT 1++
There is limited scientifi c evidence from studies of quality 1+ about the effi cacy 
of psychological therapy on academic functioning (NICE, 2009)2.
SR of RCT 1+
One RCT offers results with respect to the effi cacy of psychological treatment 
on inattention symptoms, sluggish cognitive tempo, social and organisational 
skills in a subgroup of school children with ADHD-HI (Pfi ffner, 2007)148.
RCT1+
There is strong evidence that training for parents is effective for behavioural 
disorder, including a population with ADHD (NICE, 2006)168
SR of RCT 1++
The inclusion of training programmes for parents also increases the acceptability 




The application of a behavioural training programme is recommended 
for parents of children and adolescents diagnosed with ADHD, with or 
without comorbidity.
D 7.1.2.2.
Cognitive-behavioural therapy is recommended as an initial treatment 
for ADHD in children and adolescents in any of the following situations:
 • The ADHD symptoms are mild
 • The impact of ADHD is minimal
 • There is considerable discrepancy about the frequency and intensity 
of symptoms between parents, or between these and the teachers
 • The diagnosis of ADHD is uncertain
 • Parents reject the use of medication
 • Children under 5 (although this age group is outside the scope of this 
guide).
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7.1.3. Psychological treatment of children and adolescents:
Has it proved to be effi cient/effective in the short and long 
term?
The answer is based on the NICE (2009)2, SIGN (2005)1 guidelines, and on the study by NIMH-
MTA (2004)173. The search has been updated with a RCT published in 2007 (Pfi ffner, et al., 
2007)148.
Variable: ADHD symptoms 
Scientifi c evidence
There is not suffi cient scientifi c evidence to suggest that the psychological 
intervention has positive effects on the teachers’ scores in ADHD symptoms 
6 months after treatment (2 RCT, N=101, Tutty, 2003156; Fehlings, 1991154) 
(SMD: -0.05 [95% CI: -0.4 to 0.35]).
RCT
1++
There is scientifi c evidence to suggest that the psychological intervention has 
positive effects on the parents’ scores in ADHD symptoms 6 months after the 
intervention (3 RCT, N=174, Tutty, 2003156; Sonuga-Barke, 2001150; Fehlings, 
1991154) (SMD: -0.91 [95% CI: -1.23 to -0.59]).
RCT
1++
No differences were found in the NIMH-MTA study in the ADHD symptoms 
after one year’s follow-up between the group of patients with ADHD who 
received behavioural treatment and the group of patients with ADHD that 
received normal community treatment (MTA, 2004)173.
RCT
1+
Variable: Behavioural symptoms (ODD, CD) 
Scientifi c evidence
There is not suffi cient scientifi c evidence to suggest that the psychological 
intervention has positive effects on the teachers’ scores in behavioural problem 
symptoms 3 to 4 months after treatment (1 RCT, N=18, Pfi ffner, 1997155) (SMD: 
-0.13 [95% CI:-1.05 to 0.80]).
RCT
1+
There is scientifi c evidence to suggest that the psychological intervention has 
positive effects on the parent’s scores in behavioural problem symptoms, 3 
to 5 months after treatment (2 RCT, N=68, Sonuga-Barke, 2001150; Pfi ffner, 
1997155) (SMD: -0.51, (95% CI: -1.01 to -0.01]).
RCT
1++
No differences were found in the NIMH-MTA study in behavioural disorder 
symptoms after one year’s follow-up between the group of patients with ADHD 
that received behavioural treatment and the group of patients with ADHD that 
received normal community treatment (MTA, 2004)173.
RCT
1+
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Variable: Social skills 
Scientifi c evidence
There is not suffi cient scientifi c evidence to suggest that the psychological 
intervention has positive effects on the teachers’ scores in the child’s social 
skills 3 months after treatment (1 RCT, N=18, Pfi ffner, 1997155) (SMD: -0.06 
[95% CI: -0.98 to 0.18]).
RCT
1+
There is not suffi cient scientifi c evidence to suggest that the psychological 
intervention has positive effects on the parents’ scores in the child’s social skills 
3 months after treatment (2 RCT, N=138, Antshel, 2003157; Pfi ffner, 1997155) 
(SMD: 0.06 [95% CI: -0.29 to 0.42]).
RCT
1++
There is not suffi cient scientifi c evidence to suggest that the psychological 
intervention has positive effects on the children’s scores in social skills 3 






There is not suffi cient scientifi c evidence to suggest that the psychological 
intervention has positive effects on the teachers’ scores in internalizedsymptoms 
3 months after treatment (1 RCT, N=18, Pfi ffner, 1997155) (SMD: -0.19 [95% 
CI: -1.11 to 0.74]).
RCT
1+
There is not suffi cient scientifi c evidence to suggest that the psychological 
intervention has positive effects on the parents’ scores in internalizedsymptoms 






There is limited scientifi c evidence to suggest that the psychological intervention 
has positive effects on the children’s scores in self-effi cacy 5 months after 






In the 2007 RCT that studies the effi cacy of the therapeutic programme  “Child 
Life and Attention Skills Program” (mixed home/school implementation), by 
Linda Pfi ffner for inattention subtype ADHD, the improvement in the symptoms 
of inattention, sluggish cognitive tempo, social and organisational skills, was 
maintained 3 months after treatment (Pfi ffner, et al., 2007)148.
RCT
1+
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Summary of scientifi c evidence
There is strong scientifi c evidence to suggest that psychological intervention 
maintains positive effects on ADHD and behavioural problem symptoms 
referred to by parents in the short-medium term follow-up (3-6 months) (NICE, 
2009)2.
RCT 1++
There is limited scientifi c evidence to suggest that the psychological 
intervention has positive effects on self-effi cacy in the short-medium term 
follow-up (3-6 months). However, positive results were not obtained in the 
post-treatment assessment, so it is diffi cult to attribute the improvement to the 
specifi c psychological intervention on self-effi cacy; this may possibly be due to 
a secondary benefi t of the behavioural intervention on ADHD and behavioural 
alterations (NICE, 2009)2.
RCT 1++
There is no scientifi c evidence that the psychological intervention has positive 
effects on the short-term follow-up (3-6 months) on ADHD and behavioural 
problem symptoms referred to by teachers, social skills and internalized 
symptoms (NICE, 2009)2.
RCT 1++
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7.1.4. How effective is the psychological treatment of ADHD in 
children and adolescents?
The answer is based on the NICE guideline (2009)2 and on the RCT by Hoofdaker (2007)152.
Summary of scientifi c evidence
The NICE guideline has conducted a cost-effectiveness study of the training 
interventions for parents of children with ADHD, both in group format and 
individually (NICE, 2009)2. Those quality studies that included a behavioural 
intervention for parents were included, both at group level (Hoath, 2002)151, 
and individually (Sonuga-Barke, 2001150; Bor, 2002149). The analysis concludes 
that the behavioural training treatment for parents in group format is more cost-




A recent study has assessed the effectiveness in clinical practice of the 
training treatment for parents, as a contribution to the normal community 
treatment in patients and families (Hoofdaker, 2007152). The study randomly 
distributed 96 patients into two groups:training for parents + normal treatment 
compared with normal treatment.The results of the effectiveness in post-
treatment and at the 6-month follow-up were analysed.The normal treatment + 
parenttrainingwas superiorto normal treatment inreducingbehavioural problems 
and internalizedsymptoms.No differences were found in ADHD symptoms and 
parental stress.The improvement in behavioural and internalizedsymptoms was 
maintained in the mid-term follow-up (6 months)
RCT
1+
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7.1.5. In ADHD in children and adolescents:What clinical variables 
and standardised instruments exist to evaluate the effi cacy of 
psychological treatment?At what moment of the treatment 
should its effi cacy be evaluated?
The response is based on the experts’ opinions.
Summary of scientifi c evidence
The development group considers that to evaluate the effi cacy of the 
psychological treatment, clinical variables will be taken into account, such 
as the intensity of the nuclear and associated symptoms, the family, academic 
and social repercussion.The information of the teachers and/or the information 
obtained via the standardised tools will be assessed based on the clinical 
interview with the child and parents.
Experts’ 
opinion 4
See chapter 6. Assessment tools, where the main assessment tools for ADHD in children and adolescents 
used in our medium are reviewed.
Recommendations
 7.1.5.1.
The effi cacy, possible adverse effects and therapeutic compliance must 
be assessed in psychological treatment programmes of children and 
adolescents with ADHD. The assessment of the treatment will be carried 
out 3 months after the start, at the end (in case of having a defi ned time 
limit), or when the clinician deems this appropriate.
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7.2. Psychopedagogical Treatment
Questions to be answered:
7.2.1. Psychopedagogicalintervention: What does it consist of? What must it include?
7.2.2. Which psychopedagogical interventions are effi cient/effective to treat ADHD?
7.2.3. Psychopedagogicalre-education: What does it consist of? What must it include?
7.2.4. In ADHD in children and adolescents? What adaptations are useful/recommendable in 
the school context?
7.2.5. Is the training given to teachers effi cient/effective? What must it include?
7.2.6. In ADHD in children and adolescents: What clinical variables and standardised instru-
ments exist to evaluate the effi cacy of psychopedagogical treatment? At what moment of 
the psychopedagogical treatment should its effi cacy be evaluated?
7.2.1. Psychopedagogical intervention: What does it consist of? What 
must it include?
The psychopedagogical intervention represents a series of institutionalised intervention practices 
in the learning fi eld, either as prevention and treatment of disorders, or as a modifi cation of 
the school learning process (Castorina et al., 1989)174. The psychopedagogical intervention seeks 
to understand the teaching-learning processes in school and in out-of-school contexts, and effi -
ciently intervene in their improvement, allowing the student to address the learning situations in 
a more effi cient manner.
7.2.2. Which psychopedagogical interventions are effi cient/effective to 
treat ADHD?
The answer is based on the SIGN guideline (2005)1, the review by Wells et al. (2000)175 on Irvine’s 
Paraprofessional Programme (used in the MTA study), the study of the programme by Langberg 
et al. (2008)176 and the MA by DuPaul et al. (1997)177.
Many experiments have been carried out with interventions in schools to improve the aca-
demic functioning of children and adolescents with ADHD, some of them with a multimodal or 
multisystemic nature such as Irvine’s Paraprofessional Programme, used in the MTA study, which 
includes individual interventions with the children and also training for teachers and parents, all 
of which has the aim of improving the general academic performance.
Scientifi c evidence
The Irvine Paraprofessional Program (Wells, et al., 2000)175 is an educational 
intervention based on behaviour modifi cation techniques, designed to treat 
problems at school for children with ADHD. The results of Wells, et al. 
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More specifi c interventions have also shown an improvement in general 
academic performance.A specifi c teaching system in academic skills and 
competences is relatively easier and simpler to execute than other multi-
programmes.
One of these systems would be the individual intervention proposed by 
Langberg et al.(2008)176 to teach academic skills to children with ADHD to 
held them be successful in the school environment, covering the organisation 
and management of tasks, and fostering adequate behaviours to carry them out 
(working in silence, raising their hands, persistence in the task, etc.).
RCT
1+
The MA by DuPaul, et al. (1997)177 on psychosocial interventions in the school 
context points out that contingency management strategies and academic 
interventions are more effective for behavioural change than cognitive-




Summary of scientifi c evidence
The SIGN guideline (2005)1 indicates that children with ADHD require a 
personalised school intervention programme that includes both academic or 
instruction actions, and behavioural actions.
MA of RCT1+
The psychopedagogical interventions have shown an improvement in general 





Children and adolescents with ADHD require a personalised intervention 
programme in school that will include academic, social and behavioural 
aspects (adapted from SIGN 4.1.2)1.
 7.2.2.2. The school programmes for ADHD must involve the majority of the 
teaching staff to facilitate its effi cacy.
 7.2.2.3.
School programmes for ADHD may include: Adaptations in the 
classroom, training for teachers, behaviour modifi cation techniques and 
other strategies to handle ADHD in the classroom (application of rules 
and limits, presentation of tasks, assessment systems for students with 
ADHD, etc.).
7.2.3. Psychopedagogicalre-education: What does it consist of? What 
must it include?
Psychopedagogical re-educationis personalised school tutoring that is provided during or after 
school hours and whose aim is to palliate the negative effects of ADHD in children or adolescents 
who suffer from it, in connection with their academic competence or learning.Emphasis is placed 
on the negative impactof the attention defi cit, impulsivity and hyperactivity in the school learning 
process.
Psychopedagogical re-education must include actions aimed at:
 • Improving the academic performance in the different areas, instrumental areas and the more 
specifi c areas for each school year.
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 • Working on habits that foster appropriate behaviour for learning (such as managing the time-
table and controlling the school agenda) as well as study techniques (prereading, careful read-
ing, analysis and underlining, synthesis and diagrams or summaries).
 • Preparing and teaching strategies to prepare for exams.
 • Improving self-esteem with respect to the tasks and study, identifying positive skills and in-
creasing motivation for achievement.
 • Teaching and promoting appropriate and facilitating behaviour for correct study and compli-
ance with tasks.
 • Reducing or eliminating maladaptativebehaviour such as defi ant behaviour and bad organisa-
tion habits.
 • Maintaining coordination actions with the specialist that is treating the child or adolescent 
and with the school, to establish common goals and offer the teacher strategies to manage the 
child or adolescent with ADHD in the classroom.
 • Intervening with parents to teach them to put into practice, monitor and foster the continued 
use of study organisation and management tasks at home.
The response is based on the study of the programme of Langberg et al. (2008)176.
Summary of scientifi c evidence
Langberg, et al. (2008)176 examined the effi cacy of a psychopedagogical 
organisational skill intervention programme for children with ADHD (n=37). 
Participations in the intervention group achieved a signifi cant improvement, 
unlike the control group, in organisation and competences to do homework 
during the intervention.The improvement was maintained for 8 weeks.The 
children in the intervention group also showed improvements in the teachers’ 
scores in academic performance (SMD:87) and lower parents’ scores in 
problems in doing homework (SMD: 71).
This study suggests that applying interventions focused on organising 






Personalised and specifi c treatment of teaching in academic competences 
and skills is recommended for children and adolescents with ADHD and 
repercussion on academic performance.
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7.2.4. In ADHD in children and adolescents:
What adaptations are useful/recommendable in the 
school context?
Interventions carried out at school must contemplate any adaptations considered necessary, which 
should include some or all of the following (Mena, et al., 2007)178:
 • Use behaviour modifi cation techniques: positive tutoring, token economy systems, 
modelling, extinction, response cost, time-out technique, overcorrection, etc.
 • Teach the child or adolescent training techniques in self-control, problem-solving, social 
skills training or relaxation techniques.
 • Clearly defi ne, together with the child or adolescent, the short and long-term goals, both 
referring to curricular contents and to their behaviour at school.
 • Adapt the environment and control the level of distracting elements in the classroom, 
situating the child or adolescent in a place where they can easily be supervised and at a 
distance from any stimuli that might distract them.
 • Adapt the tasks and expectations to the child’s or adolescent’s traits, and, if necessary, 
reduce the requirement level or simply the instructions given to them to carry out the 
tasks, using short, simple and clear instructions.
 • Adapt the assessment method, modifying the way of administering and assessing the 
tests and examinations.
 • Supplement the oral instructions with visual instructions and reminders.
 • Offer the child or adolescent aid systems to control their tasks every day, and complete 
short and long-term tasks (control of agenda, reminders, etc.).
 • Achieve an adequate level of motivation in students, offering frequent feedback about 
their improvements in behaviour and effort.
The answer is based on the NICE (2009)2, ICSI (2007)179 and AAP (2001)180 guidelines.
The NICE CPG (2009)2 has conducted a SR and MA of studies that assess the effi cacy of the 
teacher’s interventions (academic and environmental adaptations), and only one study was found 
that compared the intervention of the teacher with non-invention (Kapalka, 2005)181.
Scientifi c evidence
The ICSI guideline (2007)179 indicates that non-pharmacological interventions, 
such as managing contingencies and educational modifi cations and adaptations 
in the classroom, have shown that they help children with ADHD cope and 




The AAP guideline (2001)180 indicates that when ADHD has a signifi cant 
impact on the child’s academic competence, schools must make adaptations to 
help them in the classroom.
Experts’ 
opinion 4
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Teacher’s adaptations
Scientifi c evidence
There is limited scientifi c evidence to the extent that the adaptations in the 
school context have positive effects on the behaviour problems in the classroom 
(1 RCT, N=86, Kapalka, 2005181) (SMD: -1.47 [95% CI: -1.94 to -0.99]).
RCT1+
Summary of scientifi c evidence
The NICE guideline (2009)2 indicates that children and adolescents with 
ADHD require a school intervention programme that includes academic and 
behavioural actions, and recommends that teachers who have received training 






When ADHD has a signifi cant impact on the child’s or adolescent’s 
academic competence, the schools should make adaptations to help 
them in the classroom.
7.2.5. Is the training given to teachers effi cient/effective? What must it 
include?
Teachers are often the fi rst to identify a child or adolescent with ADHD. Anyone who does not 
have proper training in the disorder may not suitably appraise the alert signals.
The training programmes for teachers should include:
 • General information about the disorder: symptoms, comorbidity, nature, incidence, de-
velopment, prognosis, treatment and impacton behaviour and learning.
 • Behavioural modifi cation techniques aimed at increasing or maintaining desirable be-
haviour and at eliminating or reducing undesirable behaviour in children or adolescents 
with ADHD.
 • Cognitive techniques: For learning and practice of self-instructions and training in self-
control in children and adolescents with ADHD.
 • Educational strategies with adaptations aimed at improving functioning in the classroom 
and learning.
The answer is based on the NICE guideline (2009)2, the review by Miranda, et al. (2006)182 
and the study by Ohan, et al. (2008)183.
Information to teachers about ADHD
The NICE CPG (2009)2 has conducted a SR and MA on studies that assess the effi cacy of giving 
information to teachers about ADHD. 3 studies have been included from the search. In one study, 
a leafl et was sent to the teachers with information about ADHD, as well as management strategies 
in the classroom that had previously proved to be effi cient (DuPaul & Eckert, 1997177; Purdie, 
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2002184; Tymms, 2006)185. This same study also assessed the effectiveness of this intervention, 
adding explicit information about which of their students may have ADHD (via a screening ques-
tionnaire in the classroom) (Tymms, 2006)185. In a third study, information was sent to teachers 
at the start of the year (CHADD Educators’ Manual; Fowler, et al., 1992)186, and updates were 
sent of this same information, accompanied by suggestions from parents that emerged from the 
parents’ training (Corkum, et al., 2005)187.
Scientifi c evidence
There is not suffi cient scientifi c evidence about whether informing teachers 
via a leafl et on ADHD has possible effects on the ADHD symptoms (1 RCT, 
N=25.482; Tymms, 2006)185 (SMD: -0.19 [95% CI: -0.39 to 0.01]), performance 
in mathematics (1 RCT, N=25,482; Tymms, 2006)185 (SMD: -0.05 [95% CI: 
-0.18 to 0.09]), and reading (1 RCT, N=25.482; Tymms, 2006185) (SMD: -0.02 
[95% CI: -0.17 to 0.12]).
RCT 1+
There is limited scientifi c evidence about whether information to teachers via 
a leafl et on ADHD, adding explicit informationabout which of their students 
may have ADHD (via a screening questionnaire in the classroom) may have 
positive effects on performance in mathematics (1 RCT, N=25,482; Tymms, 
2006185) (SMD: 0.15 [95% CI:-0.01 to 0.28]), and reading (1 RCT, N=25.482; 
Tymms, 2006185) (SMD:0.19 [95% CI: -0.04 to 0.34]). On the contrary, there is 
not suffi cient scientifi c evidence about the effect on ADHD symptoms (1 RCT, 
N=25,482; Tymms, 2006)185 (SMD: -0.13 [95% CI: -0.32 to 0.07]).
RCT 1+
There is limited scientifi c evidence about whether information to 
teachersaccompanied by training for parents has positive effects on the ADHD 
symptoms (1 RCT, N=30, Corkum, 2005187) (SMD: -1.15 (CI 95%: -2.03 to 
-0.28]), not on behavioural symptoms (1 RCT, N=30; Corkum, 2005187) (SMD: 
0.08 [95% CI: -0.88 to 0.72]).
RCT 1+
Ohan et al. (2008)183 conducted a study with teachers (n=140), which 
investigated their knowledge of ADHD and its impact on behaviour reports, and 
their perceptions of children with ADHD. The results suggest that the teachers 
showed a good general knowledge of ADHD, knowledge of the symptoms and 
diagnosis, and limitation in the knowledge of the etiology and treatment.
The results suggest that a high percentage of teachers have a good knowledge 
of ADHD and that this has a positive impact on their behaviour and perceptions 
(e.g. to seek help for children with ADHD and/or perceive the benefi t of treating 
a child) and cooperate with the ADHD professionals.
However, they also predicted that these children would have a more disruptive 
behaviour in the classroom, and they informed of less confi dence in their skills 




Training teachers includes psychoeducation about the disorder, modifi cation of dysfunctional 
opinions with respect to it, and training in behavioural patterns.
The NICE CPG (2009)2 has conducted a SR and MA on studies that assess the effi cacy of 
training teachers, fi nding one single quality study (Bloomquist, 1991)153.
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Scientifi c evidence
There is not suffi cient scientifi c evidence that training for teachers compared 
with non-intervention has positive effects on the scores in ADHD symptoms 
(1 RCT, N=52, Bloomquist, 1991)153 (SMD: -0.13 [95% CI: -0.82 TO 0.57]), 
or on behavioural problems (1 RCT, N=52, Bloomquist, 1991153) (SMD: -0.33 
[95% CI: -1.03 to 0.37]).
RCT 1+
There is not suffi cient scientifi c evidence that training for teachers in multimodal 
treatment, compared with non intervention, has positive effects on the scores 
in ADHD symptoms (2 RCT, N=361, Bloomquist, 1991153; Braswell, 1997188) 
(SMD: -0.13 [95% CI: -0.80 to 0.53]), or on behavioural problems (2 RCT, 
N=361, Bloomquist, 1991153; Braswell, 1997188) (SMD: -0.49 [95% CI: -1.16 
to 0.18]).
RCT 1-
There is not suffi cient scientifi c evidence that training for teachers in multimodal 
treatment, compared with training for teachers, has positive effects on the scores 
in ADHD symptoms (1 RCT, N=52, Bloomquist, 1991153) (SMD:0.05 [95% 
CI:-0.39 to 0.50]), or on behavioural problems (1 RCT, N=52, Bloomquist, 
1991153) (SMD: -0.09 [95% CI: -0.57 to 0.56]).
RCT 1+
A recent study conducted in Spain (Miranda, 2006)182 emphasises the 
importance of training teachers in the management of ADHD combined 
subtype, achieving by way of a psychopedagogical intervention (based mainly 
on a training programme of 8 sessions lasting for 3 hours each) a signifi cant 
reduction in the hyperactivity and impulsivity symptoms in agreement with 
the teachers’ scores.In addition, an improvement was observed in the lack of 





It is recommendable for teachers to receive training that enables them 
to detect ADHD alert signals and to manage ADHD in children and 
adolescents at school.
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7.2.6. In ADHD in children and adolescents
What clinical variables and standardised instruments exist to 
evaluate the effi cacy of psychopedagogical treatment
At what moment of the psychopedagogical treatment should its 
effi cacy be evaluated?
The response is based on the experts’ opinions. 
Summary of scientifi c evidence
The development group considers that to evaluate the effi cacy of the 
psychopedagogical treatment, clinical variables will be taken into account, 
such as the intensity of the nuclear and associated symptoms, the family, 
academic and social repercussion.The information from the teachers and/or the 
information obtained via the standardised tools will be assessed based on the 
clinical interview with the child and parents.
Experts’
opinion 4
See chapter 6. Assessment tools, where the main assessment tools for ADHD in children and adolescents 
used in our medium are reviewed.
Recommendations
 7.2.6.1.
The effi cacy and possible adverse effects of psychopedagogical 
intervention that is being carried out must be assessed in the 
psychopedagogical treatment programmes of children and adolescents 
with ADHD at least once every school year whilst the treatment lasts.
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7.3. Pharmacological treatment
Questions to be answered:
7.3.1. What drugs for ADHD are available in Spain?
7.3.2. In ADHD: What pharmacological treatments are effi cient/effective? How safe are the 
pharmacological treatments?
7.3.3. In ADHD: How effective are pharmacological treatments in the short and long term?
7.3.4. In ADHD: When and with what criteria must pharmacological treatment be started?
7.3.5. In ADHD: What criteria are used to choose the drug? What are the start, suppression and 
maximum dose guidelines? Which are the fi rst and second choice drugs?
7.3.6. What are the most frequent (short term) side effects? How must the side effects be ad-
dressed?
7.3.7. In ADHD: How long should the pharmacological treatment last?
7.3.8. In ADHD: Are supplementary examinations required before starting the pharmacologi-
cal treatment in children and adolescents?
7.3.9. What is the pharmacological strategy when there is a partial response, side effects or 
contraindication?How are the different methylphenidate presentations combined?How 
to make the transition from stimulants to atomoxetine?
7.3.10. In which ADHD subtypes is pharmacological treatment more effi cient?
7.3.11. Are there differences in response depending on the gender or age?
7.3.12. Which physical parameters must be controlled before starting the pharmacological 
treatment and during it?
7.3.13. What scientifi c evidence exists about the long-term effects in pharmacological treat-
ment? Is it associated with growth retardation?
7.3.14. Pharmacological treatment of ADHD: Does it cause addiction? Does it increase the risk 
of consumption of substances?
7.3.15. Does the effi cacy of pharmacological treatment decrease with time?
7.3.16. Do the effects remain after the pharmacological treatment has been withdrawn?
7.3.17. Is it recommendable to leave stimulant-free periods during the pharmacological treat-
ment (“therapeutic holidays”)?
7.3.18. What clinical variables and standardised instruments exist to evaluate the effi cient of 
pharmacological treatment?At what moment of the treatment should its effi cacy be 
evaluated?
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7.3.1. What drugs for ADHD are available in Spain?
Introduction
The benefi cial effect of stimulants to treat patients with hyperkinetic behaviours has been known 
for more than 70 years (Bradley, 1937)5. In the United States, both methylphenidate and dexa-
mphetamine have been available since 1955. In Spain, the Rubio laboratories sold immediate 
release methylphenidate for the fi rst time in 1981 (Taylor, 2004)189. Over the last 5 years, with the 
introduction into the market of extended release methods and of non-stimulant medication such 
as atomoxetine, an important change has occurred with respect to the pharmacological treatment 
strategies available for addressing ADHD in Spain.
There are other drugs that are not indicated for ADHD that clinicians use much less frequent-
ly to treat patients with ADHD, such as:clonidine, bupropion, modafi nil reboxetine, imipramine, 
risperidone and aripiprazole.These drugs are listed in Table 7.
Table 7. Drugs used to treat symptoms of ADHD190
Chemical type Active principle
Psychostimulants Methylphenidate*




OMAI (oxidase monoamine inhibitors)***
Reboxetine***
Dopaminergic agents Modafi nil***
* Indication approved for ADHD in Spain.
** Indication approved for ADHD in Spain on 07-04-2006. Pursuant to RD 1344/2007 which regulates the 
pharmovigilance of medicines for human use, the owner is obliged to include the pictogram in all the cata-
logues, promotional material and any other type of material for dissemination to health professionals, during 
the fi rst fi ve years following the authorisation.
*** On not having approved indication for ADHD, RD 1015/2009, which regulates the availability of medicines 
in special situations, will be complied with.
Methylphenidate
Methylphenidate is a CNS stimulant. The action mechanism that reduces the ADHD symptoms is 
not known with accuracy, although it is believed that it increases the concentrations of noradrena-
line and dopamine in the front cortex and subcortical regions associated with motivation and 
reward (Volkow, et al., 2004)191. A selective inhibition of the presynaptic dopamine transporter 
occurs, inhibiting the reuptake for dopamine and noradrenaline (Bezchlibnyk et al., 2004)192.
Methylphenidate is a drug indicated as part of the holistic treatment of ADHD in children 
over 6 and adolescents when other measures are insuffi cient (technical data sheet).In Spain, it is 
sold as immediate release and extended release formulations.
The absorption of methylphenidate is fast (less than 30 minutes) and almost complete. 
However, its absolute bioavailability is low, around 30%, due to a pronounced fi rst step. The union 
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to proteins is 15% and there are no active metabolites. It is metabolised by de-sterifi cation to rital-
inic acid (which is not found in the drug detection tests in urine) and parahydroxy-MPH. It is not 
affected by citochrome P450. It is excreted by renal way, and the absorption and bioavailability of 
methylphenidate vary from one individual to another.The maximum plasmatic concentrations are 
reached, on average, between 1 and 2 hours after administering immediate action products.It has 
a relatively short half-life, between 1 and 4 hours.Therefore, immediate release methylphenidate 
requires three doses a day to achieve maximum effective coverage 12 hours a day.
The need to administer multiple doses entails several problems, such as: Forgetting to take a 
dose, diffi culties to administer the drug at school (when to administer it, where to store it) and the 
stigmatisation of the child on taking medicine in front of companions (NICE 2009)2.
These problems gave rise to the need to develop extended release methylphenidate products 
to achieve a longer duration of the effect with one single dose.These drugs are taken once a day 
in the morning, achieving an initial effect that is similar to that of the administration of a dose of 
immediate action methylphenidate, followed by a progressive release of methylphenidate whose 
duration varies between 8 and 12 hours depending on the product.
Dosage of methylphenidate
Immediate release methylphenidate
The treatment must start with low doses, which will progressively be increased. Start with 2.5 or 5 
mg (depending on the weight of the child or adolescent), two or three times a day (breakfast, lunch 
and tea; no later than 5 pm) and increase 2.5 - 5mg a week depending on the clinical response 
and the presence of side effects.The dose ranges from 0.5 to 2 mg/kg/day with a maximum daily 
dose of 60 mg per day, according to the prospectus.The plateau effect is obtained 3 weeks after 
continuous treatment.To reduce anorexia, it can be administered with the meals or after them.
The presentations of immediate release methylphenidate available today in Spain are 5 mg, 
10 mg and 20 mg.
Extended action products consist of a mixture of methylphenidate, of immediate action and 
extended release. The difference between them is the proportion of both components and in the 
release mechanism used (Taylor, et al., 2004)189.
Extended release methylphenidate with osmotic technology (OROS)
This has been sold in Spain since April 2004. The active principle (methylphenidate) coats the tab-
let as well as being on the inside and its structure permits its gradual and progressive release over 
a period of 12 hours after one single morning dose.It must be taken in the morning, swallowed, 
not chewed or broken up.Although the technical data sheet in Spain recommends not exceeding 
the dose of 54 mg/day, in other countries, the technical data sheet of the product considers doses 
of up to 72 mg/day in adolescents. However, this recommendation does not take into account 
the patient’s weight. Some authors (Banaschewski, et al., 2006)193 and guidelines (NICE, 20092; 
AACAP, 200772) indicate higher maximum doses, up to 2 mg/kg/day, not exceeding 108 mg/day.
Extended release methylphenidate with pellet technology
It has been sold in Spain since the end of 2007. This is a drug manufactured in Germany that uses 
pellet technology.The therapeutic effect starts 30 minutes after administration, once the immedi-
ate release portion has dissolved in the stomach.The extended release part has a gastric protection 
coating that resists the acid medium, so the absorption taken place when it reaches the duodenum. 
It is administered in single doses in the morning, and its action lasts for 8 hours. The capsules 
can be opened, making them easy to administer to patients who have swallowing diffi culties. 
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This does not modify the bioavailability (Mardomingo, 2007)194. In this case, the content of the 
capsule is sprinkled onto a small spoonful of yoghurt, jam, etc., and is taken immediately with a 
little fl uid.
In order to guarantee the plasmatic concentration curve, it must be taken after a meal, as 
the permanence in the acid medium of the stomach must be guaranteed for suffi cient time for the 
extended action pellets, which have a gastric juic resistant coating, to dissolve in the small intes-
tine.The decisive factor is not the fatty content of the food, but that the food should be solid (e.g. 
muesli, bread, hot meal).
It is advisable not to exceed the dose of 2 mg/kg/day or a total dose of 60 mg/day of extended 
release methylphenidate with pellet technology.
The presentation of psychostimulants with extended release available in Spain is listed in 
Table 8.
Table 8. Presentation of extended release psychostimulants in Spain.
Product Osmotic technology Pellet technology
Technology OROS Pellets
Presentation 18, 27, 36, 54 mg 10, 20, 30, 40 mg
Immediate action 22% 
4, 6, 8,12 mg
50%
5, 10.15, 20 mg
Extended action 78%
14, 21, 28, 42 mg
50%
5, 10, 15, 20 mg
Adverse effects of methylphenidate (technical data sheet)
The most frequent adverse effects of methylphenidate are: loss of appetite and weight, insomnia, 
anxiety, restlessness, nervousness, headaches, stereotypal movements, tics, increase in heart rate 
and blood pressure. Psychoses and mania induced by the drug are much more rare (Wolraich et al., 
2007)195.
Contraindications of methylphenidate:
 • Sensitivity to psychostimulants.
 • Glaucoma.
 • Cardiovascular disease.
 • Hyperthyroidism.
 • High blood pressure.
 • Anorexia nervosa
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Atomoxetine
This is a non-stimulant drug indicated for treating children aged 6 years upwards and adolescents 
diagnosed with ADHD.
The action mechanism to treat ADHD is not at all clear, but it is believed that it works by 
selective noradrenaline reuptake inhibition in the synaptic space by blocking the noradrenaline 
presynaptic transporter.
It is believed that atomoxetine acts mainly in regions of the cortex and, unlike stimulants, 
it hardly acts in subcortical brain regions associated with motivation and reward (NICE, 2009)2.
Atomoxetine is taken in one single daily dose in the morning, although some patients may 
benefi t from dividing the daily dose into twice a day, in the morning and afternoon or fi rst thing 
at night.
The absorption of atomoxetine is fast and complete after the oral administration, reaching 
maximum plasmatic concentration (Cmax) approximately 1 to 2 hours after oral administration. 
The atomoxetine bioavailability after oral administration varies between 63% and 94%, depend-
ing on inter-individual differences, depending on the fi rst-step metabolism.
The average half-life for the elimination of atomoxetine after oral administration is 3.6 hours 
in fast metabolising patients and 21 hours in slow ones.Approximately 7% of Caucasians have 
a genotype that corresponds to absence of the function of enzyme CYP2D6 (CYP2D6 slow me-
tabolisers).Patients with this genotype (slow metabolisers) have several times greater exposure to 
atomoxetine compared with those who possess a functional enzyme (fast metabolisers).
Slow metabolisers may have a greater risk of adverse effects, and in these cases a much 
slower increase of the dose is recommended.
    A low initial dose and a slow increase in dose may considerably reduce the appearance of 
side effects in the patient.
Dosage of atomoxetine
The initial dose is 0.5 mg/kg/day for 7-14 days, in one single daily dose in the morning. 
The recommended maintenance dose is approximately 1.2 mg/kg/day (depending on the patient’s 
weight and on the available presentations of atomoxetine) in one single daily dose in the morning.
If there are side effects, the total dose of atomoxetine can be administered in two doses (morning 
and evening-night) or in one single dose at night. This latter option is especially indicated in the 
case of daytime sleepiness.The maximum dose is 100 mg/day.The safety of administering single 
doses of more than 1.8 mg/kg/day and total daily doses of over 1.8 mg/kg/day has not been sys-
tematically assessed.
Adverse effects of atomoxetine
The main adverse effects of atomoxetine are: Sleepiness, abdominal pain, nausea and vomit-
ing, loss of appetite and weight, dizziness, tiredness and slight increase in heart rate and blood 
pressure (Wolraich et al., 2007)195. The side effects are usually transient and rarely lead to the 
suppression of the treatment (NICE, 2009)2.
Hepatotoxicity has been described, but very infrequently, which is manifested with an in-
crease in hepatic enzymes and an increase in bilirubin and jaundice.If this side effect appears, its 
subsequent re-introduction is not advised (Atomoxetine technical data sheet, 2007).
Suicidal behaviour has been notifi ed (suicide attempts and suicidal ideation) in patients 
treated with atomoxetine.In the double blind RCTs, the suicide attitudes occured with a frequency 
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of 0.44% in patients treated with atomoxetine (6 of the 1357 patients treated, 1 case of attempted 
suicide and 5 suicidal ideations).There were no cases in the group treated with placebo (n=851).
The age range of children who experienced these behaviours was 7 to 12 years.It must be pointed 
out that there were very few adolescent patients included in the RCT.
Contraindications of atomoxetine (technical data sheet)
 • Glaucoma.
 • It cannot be administered with MAOIs.
 • Hypersensitivity with atomoxetine.
The atomoxetine presentations are capsules of 10, 18, 25, 40, 60 and 80 mg.
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7.3.2. In ADHD: What pharmacological treatments are effi cient/
effective?How safe are the pharmacological treatments?
The answer is based on the NICE (2009)2, SIGN (2005)1, AACAP (2007)72, AAP (2005)196 guide-
lines; SR Quality 1+ and 1++ (Banaschewski, et al., 2006193; Connor, et al., 2002197; Cheng, et al., 
2007198; Faraone, et al., 2006199), Technology Assessment Reports of NICE (2006)200 and of King, 
et al. (2006)201. Two RCTs have been found in the update of scientifi c evidence (Newcorn, et al., 
2008202; Wang, et al., 2007203).
Scientifi c evidence of studies of effi cacy, safety and
cost-effectiveness of pharmacological treatments
Methylphenidate
The NICE CPG has conducted a bibliographic review and MA of methylphenidate effi cacy stud-
ies compared with placebo in school-age children and adolescents diagnosed with ADHD.From 
this review, 12 quality RCTs have been found for the MA: Butter, 1983204; Conners, 1980205; 
Findling, 2006206; Gittelman-Klein, 1976207; Greenhill, 2002208, 2006209; Ialongo, 1994210; 
Kollins, 2006211; Kurlan, 2002212; Lerer, 1977213; Pliszka, 2000214; Wilens, 2006215. The 
NICE guideline defi nes three ranges of methylphenidate dose: Low (≤0.4 mg/kg/day, medium 
(>0.4<0.8 mg/kg/day) and high (≥0.8 mg/kg/day.).
Variable: ADHD symptoms
Scientifi c evidence
There is strong scientifi c evidence that methylphenidate in high doses (≥0.8 
mg/kg/day) signifi cantly reduces the teachers’ scores in ADHD symptoms (5 
RCT, N=806, Conners, 1980205; Greenhill, 2002208; Findling, 2006206; Ialongo, 
1994210; Pliszka, 2000214) (SMD: -0.84 [95% CI: -1.06 to -0.62]).
RCT 1++
There is strong scientifi c evidence that methylphenidate in high doses (≥0.8 
mg/kg/day) signifi cantly reduces the parents’ scores in ADHD symptoms (4 
RCT, N=747, Conners, 1980205; Greenhill, 2002208; Findling, 2006206; Ialongo, 
1994210; Pliszka, 2000214) (SMD: -0.79 [95% CI: -1.14 to -0.45]).
RCT 1++
There is not suffi cient scientifi c evidence that methylphenidate in low doses 
(≤0.4 mg/kg/day) signifi cantly reduces the teachers’ scores in ADHD symptoms 
(2 RCT, N=78, Butter, 1983204; Ialongo, 1994210) (SMD: -0.40 [95% CI: -0.95 
to 0.15])
RCT 1++
There is not suffi cient scientifi c evidence that methylphenidate in low doses 
(≤0.4 mg/kg/day) signifi cantly reduces the parents’ scores in ADHD symptoms 
(1 RCT, N=48, Ialongo, 1994210) (SMD: 0.66 [95% CI: -0.06 to 1.37]).
RCT 1++
There is scientifi c evidence that methylphenidate in medium doses (>0.4- (<0.8 
mg/kg/day) signifi cantly reduces the teachers’ scores  in ADHD symptoms (1 
RCT, N=136, Kurlan, 2002212) (SMD: -1.69 [95% CI: -2.24 to -1.14]), as well 
as the parents’ scores in ADHD symptoms (1 RCT, N=136, Kurlan, 2002212) 
(SMD: -233 [95% CI: -1.94 to -1.73]).
RCT 1++
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Variable: Behavioural problems
Scientifi c evidence
There is strong scientifi c evidence that methylphenidate in high doses (≥0.8 
mg/kg/day) signifi cantly reduces the teachers’ scores in behavioural problem 
symptoms (4 RCT, N=485, Findling, 2006206; Ialongo, 1994210; Pliszka, 2000214; 
Conners, 1980205) (SMD: -0.58 [95% CI: -0.84 to -0.31]).
RCT 1++
There is strong scientifi c evidence that methylphenidate in high doses (≥0.8 
mg/kg/day) signifi cantly reduces the parents’ scores in behavioural problem 
symptoms (2 RCT, N=378, Findling, 2006206; Conners, 1980205) (SMD: -0.73 
[95% CI: -1.06 to -0.41]).
RCT 1++
There is not suffi cient scientifi c evidence that methylphenidate in low doses 
(≥0.4 mg/kg/day) signifi cantly reduces the teachers’ scores in behavioural 
problem symptoms (1 RCT, N=48, Ialongo, 1994210) (SMD: -0.43 [95% CI: 
-1.13 to 0.27]).
RCT 1+
There is scientifi c evidence that methylphenidate in medium doses (>0.4- <0.8 
mg/kg/day) signifi cantly reduces the teachers’ scores in behavioural problems 
symptoms (1 RCT, N=136, Kurlan, 2002212) (SMD: -1.21 [95% CI: -1.72 to 
-0.71]).
RCT 1++
Variable: Clinical improvement (clinician)
Scientifi c evidence
There is strong scientifi c evidence that methylphenidate in medium doses (>0.4-
<0.8 mg/kg/day) is associated with signifi cant clinical improvement (2 RCT, 
N=186, Lerer, 1977213; Kurlan, 2002212) (RR: 3.08 [95% CI: -1.40 to 6.78]).
RCT 1++
There is strong scientifi c evidence that methylphenidate in high doses (≥0.8 
mg/kg/day) is associated with signifi cant clinical improvement (5 RCT, N=823, 
Wilens, 2006215; Gittelman-Klein, 1976207; Pliszka, 2000214; Fin dling, 2006206; 




There is scientifi c evidence that methylphenidate in high doses (≥0.8 mg/ 
kg/day) is associated with a greater presence of insomnia (3 RCT, N=318, 
Conners, 1980205; Greenhill, 2006209; Wilens, 2006215) (NNTH: 12 [95% CI: 
7 toi33]) and anorexia (4 RCT, N=634, Conners, 1980205; Greenhill, 2002208; 
Greenhill, 2006209; Wilens, 2006215) (NNTH: 16 [95% CI: 11 to 50]) compared 
with placebo.
RCT 1++
There is not suffi cient scientifi c evidence that treatment with methylphenidate 
in high doses (2 RCT, N=424, Greenhill, 2002208; Wilens, 2006215), medium 
(2 RCT, N=186, Lerer, 1977213; Kurlan, 2002212) or low doses (1 RCT, N=30, 
Ialongo, 1994210), is associated with a higher premature abandonment of the 
treatment due to adverse effects compared with placebo.
RCT 1++
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There is strong scientifi c evidence that the number of abandonments of the 
treatment, for any reason, is greater in the placebo group than in the treatment 
with methylphenidate in medium doses (2 RC, N=186, Lerer, 1977213; Kurlan, 
2002212) (NNTB: 8; [95% CI: 4 to 50]) or high doses (4 RCT, N=767, Gittelman-
Klein, 1976207; Greenhill, 2002208, 2006209; Wilens, 2006215) (NNTB: 11; [95% 
CI: 6 to 25]).
RCT 1++
Other adverse effects associated with treatment with methylphenidate that have 
been found in some RCTs have been: Abdominal pain, headaches, dizziness, 
and less frequently, anxiety, irritability and emotional lability (Ahmann, 
1993216; Barkley, 1990217; SIGN, 20051).
CPG
The NICE CPG describes the presence of tics in long-term treatment with 
methylphenidate (NICE, 2009)2, although the available scientifi c evidence 
suggests that it is safe treatment for children with ADHD and tics, and only a 
minority of children with tic disorder present worsening or do not tolerate the 




Connor, et al. (2002)197 conducted a MA on studies that assessed the effi cacy of stimulants in in 
reducing aggressions. They included a total of 28 RCTs.
Scientifi c evidence
There is scientifi c evidence that stimulants are associated with a reduction in 
aggressions according to the evaluation of clinicians (18 RCT, N=367, Aman, 
1997220; Amery, 1984221; Gadow, 1990222; Hinshaw, 1984223; 1989224; 1989225, 
1992226; Kaplan, 1990227; Klein, 1997164; Kolko, 1999228; Murphy, 1992229; 
Pelham, 1985230, 1987231, 1989232, 1990233, 1991234, 1999235; Smith, 1998236) 
(SMD: 0.76 [95% CI: 0.63 to 0.88]), parents (13 RCT, N=381, Aman, 1991237, 
1997220; Arnold, 1972238, 1976239; Barkley, 1989240; Barrickman, 1995241; Bostic, 
2000242; Bukstein & Kolko, 1998243; Gadow, 1990222; Klein, 1997164; Klorman, 
1988244; Pelham, 1999235; Taylor, 1987245) (SMD: 0.71 [95% CI: 0.42 to 1.14]), 
or teachers (16 RCT, N=381, Aman, 1991237, 1997220; Arnold, 1972238, 1976239; 
Barkley, 1989240; Barrickman, 1995241; Bostic, 1984221; Bukstein & Kolko, 
1998243; Gadow, 1990222; Klein, 1997164; Klorman, 1988244; Pelham, 1999235; 
Taylor, 1987245) (SMD: 1.04 [95% CI: 0.79 to 1.32]).
RCT 1+
Comparison between immediate release methylphenidate and extended 
release methylphenidate
Summary of scientifi c evidence
There is not suffi cient scientifi c evidence of signifi cant differences between 
extended release methylphenidate and immediate release methylphenidate 
(Fitzpatrick, 1992247; Wolraich, 2001248; Pelham, 1987231; 1990233; 2001249).
SR of RCT 1+
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Atomoxetine:
The NICE CPG has conducted a bibliographic review and MA of atomoxetine effi cacy studies 
compared with placebo in school-age children and adolescents diagnosed with ADHD. 9 RCTs on 
atomoxetine compared with placebo have been found in the review: Wernicke, 2004250; Bohnstedt, 
2005251; Brown, 2006252; Kelsey, 2004253; Michelson, 2001254, 2002255, 2004256; Spencer 2002257; 
Weiss, 2005258; and 2 RCTs of atomoxetine in ADHD children + tic disorder compared with pla-
cebo: Allen, 2005259; Spencer, 2002257. The NICE CPG defi nes three ranges of atomoxetine dose: 
low (<0.8 mg/kg/day, medium (>0.8-<1.6 mg/kg/day) and high (≥1.6 mg/kg/day.).
Cheng et al. (2007)198 have performed a MA on atomoxetine effi cacy studies compared with 
placebo in school-age children and adolescents. 7 RCTs of atomoxetine compared with placebo 
in ADHD children (with mixed comorbidity) have been found based on the review:Buitelaar, 
2006260; Kelsey, 2004253; Michelson, et al., 2001254, 2002255, 2004256; Spencer 2002257; Weiss, 
2005258; and 2 RCTs with ADHD children + DND: Kaplan, 2004261; Newcorn, 2005262.
Variable: ADHD symptoms
Scientifi c evidence
There is scientifi c evidence that atomoxetine in medium doses (>0.8- <1.6 mg/
kg/day) signifi cantly reduces the teachers’ scores in ADHD symptoms (1 RCT, 
N=171, Michelson, 2002255) (SMD: -0.43 [95% CI: -0.73 to -0.12]).
RCT 1++
There is scientifi c evidence that atomoxetine in high doses (≥1.6 mg/kg/day) 
signifi cantly reduces the teachers’ scores in ADHD symptoms (4 RCT, N=738, 
Michelson, 2004256; Bohnstedt, 2005251; Weiss, 2005258; Brown, 2006252) (SMD: 
-0.37 [95% CI: -0.54 to -0.21]).
RCT 1++
There is scientifi c evidence that atomoxetine in medium doses (>0.8- <1.6 mg/
kg/day) signifi cantly reduces the parents’ scores in ADHD symptoms (2 RCT, 
N=468, Michelson, 2001254; 2002255) (SMD: -0.65 [95% CI: -0.87 to -0.43]).
RCT 1++
There is scientifi c evidence that atomoxetine in high doses (≥1.6 mg/kg/day) 
signifi cantly reduces the parents’ scores in ADHD symptoms (6 RCT, N=916, 
Michelson, 2001254; Spencer, 2002257; Kelsey, 2004253; Michelson, 2004256; 
Bohnstedt, 2005251; Brown, 2006252) (SMD: -0.59 [95% CI: -0.71 to -0.47]).
RCT 1++
There is scientifi c evidence that atomoxetine signifi cantly reduces the teachers’ 
scores in ADHD symptoms (3 RCT, N=738, Buitelaar, 2006260; Michelson, 
2002255; 2004256) (SMD: -0.34 [95% CI: -0.63 to -0.05]).
RCT 1++
There is scientifi c evidence that atomoxetine signifi cantly reduces the parents’ 
scores in ADHD symptoms (6 RCT, N=1,595, Buitelaar, 2006260; Michelson, 
2001254, 2002255, 2004256; Spencer, 2002257; Weiss, 2005258) (SMD: -0.61 [95% 
CI: -0.84 to -0.38]).
RCT 1+
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Variable: Behavioural problems
Scientifi c evidence
There is not suffi cient scientifi c evidence that atomoxetine in medium doses 
(>0.8-<1.6 mg/kg/day) signifi cantly reduces the teachers’ scores in behavioural 
problems (1 RCT, N=416, Michelson, 2004256) (SMD: 0.00 [95% CI: -0.24 
to 0.24]).
RCT 1+
There is scientifi c evidence that atomoxetine in low doses (≤0.8 mg/kg/day) 
signifi cantly reduces the parents’ scores in behavioural problems (1 RCT, 
N=126, Michelson, 2001254) (SMD: -0.46 [95% CI: -0.83 to -0.08]).
RCT 1++
There is scientifi c evidence that atomoxetine in medium doses (>0.8-<1.6mg/
kg/day) signifi cantly reduces the parents’ scores in behavioural problems (1 
RCT, N=126 N=713, Michelson, 2001254; 2004256) (SMD: -0.31 [95% CI: -0.49 
to 0.14]).
RCT 1++
Variable: Clinical improvement (clinician)
Scientifi c evidence
There is scientifi c evidence that atomoxetine is associated with a clinical 
improvement (5 RCT, N=1.165, Kelsey, 2004253; Michelson, 2002255, 2004256; 
Spencer, 2002257; Weiss, 2005258) (SMD: -0.63 [95% CI: -0.82 to -0.44]).
RCT 1+
Variable: Psychosocial functioning and quality of life
Scientifi c evidence
There is scientifi c evidence that atomoxetine is associated with an improvement 
inpsychosocial functioning and quality of life (3 RCT, N=863, Buitelaar, 




There is scientifi c evidence that atomoxetine in medium doses (>0.8-<1.6 mg/
kg/day) signifi cantly reduces the parents’ scores in the ADHD symptoms in 
children with ADHD + tic disorder (1 RCT, N=148, Allen, 2005259) (SMD: 
-0.56, (95% CI: -0.89 to -0.23]).
RCT 1++
There is limited scientifi c evidence that atomoxetine signifi cantly reduces the 
parents’ scores in ADHD symptoms in children with ADHD + ODD (2 RCT, 
N=213, Kaplan, 2004261; Newcorn, 2005262) (SMD: -0.75 [95% CI: -1.01 to 
-0.48]).
RCT 1+
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There is limited scientifi c evidence that atomoxetine signifi cantly reduces the 
parents’ scores in behavioural problem symptoms in children with ADHD + 
ODD (2 RCT, N=213, Kaplan, 2004261; Newcorn, 2005262) (SMD: -0.42 [95% 
CI: -0.70 to -0.14]).
RCT 1+
There is scientifi c evidence that atomoxetine is associated with clinical 
improvement in children with ADHD + ODD (2 RCT, N=213, Kaplan, 2004261; 
Newcorn, 2005262) (SMD: -0.59 [95% CI: -0.84 to -0.34]).
RCT 1+
Safety and adverse effects
Scientifi c evidence
There is scientifi c evidence that atomoxetine in high doses (≥1.6 mg/kg/day) 
is associated with a greater presence of nausea (2 RCT, N=275, Michelson, 
2001254; Kelsey, 2004253) (NNTH: 10 [95% CI: 5 to 33]) than the placebo.
RCT 1+
There is scientifi c evidence that atomoxetine in high doses (≥1.6 mg/kg/día) 
(2 RCT, N=468, Michelson, 2001254; Kelsey, 2004253) (NNTH: 9 [95% CI: 5 
to 25]) and medium doses (0.8-1.6 mg/kg/day) (2 RCT, N=494, Michelson 
2001254, 2002255) (NNTH: 11 [95% CI: 6 to 33]) is associated with a greater 
presence of loss of appetite than the placebo.
RCT 1++
There is scientifi c evidence that atomoxetine in medium doses (>0.8- <1.6 
mg/kg/day) is associated more often with dyspepsia (1 RCT, 1++ N=171, 
Michelson, 2002255) (NNTH: 11 [95% CI: 6 to 33]) compared with placebo.
RCT 1++
There is scientifi c evidence that atomoxetine in medium doses (>0.8- <1.6 
mg/kg/day) is associated with a greater presence of vomiting (2 RCT, N=468, 
Michelson, 2001254; 2002255) (NNTH: 12 [95% CI: 7 to 50]) than the placebo.
RCT 1++
There is scientifi c evidence that atomoxetine in high doses (≥1.6 mg/kg/day) 
is associated with a greater presence of sleepiness (2 RCT, N=494, Michelson, 
2001254; Kelsey, 2004253) (NNTH: 10 [95% CI: 6 to 20]) than the placebo.
RCT 1++
There is scientifi c evidence that atomoxetine in high doses (≥1.6 mg/kg/day) is 
associated with a greater presence of fatigue (1 RCT, N=197, Kelsey, 2004253) 
(NNTH: 12 [95% CI: 7 to 50]) than the placebo.
RCT 1+
There is scientifi c evidence that atomoxetine is associated with a greater 
presence of emotional lability (1 RCT,, N=127, Spencer, 2002257) (NNTH: 9 
[95% CI: 4 to 50]) than the placebo.
RCT 1+
There is scientifi c evidence that atomoxetine in high doses (≥1.6 mg/Kg/day) 
is associated with greater abandonment of the treatment due to side effects 
(5 RCT, N=1.189, Michelson, 2001254; Spencer, 2002257; Kelsey, 2004253; 
Michelson, 2004256; Weiss, 2005258) (NNTH: 33 [95% CI: 20 to 100]) than the 
placebo.
RCT 1++
There is not suffi cient scientifi c evidence that treatment with atomoxetine in 
high doses (≥1.6 mg/kg/day) (7 RCT, N=1485, Michelson, 2001254; Spencer, 
2002257; Kelsey, 2004253; Michelson, 2004256; Bohnstedt, 2005251; Weiss, 
2005258; Brown, 2006252), medium doses (2 RCT, N=468, Michelson, 2001254; 
2002255) or low doses (1 RCT N=297, Michelson, 2001254), is associated with 
a greater premature abandonment of the treatment due to any reason compared 
with the placebo.
RCT 1++
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There is not suffi cient scientifi c evidence that treatment with atomoxetine 
in children with ADHD + tic disorder is associated with a greater premature 
abandonment of the treatment due to side effects (1 RCT, N=148, Allen, 
2005259) compared with placebo.
RCT 1+
Clonidine
The NICE CPG performed a bibliographic review where it found one RCT on the effi cacy of 
clonidine compared with placebo. Hazell, 2003263; and one RCT on the effi cacy of clonidine in 
ADHD children + tic disorder (Kurlan, 2002)212.
Variable: ADHD symptoms
Scientifi c evidence
There is scientifi c evidence that clonidine is associated with a reduction in 
the ADHD symptoms referred to by teachers (1 RCT, N=67, Hazell, 2003263) 
(SMD: -0.57 [95% CI: -1.06 to -0.08]).
RCT 1++
There is not suffi cient scientifi c evidence to suggest that clonidine is associated 
with a reduction in ADHD symptoms referred to by parents (1 RCT N=67, 
Hazell, 2003263) (SMD: -0.16 [95% CI: -0.64 to 0.32]).
RCT 1++
There is scientifi c evidence that clonidine is associated with a reduction in 
the ADHD symptoms referred to by teachers in patients with ADHD and tic 
disorder (1 RCT, N=136, Kurlan, 2002212) (SMD:-2.42, (95% CI: -3.07 to 
-1.76]).
RCT 1++
There is limited scientifi c evidence that clonidine is associated with a reduction 
in the ADHD symptoms referred to by parents in patients with ADHD and 
tic disorder (1 RCT, N=136, Kurlan, 2002212) (SMD: -2.41, (95% CI: -3.07 to 
-1.75]).
RCT 1++
A recent RCT (Palumbo, 2008)264 has found signifi cant differencesin the 
treatment with clonidine compared with placebo in the reduction of ADHD 
symptoms referred to by parents but not in that referred to by teachers.
RCT 1+
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Variable: Behavioural problems
Scientifi c evidence
There is limited scientifi c evidence that clonidine is associated with a reduction 
in the behavioural problem symptoms referred to by the teachers (1 RCT N=67, 
Hazell, 2003263) (SMD: -0.68 [95% CI: -1.18 to -0.18]).
RCT 1++
There is not suffi cient scientifi c evidence to suggest that clonidine is associated 
with a reduction in behavioural problem symptoms referred to by parents (1 
RCT N=67, Hazell, 2003263) (SMD: -0.31 [95% CI: -0.8 to 0.17]).
RCT 1++
There is limited scientifi c evidence that clonidine is associated with a reduction 
in the behavioural problem symptoms referred to by the teachers in patients 
with ADHD and tic disorder (1 RCT, N=136, Kurlan, 2002212) (SMD:-1.11, 
(95% CI: -1.64 to -0.58]).
RCT 1++
Variable: Clinical improvement (clinician)
Scientifi c evidence
There is scientifi c evidence that clonidine is associated with a clinical 
improvement in patients with ADHD + tic disorder (1 RCT, N=136, Kurlan, 
2002212) (RR: 1.98 [95% CI: -1.11 to 3.52]).
RCT 1++
Safety and adverse effects
Scientifi c evidence
Clonidine is associated with sedation and a reduction in heart rate (NICE, 
2009)2.
SR of RCT 1+
There is not suffi cient scientifi c evidence about the existence of signifi cant 
differences in the premature abandonment of the treatment for any reason 
between treatment with clonidine and placebo (1 RCT, N=67, Hazell, 2003263).
RCT 1+
There is not suffi cient scientifi c evidence about the existence of signifi cant 
differences in the premature abandonment of the treatment for any reason 
between treatment with clonidine and placebo (1 RCT, N=136, Kurlan, 2002212).
RCT 1++
In a recent RCT (Daviss, 2008)265, the adverse effects most frequently associated 
with treatment with clonidine were:tiredness, dry mouth, sedation, sleepiness 
and reduction of heart rate.
RCT 1+
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Bupropion
The NICE CPG performed a bibliographic review where it found two RCTs on the effi cacy of 
bupropion compared with placebo. Casat, 1987266; Conners, 1996267.
Variable: ADHD symptoms
Scientifi c evidence
There is not suffi cient scientifi c evidence to suggest that bupropion is associated 
with a reduction in ADHD symptoms referred to by teachers (2 RCT, N=139; 
Casat, 1987266; Conners, 1996267). (SMD: -0.70 [95% CI: -1.11 to 0.29]).
RCT 1++
There is not suffi cient scientifi c evidence to suggest that bupropion is associated 
with a reduction in ADHD symptoms referred to by parents (2 RCT, N=139; 




There is not suffi cient scientifi c evidence to suggest that bupropion is associated 
with a reduction in behavioural problem symptoms referred to by teachers (1 
RCT, N=30; Casat, 1987266) (SMD: -0,44 [95% CI -1.21 to 0.32]).
RCT 1+
There is not suffi cient scientifi c evidence to suggest that bupropion is associated 
with a reduction in behavioural problem symptoms referred to by parents (1 
RCT, N=30; Casat, 1987266) (SMD: 0.00 (CI 95%: -0.76 to 0.76]).
RCT 1+
Safety and adverse effects
Scientifi c evidence
Bupropion is associated with dry mouth, gastrointestinal disturbances, 
insomnia, concentration impairment, headaches, depression, anxiety, agitation, 
tremor, rash, pruritus, and to a lesser extent, cardiovascular and metabolic 




Bupropion has been associated with a dose-related presence of convulsions, 
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Modafi nil
The NICE CPG performed a bibliographic review where it found 5 RCTs on the effi cacy of 
modafi nil compared with placebo. Biederman, 2005268, 2006269; Greenhill, 2006270; Rugino, 
2003271; Swanson, 2006272. Dose of modafi nil used in the studies: from 264 to 425 mg/day.
Variable: ADHD symptoms
Scientifi c evidence
There is limited scientifi c evidence that modafi nil is associated with a reduction 
in the ADHD symptoms referred to by teachers (2 RCT, N=438, Biederman, 
2005268; Swanson, 2006272) (SMD: -0.63 [95% CI: -0.84 to -0.43])
RCT 1++
There is limited scientifi c evidence that modafi nil is associated with a reduction 
in the ADHD symptoms referred to by parents (2 RCT, N=438, Biederman, 




There is limited scientifi c evidence that modafi nil is associated with a reduction 
in the behavioural problem symptoms referred to by parents (1 RCTA, N=248, 




There is scientifi c evidence that modafi nil is associated with a clinical 
improvement (3 RCT, N=686, Biederman, 2005268; 2006269; Swanson, 2006272) 
(RR: 2.79 [95% CI: -2.02 to 3.86]).
RCT 1+
Safety and adverse effects
Scientifi c evidence
There is scientifi c evidence that modafi nil is associated with a greater presence 
of insomnia (2 RCT, N=438, Biederman, 2005268; Swanson, 2006272) 
(NNTH: 4 [95% CI: 3 to 5]) than the placebo.
RCT 1++
There is scientifi c evidence that modafi nil is associated with a greater presence 
of loss of appetite than placebo (1 RCT, N=24, Biederman, 2005268) (NNTH: 
8 [95% CI: 5 to 12]).
RCT 1+
There is not suffi cient scientifi c evidence that treatment with modafi nil
is associated with a greater abandonment of the treatment due to side effects (4 
RCT, N=720, Rugino, 2003271; Biederman, 2005268, 2006269; Greenhill, 2006270) 
than the placebo.
RCT 1+
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There is not suffi cient scientifi c evidence that treatment with modafi nil is 
associated with a greater premature abandonment of the treatment due to any 
reason compared with placebo (4 RCT, N=662, Rugino, 2003271; Biederman, 
2006269; Greenhill, 2006270; Swanson, 2006272).
RCT 1+
Treatment with modafi nil is normally associated with insomnia, loss of appetite, 




Imipramine, SSRIs or SNRIs are not considered of value to treat the symptoms of ADHD (NICE, 
2009)2
Desipramine, not available in Spain, is not recommended by a recent guideline due to its 
potential cardiotoxicity (NICE, 2009)2
Scientifi c evidence
The SIGN CPG (2005)1 refers to scientifi c evidence of the treatment with 
tricyclic antidepressants to treat ADHD in children and in adolescents. More 
specifi cally, more than 70% of children with ADHD treated with tricyclic 
antidepressants (TCAs) showed an improvement in the behavioural symptoms 




The CPG of the AAP (Brown, 2005196; Jadad, 1999276) performed a review of 
scientifi c evidence with respect to the treatment of ADHD in children and in 
adolescents with TCAs.They found 9 RCTs that compared the effi cacy of the 
treatment with TCAs compared with placebo: 6 that examined the effects of 
desipramine (Rapport, 1993277; Biederman, 1989275, 1993278, 1989275; Donnelly, 
1986279; Gualtieri, 1991280; Singer, 1995281; Wilens, 1996282), and 3 that 
examined the effects of imipramine (Gualtieri, 1988283; Winsberg, 1980284; 
Werry, 1980285). The studies included are, in general, of regular quality (1+), 
showing a lack of consistent scientifi c evidence for imipramine, and limited 
scientifi c evidence for desipramine (Brown, 2005)196.
RCT 1+
Arabgol, et al. (2009)286 performed a 6-week RCT on the effi cacy and tolerability 
of reboxetine compared with methylphenidate to treat ADHD in children and 
adolescents (n=33, 7-16 years). The adverse effects of reboxetine included 
sleepiness and anorexia its seriousness varying from light to moderate. 
The authors of the study conclude that reboxetine may have benefi cial effects 
to treat ADHD, although more studies are required to clarify the potential 




There is not scientifi c evidence that treatment with atypical antipsychotics are of value to treat the 
symptoms of ADHD (NICE, 2009)2
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Cost-effectiveness studiest
Scientifi c evidence
The NICE CPG (2009)2 has made a summary of scientifi c evidence available 
on economic cost-effectiveness studies with methylphenidate, atomoxetine or 
dexamphetamine. Donnelly, et al., 2004287; Gilmore & Milne, 2001288; King, et 
al., 2006201; Narayan & Hay, 2004289; and Zupancic, et al., 1998290. The review 
of the scientifi c evidence suggests that the pharmacological treatment is cost-






In the MA by Faraone (2006)199 the effi cacy of the different medications for 
ADHD was compared.They included 29 RCTs that included immediate release 
stimulants, extended release stimulants and non-stimulants (atomoxetine, 
modafi nil and bupropion). The results indicated that both the immediate 
and extended release stimulants had signifi cantly greater effi cacy than non-
stimulant drugs after control by confusion variables (Faraone, 2006)199.
MA of RCT 1++
In the MA by Banaschewski, et al.(2006)193, the effi cacy of the different 
extended release medications for ADHD was compared.The results indicate 
greater effects of extended release stimulants compared with the effects of non-
stimulant drugs (atomoxetine and modafi nil) (Banaschewski, et al., 2006)193
MA of RCT 1++
Two quality RCTs have been found that directly compared methylphenidate 
with atomoxetine (Newcorn, 2008 202; Wang, 2007203).In the study by Wang 
(2007)203, no signifi cant differences were found between the two medications; 
however, relative low doses of methylphenidate (0.2 to 0.6 mg/kg/day) were 
used.In the more recent study by Newcorn (2008)202 a signifi cantly higher 
percentage of responders to methylphenidate (56%) than to atomoxetine (45%) 
was found.
RCT1++
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Summary of the scientifi c evidence on the effi cacy of pharmacological treatments
Methylphenidate and atomoxetine are the only medicines that have shown to be 
clearly effi cient in reducing ADHD symptoms (NICE, 2009)2.
RCT1++
The MAs that compare stimulant drugs with non-stimulant drugs suggest greater 
effi cacy of the treatment with stimulants compared with non-stimulant drugs 
(Faraone, 2006199; Banaschewski, et al., 2006193). In the RCTs conducted that 
compared methylphenidate with atomoxetine, very different results are found, 
with one study that suggests superiority of methylphenidate over atomoxetine 
(Newcorn, 2008)202 and another where no signifi cant differences were found 
(Wang, 2007)203.
MA of RCT 1++
There is no scientifi c evidence that tricyclic antidepressants, SSRIs, SNRIs are 





Methylphenidate and atomoxetine are the recommended drugs today 
to treat ADHD in children and adolescents based on their effi cacy and 
safety at recommended doses (adapted from NICE 10.18.5.1)2.
114  CLINICAL PRACTICE GUIDELINE ON ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) IN CHILDREN AND ADOLESCENTS
7.3.3. In ADHD: How effective are pharmacological treatments in the 
short and long term?
The answer is based on the studies of MTA (1999)39, MTA (2004)173, Jensen, et al. (2007)291, 
Kratochvil, et al. (2006)299 and Wilens (2006)300, as well as on the NICE (2009)2, AAP (2005)196 
and SIGN (2005)1 guidelines.
Scientifi c evidence
The MTA study assessed the effi cacy of the long-term treatment (14 months) 
with 3 doses of methylphenidate, compared with behavioural therapy, with 
methylphenidate + behavioural therapy, and with normal treatment in the 
community (MTA, 1999)39. After 14 months’ treatment, the pharmacological 
treatment with methylphenidate proved to be effi cient in reducing nuclear 
symptoms of the disorder (hyperactivity/impulsivity and inattention) compared 
with the intervention in the community (MTA, 1999)39. When the trial ended, 
a naturalistic follow-up was carried out with follow-up results after 2 and 3 
years. In the 2-year results, the positive effect of the pharmacological treatment 
is maintained regarding the intervention in the community in the reduction of 
the nuclear symptoms of the disorder (MTA, 2004)173; however, in the 3-year 
follow-up no signifi cant differences between the groups are obtained (Jensen, et 
al., 2007)291. These results must be interpreted with caution because the follow-
up after the intervention is naturalistic, with no control over the intervention, 
and because of the lack of a control group without treatment.
RCT1++
The NICE guideline (2009)2 indicates that the results of pharmacological 
intervention studies, regardless of the type of drug, and lasting for 2 weeks 
or more, suggest a clinical improvement tendency with continued treatment 
(MTA, 199939; Kupietz, 1988292; Quinn, 1975293; Brown, 1985161; Conrad, 
1971294; Firestone, 1986295; Brown, 1986162; Fehlings, 1991154; Gillberg, 1997296; 
Gittelman-Klein, 1976297; Schachar, 1997298).
RCT
1+, 1++
In the follow-up after 2 years’ treatment with atomoxetine the improvement 
attained during the fi rst months’ treatment is maintained both in children 
(Kratochvil, et al., 2006)299 and in adolescents (Wilens, 2006)300.
Cohorts- Study
2+
Summary of the scientifi c evidence on the effi cacy of pharmacological treatments
There is scientifi c evidence of long-term effectiveness (from 12 weeks to 24 




A 7.3.3.1. Long-term treatment with methylphenidate and atomoxetine can be 
recommended as its effectiveness is not reduced.
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7.3.4. In ADHD: When and with what criteria must pharmacological 
treatment be started?
The answer is based on the AACAP (2007)72 and NICE (2009)2 guidelines.
Summary of the scientifi c evidence
The AACAP guideline (2007)72 recommends pharmacological treatment and/
or behavioural treatment as fi rst choice bearing in mind the treatments thathave 




The pharmacological treatment must be started by a suitably qualifi ed physician 






Pharmacological and/or behavioural treatment must be considered as 
fi rst choice for ADHD in children and adolescents bearing in mind the 
age of the patient, the seriousness of the symptoms, their functional 
repercussion and the family’s characteristics and preferences.
D 7.3.4.2.
Pharmacological treatment must be started by a properly qualifi ed 
physician who is an expert in treating ADHD and its most frequent 
comorbidities.
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7.3.5. In ADHD: What criteria are used to choose the drug? What are 
the start, suppression and maximum dose guidelines?Which are 
the fi rst and second choice drugs?
The answer is based on the NICE (2009)2; AACAP (2007)72, AAP (2001180; 2005196) guidelines 
and on the SR by Faraone (2006)199 and Banaschewski, et al. (2006)193.
Summary of the scientifi c evidence
The scientifi c evidence available that compares the effi cacy of methylphenidate 
compared with atomoxetine suggests greater effi cacy of methylphenidate in the 
reduction of the nuclear symptoms of ADHD (NICE, 20092; Faraone, 2006199; 
Banaschewski, et al., 2006193).
SR of RCT 1+
The AACAP guideline (2007)72, and the AAP guidelines (2001180; 2005196) 




The choice of atomoxetine as a fi rst line drug in patients with active substance 
abuse, comorbidity with anxiety or tics can be considered (AACAP, 200772; 
NICE, 20092). It must also be considered if the patient has experienced 




The choice of extended release methylphenidate can be considered in order to 
improve therapeutic compliance, as it is easy to administer (it need not be taken 
at school) or due to its pharmacokinetic profi les (NICE, 2009)2. Immediate 
release formulas are normally used in small children (<16 kg), who require 




Although the use of methylphenidate is contraindicated in the technical data 
sheet for patients with ADHD and comorbidity with tic disorder, based on the 
clinical experience of the development group, methylphenidate can be used in 
these patients with certain caution, in lower initial doses, increasing them much 




Table 9 includes a list of the doses of the drugs for ADHD available in Spain.
Table 9. Doses of the drugs for ADHD
Drugs Presentations Initial dose Maximum dose
Immediate release 
methylphenidate





18, 27, 36, 54 mg 18 mg






10, 20, 30, 40 mg 10 mg 2 mg/kg/day up to 60 mg/day
Atomoxetine
10, 18, 25, 40, 60, 
80 mg
0.5 mg/kg/day
1.8 mg/kg/day up to 
100 mg/day
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Methylphenidate
Summary of the scientifi c evidence
In general, there is a linear relationship between the dose and the clinical 
response (AACAP, 2007)72. Likewise, the adverse effects are also dose 
dependent (SIGN, 2005)1. The treatment should seek the minimum effective 
dose that would produce the maximum therapeutic effect, keeping the adverse 
effects to a minimum (SIGN, 2005)1. The response threshold to methylphenidate 
is variable in each patient, in other words, each one has a unique dose-response 
curve (SIGN, 20051; AACAP, 200772).
RCT
1+
Some patients may require higher doses than those recommended in Table 9 to 
obtain a therapeutic response (AACAP, 2007)72. In these cases, suitable clinical 




Once the treatment has started with the initial dose, the physician should 
increase it every 1 to 3 weeks until the maximum dose has been reached, or the 
ADHD symptoms have disappeared, or the presence of adverse effects prevents 





Summary of the scientifi c evidence
Atomoxetine has greater effects than the placebo already in the fi rst week of 






The decision about which drug to choose must be based on (adapted 
from NICE 10.18.5.2)2:
 • The presence of comorbid conditions (tic disorders, Tourette’s syn-
drome, epilepsy and anxiety).
 • The adverse effects of the drugs
 • Previous experiences of lack of effi cacy
 • Issues regarding compliance, for example, problems associated with 
the need to administer a dose at school
 • Potential abuse
 • The preferences of the child/adolescent and his or her family
118  CLINICAL PRACTICE GUIDELINE ON ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) IN CHILDREN AND ADOLESCENTS
7.3.6. What are the most frequent (short term) side effects? How to 
address them?
The answer is based on the SIGN guideline (2005)1.
Summary of the scientifi c evidence
The majority of the adverse effects of treatment with stimulants are dose-
dependent and subject to individual differences (SIGN, 2005)1. Normally they 
decrease between weeks 1 and 2 after having started the treatment and they 
disappear if this is interrupted or the dose is reduced (SIGN, 2005)1
RCT
1+
A regular follow-up of the adverse effects is recommended between the 
physician and family to address problems that might appear when stimulants 




Once the effective dose has been reached, regular visits are necessary to assess 
the adverse effects, and monitoring the evolution of the height, weight, heart 




Table 10 shows the main adverse effects of methylphenidate and how to address them 
(SIGN, 2005)1.
Table 10. Adverse effects of methylphenidate*
Adverse effects of 
methylphenidate
How to address them?
Anorexia, nausea, loss of 
appetite
Monitoring, administer medication with meals, prescribe 
dietetic supplements.
Effects on growth
If signifi cant (rare in long term) or if it causes parental 
concern, try “therapeutic holidays”
Insomnia Monitoring, reduction or omission of the last dose
Dizziness or headache Monitoring (blood pressure), increase intake of fl uids
Involuntary movements, tics
Reduction, and if it persists, suspension of medication, 
consider alternative
Loss of spontaneity, dysphoria, 
agitation
Reduction or suspension (suspend if psychosis is 
suspected –rare-).
Irritability
Monitoring, reduce dose, assess if comorbidity (ODD, 
emotional disorder)
Rebound effect Increase afternoon dose
* Adapted from SIGN (2005)1
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Atomoxetine
Summary of the scientifi c evidence
In September 2005, the FDA alerted about the risk of suicidalideation with 
treatment with atomoxetine in children and adolescents(US Food and Drug 
Administration, 2005)301. In 12 RCTs that included 1357 patients, the risk of 
suicidalideation was 4/1000 in the group treated with atomoxetine compared 
with none in the placebo group (AACAP, 2007)72.
RCT
1++
Table 11 shows the main adverse effects of atomoxetine and how to address them.
Table 11. Adverse effects of atomoxetine
Adverse eff ects of atomoxetine How to address them?
Anorexia, nausea
Monitoring, administer medication with meals, prescribe 
dietetic supplements.
Abdominal pain Slow scaling-down or reduction of dose
Eff ects on growth
If signifi cant (rare in long term) or it it causes parental 
concern, try “therapeutic holidays”
Sleepiness Night-time dose or divide into two doses
Dizziness or headache
Monitoring (blood pressure), increase intake of fl uids.
Slow scaling of dose
Ideation and/or suicidal 
behaviour
Suspend medication and observation
Hepatotoxicity Suspension of medication and not reintroduce it again
Recommendations
D 7.3.6.1. Periodic follow-up and monitoring of the possible adverse effects of 
methylphenidate and atomoxetine are recommended
7.3.7. In ADHD: How long should the pharmacological treatment last?
The answer is based on the SIGN (2005)1 and AACAP (2007)72 guidelines. 
Summary of the scientifi c evidence
As ADHD tends to persist in adolescents, and in some cases in adult age, and 
due to the fast re-appearance of the symptoms if the treatment is suspended, 
the pharmacological treatment for ADHD should be long-term (SIGN, 2005)1.
Experts’
opinion 4
Periodic controls must be carried out to assess the persistence or disappearance 
of the symptoms (AACAP, 2007)72.
Experts’
opinion 4
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One accepted practice is to leave short periods (1 to 2 weeks) each year without 
treatment, obtaining feedback about the child’s behaviour from the family and 
school (SIGN, 2005)1. Another possibility would be for the period without 
treatment to coincide with holidays, trying to get the family to suggest tasks to 
the child that require a demand with respect to cognitive resources (reading a 
book, maths problems, etc.) (AACAP, 2007)72.
Experts’
opinion 4
The long-term effectiveness studies of pharmacological treatments support 
the positive effect of the long-term treatment, especially in those patients with 





The duration of the treatment must be established on a personal basis 
depending on the symptoms and functional repercussion. In some cases 
the treatment can last for several years.
 7.3.7.2.
It is advisable to periodically evaluate the persistence or remission of 
the symptoms.An accepted practice is to suspend the pharmacological 
treatment for short periods of 1 or 2 weeks a year, obtaining information 
about the functioning of the child or adolescent from the family and 
from the school.
7.3.8. In ADHD: Are supplementary examinations required before 
starting the pharmacological treatment in children and 
adolescents?
The answer is based on the study by the American Heart Association (AHA, 2008)304, on the study 
by Perrin, et al. (2008)306 and on the note from the Spanish Medicine and Health Products Agency 
(Ref. 2009/01).
The Spanish Medicine and Health Products Agency has published a note (Ref.2009/01) 
where it informs of the possible cardiovascular effects of methylphenidate (including an increase 
in blood pressure and heart rate disturbances), so a thorough cardiovascular examination should 
be carried out before starting the treatment and follow-up must also be carried out.
Summary of the scientifi c evidence
 Methylphenidate has a statistically signifi cant association with the presence 
of clinically insignifi cant haemodynamic alterations (AHA, 2008)304. Sudden 
deaths that are directly associated with the drug are very rare, although 
ventricular arrhythmias have been found as well as suppression of the cardiac 
function associated with abuse of methylphenidate (AHA, 2008)304.
Cohorts 
study 2+
Short-term studies have associated a slight increase in systolic blood pressure 
in adults with atomoxetine as well as a marginal increase in diastolic blood 
pressure in adults and children, which decreases with the suspension of the 
medication (Wernicke, 2003305). Sudden deaths have been referred to in children 
receiving treatment with atomoxetine (AHA, 2008)304.
Cohorts 
study 2+
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The consensus of the American Heart Association (2008)304 recommends 
the execution of an anamnesis, of the family and of the patient, a physical 
examination and an electrocardiogram (ECG) before starting pharmacological 
treatment. The American Paediatrics Association (Perrin, et al., 2008)306 
considered later on that the ECG is not necessary due to the lack of clear 






The systematic execution of supplementary examinations is not 
recommended, unless indicated by the physical exploration or 
anamnesis.
7.3.9. What is the pharmacological strategy when there is a partial 
response, side effects or contraindication?
 How are the different methylphenidate presentations combined? 
How to make the transition from stimulants to atomoxetine?
The answer is based on the AAP guidelines (2001)180 and Banachewski, et al. (2006)193, the study 
by Quintana (2007)307 and the narrative review of Weiss (2006)308.
Summary of the scientifi c evidence
The AAP CPG (2001)180 indicates that in the cases of children in whom the 
highest possible dose of a stimulant medication does not work, the clinician 
should recommend another stimulant drug.
In the cases of children with ADHD in whom the pharmacological intervention 
does not show positive effects or who present intolerable side effects, they 
should be administered another of the stimulant medications recommended.
It should be noted that in Spain methylphenidate is only available as a stimulant 
drug with different presentations.
The lack of response to the treatment may lead clinicians to re-assessthe initial 
diagnosis and the possibility of non-diagnosed comorbid disorders.
The lack of response to the treatment may refl ect: 1) not very realistic 
objectives; 2) lack of information about the behaviour of the child; 3) incorrect 
diagnosis; 4) a co-existent disorder that affects the ADHD treatment; 5) lack of 
complianceto the treatment regime, and 6) failure of the treatment.
The treatment of ADHD decreases the frequency and intensity of the nuclear 
symptoms of the disorder but it may not eliminate them in their entirety.
Similarly, children with ADHD may continue experiencing diffi culties in their 
relationships with companions although the treatment is the right one, and there 
may be no association, either, with the improvement in academic performance.
Experts’
opinion 4
It is possible to complete the effect of extended methylphenidate products with 
immediate release ones (Banachewski, et al., 2006)193.
SR 1+
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There is no scientifi c evidence to decide which pattern must be followed in 
those patients treated with stimulants, whose treatment must be changed to 
atomoxetine due to lack of response or side effects.Quintana (2007)307 proposes 
a fast change from the stimulant to atomoxetine with the following pattern:
 • First week: full dose of the stimulant and atomoxetine in doses of 0.5 mg/
kg/day.
 • Second week: Reduce the dose of stimulant to half and administer atomox-
etine in doses of 1.2 mg/kg/day.
 • Third week: Suspend the stimulant and maintain the dose of atomoxetine at 
1.2 mg/kg/day.
However, other clinicians such as Weiss (2006)308 believe that the transition 
should be made much more slowly, due to the time that elapses until the 







If there is a partial response to the drug, increase the dose until the 
maximum indicated or tolerated.If there is no response with maximum 
doses, consider the alternative drug that has not been used with this child 
or adolescent (another methylphenidate or atomoxetine presentation).
 7.3.9.2. If side effects appear, address them adequately. If they persist or are not 
tolerated, evaluate a change in medication.
 7.3.9.3. In the case of contraindication, evaluate the use of the alternative drug.
 7.3.9.4.
If extended release methylphenidate is used with osmotic technology and 
an adequate adjustment of the dose is not achieved, a dose of immediate 
release methylphenidate can be added to the treatment at breakfast and/
or mid afternoon, to thus adjust the total dose in agreement with the 
weight of the child or adolescent with ADHD and with the clinical 
response.
If a 12-hour therapeutic action is required and the child or adolescent with 
ADHD is not able to swallow tablets, extended release methylphenidate 
can be administered with pellet technology in the morning (opening 
the capsule) and in the afternoon, after school, administer a dose of 
immediate release methylphenidate.This latter pattern can also be 
followed if there is a rebound effect in the afternoon with extended 
release methylphenidate with pellet technology.
7.3.10. In which ADHD subtypes is pharmacological treatment more effi cient?
The answer is based on the studies by Barbaresi (2006)303 and by Stein, (2003)309.
Scientifi c evidence
The long-term effectiveness studies have not found any signifi cant differences 
between the ADHD subtype and the effectiveness of the pharmacological 
treatment (Barbaresi, 2006)303.
Cohorts study 2+
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In a RCT that studied the effi cacy of extended release methylphenidate, a group 
of patients with combined ADHD was compared with a group of patients with 
inattentive ADHD (Stein, 2003)309. It was found that methylphenidate was 
equally effi cient in both groups; however, in the group with combined ADHD, 
a linear relationship was verifi ed between the dose and therapeutic response; on 
the contrary, in the group of inattentive ADHD there was a therapeutic response 
with lower doses of methylphenidate (60% responded with 36 mg/day or less).
RCT1+
Recommendations
7.3.11. Are there differences in response depending on the gender or age?
The answer is based on the AACAP guideline (2007)72 and on the studies by Barbaresi (2006) 303, 
Smith, et al. (1998)236, Wilens (2006)310 and Cox, et al. (2004)311.
Scientifi c evidence
Long-term effectiveness studies have not found any signifi cant differences 
between the gender and the effectiveness of the pharmacological treatment 
(Barbaresi, 2006)303.
Cohorts study 2+
The treatment with methylphenidate is equally effi cient in children and in 
adolescents (Smith, et al., 1998)236.
RCT1++
The treatment with atomoxetine is equally effi cient in children and adolescents 
(Wilens, 2006)310.
Cohorts study 2+
The AACAP CPG (2007)72 indicates, related to the response in agreement with 
the age, that the use of immediate or extended action stimulations has proved 
to be equally effi cient in children and in adolescents. In connection with the use 
of extended action drugs, it must be pointed that this is much more convenient 
for the patient who complies better with the treatment.
RCT1++
In adolescents, extended action methylphenidate can improve the driving ability 
compared with the use of short action methylphenidate (Cox, et al., 2004)311.
Cohorts study 2+
Summary of the scientifi c evidence
There are no differences in the response to the pharmacological treatment in 







Methylphenidate and atomoxetine are recommended as 
pharmacological treatments of choice for ADHD in children and 
adolescents regardless of the ADHD subtype.
Recommendations
B 7.3.11.1.
Methylphenidate and atomoxetine are recommended as 
pharmacological treatments of choice for ADHD in children and 
adolescents regardless of the age and gender.
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7.3.12. Which physical parameters (weight, height, blood pressure, 
etc.) must be controlled before starting the pharmacological 
treatment and during it?
The answer is based on the AACAP (2007)72 and NICE (2009)2 guidelines.
Summary of the scientifi c evidence
The AACAP72 guideline indicates that for pharmacological interventions, the 
follow-up must be carried out several times a year.
The procedures applied in each visit may vary depending on the clinical needs, 
but throughout the treatment, the clinician must review the child’s academic 
and behavioural function.
Regarding physical parameters, the height, weight, blood pressure and heart 
rate are determined regularly.




There is consistency between previous guidelines in that in patients with 
ADHD a regular follow-up must be carried out to introduce adjustments in the 
medication that will guarantee that the treatment is still effective, that the dose 





A physical examination must be performed before starting the 
pharmacological treatment, which will include taking the blood pressure, 
measuring heart rate, weight and height.Personal and family history of 
cardiac diseases must be sought, as well as a history of syncope related 
to exercise or other cardiovascular symptoms (adapted from NICE, 
10.18.4.1)2.
D 7.3.12.2.
A preliminary cardiovascular study must be carried out at the start of the 
pharmacological treatment if there is a personal and/or family history 
of cardiac diseases or history of serious cardiovascular problems or 
sudden death in the family or abnormal fi nding in the initial physical 
examination (adapted from NICE, 10.18.4.1.)2.
 7.3.12.3.
In children and adolescents with ADHDreceiving treatment with 
methylphenidate or atomoxetine:the height must be measured every 6 
months, the weight must be controlled 3 and 6 months after starting 
the pharmacological treatment, and every 6 months during the 
administration of the treatment.
 7.3.12.4.
The height and weight in children and adolescents with ADHD in 
pharmacological treatment must be plotted on a growth chart and 
reviewed by the physician responsible for the treatment.
 7.3.12.5.
The heart rate and blood pressure must be monitored in children and 
adolescents with ADHD receiving pharmacological treatment, plotting 
them before and after every change in dose, and systematically every 3 
months.
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7.3.13. What scientifi c evidence exists about the long-term effects 
in pharmacological treatment?Is it associated with growth 
retardation?
The answer is based on the AACAP guideline (2007)72 and on the studies by Charach (2006)312; 
MTA (2004)313; (2007)314, Spencer, et al.
Scientifi c evidence
Treatment with methylphenidate has been associated with a growth retardation 
at 2 and 5 years’ follow-up (Charach, 2006312; MTA, 2004313; 2007314).
Cohorts study 2++
In the MTA study, the average height found 2 years into follow-up was 1.38 cm 
less than that expected for the age, and an average weight of 1.3 kg. less (MTA, 
2004)313. 3 years into the follow-up, the group that received pharmacological 
treatment showed a growth of 2 cm less than the non-medicated group and an 
average weight of 2.7 kg less (MTA, 2007)314.
Cohorts study 2++
Charach (2006)312 has found a relationship between the dose of methylphenidate 
and growth retardation; this was signifi cant 4 years into the follow-up with 
higher doses than 2.5 mg/kg/day.
Cohorts study 2++
The growth retardation is greater during the fi rst year’s treatment but decreases 
afterwards (AACAP, 2007)72.
Cohorts study 2++
In the treatment with atomoxetine, retardation was also found (0.44 cm less 
and 0.87 kg less than expected for the age) in growth 2 years into follow-
up (Spencer, et al., 2005)315. After 5 years’ follow-up a smaller growth was 
observed than expected only in patients situated in the higher height quartiles, 
whilst there was a reverse tendency in children situated in the lower height 
quartiles (Spencer, et al., 2007)316.
Cohorts study 
2+
Summary of the scientifi c evidence
There is no consensus related to the long-term repercussion on the growth 
of children and adolescents receiving pharmacological treatment with 
methylphenidate and atomoxetine.
There may be a slight decrease in weight and height. These effects seem to 






A regular follow-up of the growth of children and adolescents with 
ADHD is recommended during the pharmacological treatment with 
methylphenidate and atomoxetine.
 7.3.13.2.
The assurance of an adequate nutritional intake is recommended in 
children and adolescents receiving pharmacological treatment with 
ADHD with secondary anorexia to the treatment.
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7.3.14. Pharmacological treatment of ADHD: Does it cause addiction? 
Does it increase the risk of consumption of substances?
The answer is based on the MA of Wilens (2005)317, (2003)318 and (2008)319, and on the study by 
Biederman (2008)320
Scientifi c evidence
Wilens (2005)317 has performed a MA on the effi cacy of the treatment with 
stimulants in adults and adolescents with ADHD + SUD (substance use 
disorder).He found effi cacy of the treatment with stimulants in patients with 
ADHD + SUD that was not upheld with the analysis performed exclusively 
with controlled studies.The treatment with stimulants was not associated with 
a worsening of the SUD.
MA openended 
studies and RCT
Treatment with stimulants in childhood is associated with a reduction in the 
risk of consuming alcohol, tobacco and other substances in adolescents with 
ADHD (Wilens, 2003318; 2008319).
MA Cohorts study 
2++
Biederman (2008)320, in the naturalistic 10-year follow-up, indicates that there 
is no association between treatment with methylphenidate in children with 
ADHD and the consumption of substances.
Cohorts’ study 2++
Summary of the scientifi c evidence
The treatment with stimulants does not increase the risk of substance use 





The use of methylphenidate and atomoxetine is recommended to treat 
ADHD in children and adolescents, at the right doses, as it does not 
cause addiction or increase the risk of substance abuse.
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7.3.15. Does the effi cacy of pharmacological treatment decrease with 
time?
The answer is based on the studies of MTA (1999)39, (2004)313, Jensen, et al.(2007)291 and Wilens, 
et al. (2006)300.
Scientifi c evidence
The MTA study appraised the effi cacy of the long-term treatment (14 months) 
with 3 doses of methylphenidate, compared with behavioural therapy,  
comparedwith methylphenidate + behavioural therapy, compared with 
normal treatment in community (MTA, 1999)39. After 14 months’ therapy, 
the pharmacological treatment with methylphenidate proved to be effi cient 
in reducing the nuclear symptoms of the disorder (hyperactivity/impulsivity 
and inattention) compared with the intervention in community (MTA, 199939). 
When the trial ended, a naturalistic follow-up was performed with follow-up 
results after 2 and 3 years. The positive effect of the pharmacological treatment 
on the intervention in communityis maintained in the 2-year results, regarding 
the reduction of the nuclear symptoms of the disorder (MTA, 2004)313. However, 
in the 2-year follow-up no signifi cant differences are found between the groups 
(Jensen, et al., 2007)291. These results must be interpreted with caution due to 
the fact that the follow-up after the intervention is naturalistic, not controlling 
the intervention, and to the lack of a control group without treatment.
RCT 1++
Wilens, et al. (2006)300 described the follow-up of 601 adolescents with ADHD 
treated with atomoxetine, of whom 219 had completed 2 years’ treatment. A 
total of 99 (16.5%) patients suspended the treatment of atomoxetine due to the 





Pharmacological treatment with methylphenidate and atomoxetine for 
ADHD in children and adolescents should be continued in time whilst 
the clinical effectiveness is demonstrated.
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7.3.16. Do the effects remain after the pharmacological treatment has 
been withdrawn?
The answer is based on the AAP (2005)196; SIGN (2005)1 guidelines, and on the study by Michelson 
(2004)256.
Summary of the scientifi c evidence
There is scientifi c evidence of the long-term effectiveness (from 12 weeks to 




The patients then followed a relapse prevention RCT with two conditions: 
atomoxetine and placebo. The atomoxetine (22.3% relapse rate) was greater 
than the placebo (37.9% relapse rate) in the prevention of relapses after 
9 months’ follow-up.The low rate of relapses in the placebo group is worth 
pointing out. These results do, nevertheless, require further studies.
RCT
1+
7.3.17. Is it recommendable to leave stimulant-free periods during the 
pharmacological treatment (“therapeutic holidays ”)?
The answer is based on the NICE guideline (2009)2
Summary of the scientifi c evidence
The NICE CPG (2009)2 indicates that the use of the drug should be continued 
for as long as its clinical effectiveness lasts. The pharmacological treatment 
should be revised at least once a year. This revision should include an appraisal 
by clinical needs, benefi ts and side effects, taking into consideration the points 
of view of the child or adolescent, as well as those of their parents, carers and 
teachers.The effect of missed doses, planned reductions or short treatment-free 
periods must be taken into account, and the preferred pattern of use must be 
assessed.
The comorbid disorders must be assessed as well as their treatment or 
relative referral, as well as possible needs for psychological treatment or 
social support.“Therapeutic holidays” from the drug are not systematically 
recommended.However, parents or carers and health professional should work 
together to fi nd the best pattern of use, which may include periods without 
pharmacological treatment.
In children and adolescents with ADHD, whose growth is signifi cantly affected 
by the pharmacological treatment, the option of resting from the drug during 
school holidays may be considered to permit reaching the right growth.
Experts’ 
opinion 4
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Recommendations
 7.3.17.1. Pharmacological treatment rest periods (“therapeutic holidays”) are not 
systematically recommended during treatment of ADHD.
 7.3.17.2.
In some cases, periods without pharmacological treatment or with 
a lower dose can be included, when agreed between the family, the 
physician and child or adolescent, with the specifi c objective of:
 • Assessing the need to maintain the treatment or not.
 • Reduce adverse effects (lack of appetite, slowing-down in height 
growth, etc.).
7.3.18. What clinical variables and standardised instruments exist to 
evaluate the effi cacy of pharmacological treatment? At what 
moment of the treatment should its effi cacy be evaluated?
The response is based on the experts’ opinions. 
Summary of the scientifi c evidence
To evaluate the effi cacy of the pharmacological treatment, clinical variables 
will be taken into account, such as the intensity of the nuclear and associated 
symptoms, the family, academic and social repercussion.The information from 
the teachers and/or the information obtained via the standardised tools will be 
assessed based on the clinical interview with the child and parents.
Experts’ 
opinion 4
See chapter 6. Assessment tools, which reviews the main assessment tools used in our medium to evaluate 
ADHD in children and adolescents.
Recommendations
 7.3.18.1.
The assessment of the effi cacy and tolerability of the intervention will be 
carried out in the pharmacological treatment of children and adolescents 
with ADHD at least 1, 3 and 6 months after the start of the treatment, 
and later every 6 months whilst it lasts, or else, whenever adjustments 
are made in the dose or changes are made in the drug.
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7.4. Combined treatment
Questions to be answered:
7.4.1. Combined treatment: What does it consist of? What must it include?
7.4.2. In ADHD in children and adolescents: Which intervention or combination of interven-
tions has proved to be more effi cient in the short and long term?
7.4.1. Combined treatment: What does it consist of? What must it 
include?
Combined treatment for ADHD refers to the use of a combination of treatments that make it pos-
sible to increase the effects of the interventions in different areas:the medication that addresses the 
nuclear symptoms and the psychological treatment of secondary as well as comorbid problems 
associated with ADHD.
The combination of pharmacological and psychological treatments has immediate effects on 
the symptoms of ADHD via the use of the medication, as well as long-term effects via the devel-
opment of cognitive and behavioural skills and strategies.
Another area of interest related to combined treatment is the possibility of reducing the risk 
of side effects of the medication, if the effects of the combined treatment are equivalent to those 
of the pharmacological treatment alone but with lower doses of medication (NICE, 20092; SIGN, 
20051).
7.4.2. In ADHD in children and adolescents:Which intervention or 
combination of interventions has proved to be more effi cient in 
the short and long term?
In this section, the scientifi c evidence on the effi cacy, safety and cost-effectiveness of combining 
psychological and pharmacological interventions to treat ADHD is described.
Psychological intervention refers to the cognitive behavioural or behavioural treatment. 
Pharmacological intervention refers to the intervention with stimulants.
The answer is based on the NICE (2009)2, SIGN (2005)1, AACAP (2007)72 guidelines and 
the MA by Van der Oord, et al. (2008)147.
The NICE Guideline (2009)2 performs two SRs and MAs on combined treatment for ADHD.
In the fi rst SR and MA, 7 RCTs of studies published between 1976 and 2004 were in-
cluded (Abikoff 2004321; Brown 1985161; Firestone 1981322, 1986295; Gittelman-Klein 1976297; 
Klein 1997164; MTA 199939; n=544, ages 5-12 years). The fi rst review includes trials that compare 
groups with combined treatment (medication for ADHD and concurrent psychological interven-
tion) with pharmacological treatment alone.The trials that compared the combined treatment with 
the psychological treatment alone or with controls were not included.
Another analysis was performed to compare intensive combined treatment with normal 
treatment that could include medication. This analysis is based on the data of the MTA study 
(MTA, 1999)39 with a view to comparing what could be considered today as the best treatment for 
ADHD with the highest standard level of care in clinical practice.
CLINICAL PRACTICE GUIDELINES IN THE SPANISH NHS 131
Scientifi c evidence
The scientifi c evidence reviewed by the SIGN Guideline (2005)1 suggests that 
the combination of non-pharmacological interventions only produces a slight 
additive effect. However, it indicates that it may be benefi cial in those cases 
where there is comorbidity (Horn, et al., 1991159; MTA, 199939).
The study by Ialongo, et al. (1994)210 did not fi nd any additive effects for 
the combination of medication, intervention in self-control for the child and 
training for parents.
With respect to the MTA study (1999)39, it fi nds that the effects of methylphenidate 
were only equivalent to the combination of psychosocial and pharmacological 
intervention. The combined group, however, attained an equivalent degree of 
improvement with a signifi cantly lower dose of medication.
The SIGN guideline (2005)1 expresses the methodological limitations of the 
MTA study and the need to carry out more research.
RCT 
1++
Van der Oord, et al. (2008)147 performed a MA that included those quality RCTs 
that assessed the effi cacy of methylphenidate, psychosocial treatments and a 
combination of both to treat ADHD, published between 1985 and 2006. The 
participants with ADHD were aged, on average, between 6 and 12.
The authors evaluated the effi cacy in ADHD symptoms, oppositionism, 
behaviour, social skills and academic performance.
6 RCTs satisfi ed the inclusion criteria, and included a condition of psychological 
treatment based on the principles of CBT and methylphenidate that lasted for 
a short period of time: Abikoff, 2004321; Brown, 1985161, 1986162; Klein & 




The conclusions of these authors suggest that both methylphenidate and the 
psychosocial treatments are effective in reducing ADHD symptoms.However, 
psychosocial treatment has less effect than the other treatment conditions. The 
psychosocial treatment has no additional value to methylphenidate to reduce 
ADHD or the oppositionist and defi ant symptoms evaluated by the teachers.
However, for the social skills and oppositionist and defi ant symptoms evaluated 
by the parents, the three treatments were equally effective.No effi cacy was 
proved in improving academic performance.
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Variable: Clinical improvement at the end of the treatment
Scientifi c evidence
There is not suffi cient scientifi c evidence to suggest that the combined treatment 
compared with pharmacological treatment has positive effects on the teachers’ 
scores in ADHD symptoms at the end of the treatment (7 RCT, N=482, Abikoff 
2004321; Brown 1985161; Firestone 1981322, 1986295; Gittelman-Klein 1976297; 
Klein 1997164; MTA 199939) (SMD: -0.06 [95% CI: -0.24 to 0.12]).
RCT 1++
There is not suffi cient scientifi c evidence to suggest that the combined treatment 
compared with pharmacological treatment has positive effects on the parents’ 
scores in ADHD symptoms at the end of the treatment (6 RCT, N=428, Abikoff 
2004321; Brown 1985161; Firestone 1981322, Gittelman-Klein 1976297; Klein 
1997164; MTA 199939) (SMD: -0.12 [95% CI: -0.31 to 0.07]).
RCT 1++
There is not suffi cient scientifi c evidence to suggest that the combined 
treatment compared with pharmacological treatment has positive effects on 
the teachers’ scores in behaviour at the end of the treatment (6 RCT, N=461 
Abikoff 2004321; Firestone 1981322, 1986295; Gittelman-Klein 1976297; Klein 
1997164; MTA 199939) (SMD: -0.07 [95% CI: -0.26 to 0.11]).
RCT 1++
There is limited scientifi c evidence to suggest that the combined treatment 
compared with pharmacological treatment has positive effects on the parents’ 
scores in behaviour at the end of the treatment (3 RCT, N=378, Abikoff 2004321; 
Klein 1997164, MTA 199939) (SMD: -0.21 [95% CI: -0.41 to -0.01]).
RCT 1++
There is not suffi cient scientifi c evidence to suggest that the combined treatment 
compared with pharmacological treatment has positive effects on the teachers’ 
scores in social skills at the end of the treatment (3 RCT, N=333, Abikoff 
2004321; Klein 1997164, MTA 199939) (SMD: -0.03 [95% CI: -0.11 to 0.05]).
RCT 1++
There is not suffi cient scientifi c evidence to suggest that the combined treatment 
compared with pharmacological treatment has positive effects on the scores of 
the parents in social skills at the end of the treatment (2 RCT, N=315, Abikoff 
2004321; MTA 199939) (SMD:0.14, (95% CI: -0.36 to 0.09]).
RCT 1++
There is not suffi cient scientifi c evidence to suggest that the combined treatment 
compared with pharmacological treatment has positive effects on the children’s 
scores in social skills at the end of the treatment (1 RCT, N=68, Abikoff 2004321) 
(SMD: -0.07 [95% CI: -0.54 to 0.41]).
RCT 1+
There is not suffi cient scientifi c evidence to suggest that the combined treatment 
compared with pharmacological treatment has positive effects on the teachers’ 
scores in emotional symptoms (internalized) at the end of the treatment (2 RCT 
N=265, Klein 1997164; MTA 199939) (SMD: 0.15 [95% CI: -0.09 to 0.39]).
RCT 1++
There is not suffi cient scientifi c evidence to suggest that the combined treatment 
compared with pharmacological treatment has positive effects on the parents’ 
scores in emotional symptoms (internalized) at the end of the treatment (3 RCT 
N=327, Firestone 1981322; Klein 1997164; MTA 199939) (SMD:-0.03, (95% CI: 
-0.25 to 0.19]).
RCT 1++
There is not suffi cient scientifi c evidence to suggest that the combined treatment 
compared with pharmacological treatment has positive effects on the children’s 
scores in emotional symptoms (internalized) at the end of the treatment (1 RCT 
N=689, Abikoff 2004321) (SMD:0.28 [95% CI: -0.20 to 0.76]).
RCT 1++
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There is not suffi cient scientifi c evidence to suggest that the combined treatment 
compared with pharmacological treatment has positive effects on the children’s 
scores in self-effi cacy at the end of the treatment (1RCT, N=68, Abikoff 2004321) 
(SMD: -0.02 [95% CI: -0.50 to 0.45]).
RCT 1+
Variable: Clinical improvement 3 to 6 months after the treatment 
Scientifi c evidence
There is not suffi cient scientifi c evidence to suggest that the combined treatment 
compared with pharmacological treatment has positive effects on the teachers’ 
scores in the ADHD symptoms 3 months after treatment (1 RCT, N=20, Brown 
1985161) (SMD: -0.05, (95% CI: -0.93 to 0.82]).
RCT 1+
There is not suffi cient scientifi c evidence to suggest that the combined treatment 
compared with pharmacological treatment has positive effects on the parents’ 
scores in the ADHD symptoms 3 months after treatment (1 RCT, N=20, Brown 
1985161) (SMD:0.25 [95% CI: -0.63 to 1.13]).
RCT 1+
Variable: Clinical improvement 7 to 12 months after the treatment
Scientifi c evidence
There is not suffi cient scientifi c evidence to suggest that the combined treatment 
compared with pharmacological treatment has positive effects on the teachers’ 
scores in ADHD symptoms 7-9 months after treatment (1 RCT, N=44, Firestone 
1986295) (SMD: 0.00 [95% CI: -0.59 to 0.59]).
RCT 1+
There is not suffi cient scientifi c evidence to suggest that the combined treatment 
compared with pharmacological treatment has positive effects on the parents’ 
and teachers’ scores in ADHD symptoms 10 months after treatment (1 RCT, 
N=264, MTA 199939) (SMD: -0.06 [95% CI: -0.30 to 0.18]).
RCT 1++
There is not suffi cient scientifi c evidence to suggest that the combined treatment 
compared with pharmacological treatment has positive effects on the teachers’ 
scores in behaviour 7-9 months after treatment (1 RCT, N=37, Firestone 
1986295) (SMD: 0.00 [95% CI: -0.65 to 0.65]).
RCT 1+
There is not suffi cient scientifi c evidence to suggest that the combined treatment 
compared with pharmacological treatment has positive effects on the parents’ 
and teachers’ scores in ADHD symptoms 10 months after treatment (1 RCT, 
N=264, MTA 199939) (SMD: -0.18, (95% CI: -0.42 to 0.06]).
RCT 1++
There is not suffi cient scientifi c evidence to suggest that the combined treatment 
compared with pharmacological treatment has positive effects on the parents’ 
and teachers’ scores in social skills 10 months after treatment (1 RCT, N=264, 
MTA 199939) (SMD: -0.21 [95% CI: -0.45 to 0.03]).
RCT 1++
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Variable: Clinical improvement 13 to 24 months after the treatment
Scientifi c evidence
There is not suffi cient scientifi c evidence to suggest that the combined treatment 
compared with pharmacological treatment has positive effects on the teachers’ 
scores in ADHD symptoms 19-21 months after treatment (1 RCT, N=21, 
Firestone 1986295) (SMD: -0.05 [95% CI: -0.90 to 0.81]).
RCT 1+
There is not suffi cient scientifi c evidence to suggest that the combined treatment 
compared with pharmacological treatment has positive effects on the parents’ 
and teachers’ scores in ADHD symptoms 22 months after treatment (1 RCT, 
N=242, MTA 199939) (SMD: -0.02 [95% CI: -0.27 to 0.23]).
RCT 1++
There is not suffi cient scientifi c evidence to suggest that the combined treatment 
compared with pharmacological treatment has positive effects on the teachers’ 
scores in behaviour 19-21 months after treatment (1 RCT, N=21, Firestone 
1986295) (SMD:-0.23IC95%: -1.09 to 0.63]).
RCT 1+
There is not suffi cient scientifi c evidence to suggest that the combined treatment 
compared with pharmacological treatment has positive effects on the parents’ 
and teachers’ scores in ADHD symptoms 22 months after treatment (1 RCT, 
N=242, MTA 199939) (SMD:-0.03, (95% CI: -0.27 to 0.20]).
RCT 1++
There is not suffi cient scientifi c evidence to suggest that the combined treatment 
compared with pharmacological treatment has positive effects1+ on the parents’ 
and teachers’ scores in social skills 22 months after treatment (1 RCT, N=242, 
MTA 199939) (SMD: 0.04 [95% CI: -0.21 to 0.29]).
RCT 1++
Variable: Educational aspects at the end of the treatment
Scientifi c evidence
There is not suffi cient scientifi c evidence to suggest that the combined treatment 
compared with pharmacological treatment has positive effects on reading after 
treatment (6 RCT, N=478, Abikoff 2004321; Brown 1985161; Firestone 1981322, 
1986295; Klein 1997164; MTA 199939) (SMD: 0.04 [95% CI: -0.14 to 0.22]).
RCT 1++
There is not suffi cient scientifi c evidence to suggest that combined treatment 
compared with pharmacological treatment has positive effects on mathematics 
after treatment (5 RCT, N=437, Abikoff 2004321; Brown 1985161; Firestone 
1986295; Klein 1997164; MTA 199939) (SMD: -0.03 [95% CI: -0.22 to 0.15]).
Variable: Educational aspects 3 to 6 months after treatment
Scientifi c evidence
There is not suffi cient scientifi c evidence to suggest that the combined treatment 
compared with pharmacological treatment has positive effects on reading 3 
months after treatment (1 RCT, N=20, Brown 1985161) (SMD: 0.19 [95% CI: 
-0.69 to 1.07]).
RCT 1+
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There is not suffi cient scientifi c evidence to suggest that the combined treatment 
compared with pharmacological treatment has positive effects on mathematics 
3 months after treatment (1 RCT, N=20, Brown 1985161) (SMD: -0.52 [95% CI: 
-1.42 to 0.37]).
RCT 1+
Variable: Educational aspects 7 to 12 months after treatment
Scientifi c evidence
There is not suffi cient scientifi c evidence to suggest that the combined treatment 
compared with pharmacological treatment has positive effects on reading 7-12 
months after treatment (2 RCT, N=303, Firestone 1986295, MTA 199939) (SMD: 
-0.02 [95% CI: -0.25 to 0.20]).
RCT 1++
Variable: Educational aspects 13 to 24 months after treatment
Scientifi c evidence
There is not suffi cient scientifi c evidence to suggest that the combined treatment 
compared with pharmacological treatment has positive effects on reading 13-
24 months after treatment (2 RCT, N=261, Firestone 1986295, MTA 199939) 
(SMD: -0.02 [95% CI: -0.26 to 0.23]).
RCT 1++
Summary of the scientifi c evidence
The results of the trials included in the NICE review (2009)2 on treatment 
of children with ADHD that compare the combined intervention with the 
pharmacological treatment alone indicate that there is little or no advantage of 
the combined intervention over medication alone. Compared with medication, 
there is no scientifi c evidence that the combined treatment provides advantages 
in measuring nuclear symptoms of ADHD, emotional state or self-effi cacy.
MA of RCT
1++
The only scientifi c evidence of the benefi t of the combined treatment over the 
medication alone is for the parents’ scores in behavioural problems at the end of 
the treatment; however, the benefi ts are limited, depending on the results of the 
effect size.No benefi ts were detected for the combined treatment in subsequent 
follow-ups after the end of treatment.
The MTA study (MTA 1999)39 is the trial with the largest number of cases of 
combined treatments with ADHD. Although the MTA data suggest that there 
is a small benefi cial effect of the combined treatment over medication for the 
parent’s scores with respect to behavioural problems at the end of the treatment, 
the effect size is small.
RCT
1++
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Clinical evidence of intensive combined treatment compared with 
normal (community) treatment for children with ADHD
The MTA study
The comparison between the intensive combined treatment of the MTA study (medication plus 
a multimodal psychological treatment for ADHD that consisted of intervention with the child, 
parents and intervention in the classroom) and the treatment group in community or normal treat-
ment, enables a comparison to be made between intensive treatment and standard care (MTA 
1999)39.
In the MTA study, children with ADHD were randomly assigned to the following four 
groups:pharmacological treatment, psychosocial treatment, a combination of pharmacological 
and psychosocial treatment, and normal treatment in community.The pharmacological treatment 
consisted of scheduled monthly visits when the medication dose was meticulously adapted in 
agreement with the evaluation scales of parents and teachers.A reduction in ADHD symptoms 
was shown in the children from the four treatment groups after 14 months, compared with the 
basal situation. The results of the two groups that had received pharmacological treatment (alone 
and combined) was better, regarding ADHD symptoms, than the results of the patients who only 
received psychosocial treatment or normal treatment in community (MTA, 1999)39. The improve-
ment of patients who only received psychosocial treatment was not signifi cantly greater than the 
improvement of the control group who received normal treatment in community (two thirds of 
the individuals from this group received treatment with stimulants). The normal treatment group 
in community had a more limited medical follow-up and was treated with lower daily doses of 
stimulants than those given to the group receiving pharmacological treatment.Almost a quarter of 
the individuals to whom the psychosocial treatment alone was assigned, required treatment with 
medication during the trial, due to the lack of effectiveness of the behavioural therapy.
The combined intervention of the MTA study gives an example of what could be considered 
as intensive care treatment for children with ADHD that continued for 1 year or more.
Variable: Benefi ts at the end of treatment
Scientifi c evidence
There is scientifi c evidence to suggest that the combined treatment compared 
with normal treatment in community has positive effects on the ADHD 
symptoms at the end of the treatment according to the teachers’ appraisal (1 
RCT, N=263, MTA 1999)39 (SMD: -0.64 [95% CI: -0.89 to -0.39]).
RCT 1++
There is scientifi c evidence to suggest that the combined treatment compared 
with normal treatment in community has positive effects on the ADHD 
symptoms at the end of the treatment according to the appraisal by parents (1 
RCT, N=263, MTA 1999)39 (SMD: -0.74 [95% CI: -0.99 to -0.49]).
RCT 1++
There is scientifi c evidence to suggest that the combined treatment compared 
with normal treatment in community has positive effects on behaviour at the 
end of the treatment according to the teachers’ appraisal (1 RCT, N=263, MTA 
1999)39 (SMD: -0.51 [95% CI: -0.76 to -0.26]).
RCT 1++
There is scientifi c evidence to suggest that the combined treatment compared 
with normal treatment in community has positive effects on  1++
behaviour at the end of the treatment according to the parents’ appraisal (1 
RCT, N=263, MTA 1999)39 (SMD: -0.53 [95% CI: -0.78 to -0.29]).
RCT 1++
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There is limited scientifi c evidence to suggest that the combined compared with 
normal treatment in community has positive effects on social skills at the end of 
the treatment according to the teachers’ appraisal (1 RCT, N=213, MTA 1999)39 
(SMD:-0.14 [95% CI: -0.22 to -0.06]).
RCT 1++
There is limited scientifi c evidence to suggest that the combined compared with 
normal treatment in community has positive effects on social skills at the end of 
the treatment according to the parents’ appraisal (1 RCT, N=252, MTA 1999)39 
(SMD:-0.27, (95% CI: -0.52 to -0.02]).
RCT 1+
There is not suffi cient scientifi c evidence to suggest that the combined treatment 
with normal treatment in community has positive effects on emotional results 
at the end of the treatment according to the teachers’ appraisal (1 RCT, N=213, 
MTA 1999)39 (SMD: -0.02 [95% CI: -0.29 to 0.25]).
RCT 1++
There is limited scientifi c evidence to suggest that the combined treatment 
compared with normal treatment in community has positive effects on emotional 
results at the end of the treatment according to the parents’ appraisal (1 RCT, 
N=252, MTA 1999)39 (SMD:0.27 [95% CI: -0.02 to 0.52]).
RCT 1++
Variable: Benefi ts 7 to 12 months after treatment
Scientifi c evidence
There is limited scientifi c evidence to suggest that the combined treatment 
compared with normal treatment in community has positive effects on ADHD 
symptoms 10 months after treatment according to the combined score of 
parents and teachers (1 RCT, N=273, MTA 199939) (SMD: -0.34, (95% CI: 
-0.58 to -0.10]).
RCT 1++
There is limited scientifi c evidence to suggest that the combined treatment 
compared with normal treatment in community has positive effects on behaviour 
10 months after treatment according to the combined score of parents and 
teachers (1 RCT,, N=273, MTA 199939) (SMD: -0.31 (95% CI: -0.55 to -0.07]).
RCT 1++
There is not suffi cient scientifi c evidence to suggest that the combined treatment 
with normal treatment in community has positive effects on social skills 10 
months after treatment according to the combined score of parents and teachers 
(1 RCT, N=273, MTA 199939) (SMD: -0.17 [95% CI: -0.41 to 0.06]).
RCT 1+
Variable: Benefi ts 13 to 24 months after treatment
Scientifi c evidence
There is not suffi cient scientifi c evidence to suggest that the combined treatment 
with normal treatment in community has positive effects on ADHD symptoms 
22 months after treatment according to the combined score of parents and 
teachers (1 RCT, N=243, MTA 199939) (SMD: -0.11 [95% CI: -0.36 to 0.15]).
RCT 1+
There is strong scientifi c evidence to suggest that the combined treatment 
compared with normal treatment in community has positive effects on behaviour 
22 months after treatment according to the combined score of parents and 
teachers (1 RCT, N=243, MTA 199939) (SMD: -0.82 [95% CI: -1.08 to -0.56]).
RCT 1++
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There is not suffi cient scientifi c evidence to suggest that the combined treatment 
with normal treatment in community has positive effects on social skills 22 
months after treatment according to the combined score of parents and teachers 
(1 RCT, N=243, MTA 199939) (SMD: 0.04 [95% CI: -0.21 to 0.29]).
RCT 1++
Variable: Educational aspects at the end of treatment
Scientifi c evidence
There is little scientifi c evidence to suggest that the combined treatment 
compared with normal treatment in community has positive effects on reading 
after treatment (1 RCT, N=267, MTA 199939) (SMD: -0.27 [95% CI: -0.51 to 
-0.03]).
RCT 1++
There is not suffi cient scientifi c evidence to suggest that the combined 
treatment compared with normal treatment in community has positive effects 
on mathematics after treatment (1 RCT, N=267, MTA 199939) (SMD: -0.01 
[95% CI: -0.25 to 0.23]).
RCT 1++
Variable: Educational aspects 7 to 12 months after end of treatment
Scientifi c evidence
There is little scientifi c evidence to suggest that the combined treatment 
compared with normal treatment in community has positive effects on reading 
after treatment (1 RCT, N=267, MTA 199939) (SMD: -0.27 [95% CI: -0.51 to 
-0.03]).
RCT 1++
There is not suffi cient scientifi c evidence to suggest that the combined 
treatment compared with normal treatment in community has positive effects 
on mathematics after treatment (1 RCT, N=267, MTA 199939) (SMD: -0.01 
[95% CI: -0.25 to 0.23]).
RCT 1++
Variable: Educational aspects 7 to 12 months after end of treatment
Scientifi c evidence
There is not suffi cient scientifi c evidence to suggest that the combined treatment 
compared with normal treatment in community has positive on reading 10 
months after treatment (1 RCT, N=273, MTA 199939) (SMD: -0.19 [95% CI: 
-0.43 to 0.05]).
RCT 1++
There is not suffi cient scientifi c evidence to suggest that the combined treatment 
compared with normal treatment in community has positive effects on reading 
after treatment (1 RCT, N=243, MTA 199939) (SMD: -0.12 [95% CI: -0.37 to 
0.13]).
RCT 1++
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The combined intervention of MTA is generally more effi cient than normal treatment in the 
community according to the scores of parents and teachers for ADHD symptoms and behaviour 
problems.According to the joint appraisals of parents and teachers of ADHD symptoms in follow-
ups, the combined treatment continues having better results than normal treatment in community 
10 months after the intervention, but the effect size is small.In the 22-month follow-up, neither 
the combined treatment nor the normal treatment in the community obtained positive results 
according to the joint appraisals for ADHD symptoms. However, in the measurements of the 
behaviour problems, the combined treatment is more effi cient than normal treatment. At the end 
of the intervention, according to scores of parents and teachers, the reduction of the behaviour 
problems was greater with the combined treatment than with the normal treatment, the effect size 
being moderate. The score of parents and teachers for behaviour problems in subsequent follow-
ups indicated that the benefi cial effect of the combined treatment was reduced to a small effect 10 
months after the intervention, but this effect was greater 22 months after treatment.
The scores of parents and teachers on social skills at the end of the intervention show small 
improvements with the combined treatment compared with normal treatment in the community, 
but this small effect disappears in subsequent follow-ups, according to the joint appraisals for 
parents and teachers.
The parents’ scores on the emotional state of the child show a small advantage of the 
combined treatment compared with the normal treatment at the end of the intervention.However, 
the teachers’ scores do not show this advantage at the end of the intervention.
When the joint results are taken into consideration, it seems that there is some benefi t of the 
combined treatment over the normal treatment in the community.The measurements of ADHD 
symptoms at the end of the intervention indicate that the combined treatment is moderately more 
effective in nuclear symptoms than the treatment in the community, and that it may have benefi cial 
effects on behaviour problems.However, the key factor to generate the positive effects of the 
combined treatment may be the management of the medication.In any case, the comparison of 
the results of the MTA study on the combined intensive treatment group and the normal treatment 
in community does not offer a consistent indication that the intensive treatment is more effective 
than the normal treatment, which includes medication for ADHD.The advantage of the combined 
intensive treatment over the normal treatment should be considered in the context of the evaluation 
of whether the combined treatment is effi cient compared with a specifi c pharmacological treatment.
Summary of the scientifi c evidence
The scientifi c evidence of the trials that compare combined treatment with 
pharmacological treatment alone shows no benefi cial effects when adding 
psychological intervention to the medication protocol. The data suggest that 
if the pharmacological treatment for ADHD has already been established, and 
the child has responded positively, adding psychological intervention to treat 
ADHD (parenttraining programmeor directly for the child) show no additive 
effects over the nuclear symptoms of ADHD, disturbing behaviour, emotional 
state and/or self-effi cacy(NICE, 2009)2.
MA of RCT
1++
The psychological intervention is effective as a contribution to the normal 
medication. This may be because the medication is less effective in normal 
clinical practice than in the context of a clinical trial. The same occurs in the MTA 
study (MTA, 1999)39, which suggests that the combination of interventions may 
help treat certain problems and favour some results. Several authors defi ned the 
usefulness of multimodal treatment to improve the symptoms.
RCT
1++
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Clinical evidence of intensive combined treatment compared with 
normal (community) treatment for children with ADHD
Summary of the scientifi c evidence
The NICE guideline (2009)2 conducts a direct review of the effi cacy of the 
psychological and pharmacological treatments for ADHD.
6 RCTs of studies published between 1976 and 1999 are included (Brown 
1985161; Firestone 1981322, 1986295; Gittelman-Klein 1976297; Klein 1997164; 
MTA 199939).
Generally speaking, for children with ADHD, the scientifi c evidence of the 
trials that compare stimulant medication (predominantly methylphenidate) 
with psychological intervention given to a group without pharmacological 
treatment, generally favours stimulant medication, although in the cases where 
it reaches statistical signifi cance, the effect sizes are not great.
The quality of the trials is moderate to high.
MA of RCT 
1+, 1++
The AACAP guideline (2007)72 specifi es the study by Jadad, et al. (1999)276, that 
reviewed 78 ADHD treatment studies; 6 of these compared pharmacological 
and non-pharmacological interventions. The reviewers indicated that the 




Variable: Benefi ts at the end of treatment
Scientifi c evidence
There is strong scientifi c evidence to suggest that pharmacological treatment 
compared with psychological treatment has positive effects on ADHD 
symptoms at the end of the treatment according to the teachers’ appraisal (5 
RCT, N=392, Brown 1985161; Firestone 1981322, 1986295; Klein 1997164; MTA 
199939) (SMD: -0.72 [95% CI: -1.12 to -0.32]).
RCT 1++
There is scientifi c evidence to suggest that pharmacological treatment compared 
with psychological treatment has positive effects on  ADHD symptoms at the 
end of the treatment according to the parents’ appraisal(4 RCT, N=350, Brown 
1985161; Firestone 1981322, 1986295; Klein 1997164; MTA 199939) (SMD: -0.45 
[95% CI: -0.66 to -0.23]).
RCT 1++
There is scientifi c evidence to suggest that pharmacological treatment compared 
with psychological treatment has positive effects on behaviour at the end of the 
treatment according to the teachers’ appraisal(3 RCT, N=321; Firestone 1981322, 
1986295; Klein 1997164; MTA 199939) (SMD: -0.48 [95% CI: -0.70 to -0.25]).
RCT 1++
There is limited scientifi c evidence to suggest that pharmacological treatment 
compared with psychological treatment has positive effects on behaviour at 
the end of the treatment according to the parents’ appraisal(3 RCT, N=355; 
Firestone 1986295, 1986295; Klein 1997164; MTA 199939) (SMD: -0.22 [95% CI: 
-0.43 to -0.01]).
RCT 1++
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There is limited scientifi c evidence to suggest that pharmacological treatment 
compared with psychological treatment has positive effects on social skills at 
the end of the treatment according to the teachers’ appraisal (2 RCT, N=258, 
Klein 1997164; MTA 199939) (SMD:-0.33 [95% CI: -0.57 to -0.08]).
RCT 1++
There is not scientifi c evidence to suggest that pharmacological treatment 
compared with psychological treatment has positive effects on social skills at 
the end of the treatment according to the parents’ appraisal (1 RCT, N=151, 
MTA 199939) (SMD: -0.08 [95% CI: -0.33 to 0.17]).
RCT 1++
There is not suffi cient scientifi c evidence to suggest that the combined treatment 
compared with psychological treatment has positive effects on (internalized) 
emotional symptoms at the end of the treatment according to the teachers’ 
appraisal (2 RCT, N=158, Klein 1997164; MTA 199939) (SMD: 0.14 [95% CI: 
-0.10 to 0.39]).
RCT 1++
There is limited scientifi c evidence to suggest that pharmacological treatment 
compared with psychological treatment has positive effects on (internalized) 
emotional symptoms at the end of the treatment according to the parents’ 
appraisal(3 RCT, N=331; Firestone 1981322, 1986295; Klein 1997164; MTA 
199939) (SMD: -0.23 [95% CI: -0.45 to -0.01]).
RCT 1++
Variable: Benefi ts 3 to 6 months after treatment
Scientifi c evidence
There is not suffi cient scientifi c evidence to suggest that the combined treatment 
compared with psychological treatment has positive effects effects on ADHD 
symptoms 3 months after treatment according to the score of teachers (1 RCT, 
N=20, Brown 1985161) (SMD:-0.20 [95% CI: -1.58 to 0.68]).
RCT 1+
There is not suffi cient scientifi c evidence to suggest that the combined 
treatment compared with psychological treatment has positive effects on 
ADHD symptoms 6 months after treatment according to the score of parents (1 
RCT, N=20, Brown 1985161) (SMD: -0,82[95% CI -1.74 to 0.11]).
RCT 1+
Variable: Benefi ts 7 to 12 months after treatment
Scientifi c evidence
There is not suffi cient scientifi c evidence to suggest that the combined treatment 
compared with psychological treatment has positive effects on ADHD 
symptoms 7 to 9 months after treatment according to the score of teachers (1 
RCT, N=35, Firestone 1986295) (SMD: -0.53 [95% CI: -1.23 to 0.17]).
RCT 1+
There is limited scientifi c evidence to suggest that pharmacological treatment 
compared with psychological treatment has positive effects on on ADHD 
symptoms 10 months after treatment according to the combined score of 
parents and teachers (1 RCT, N=267, MTA 199939) (SMD: -0.25 [95% CI: 
-0.49 to -0.01]).
RCT 1++
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There is not suffi cient scientifi c evidence to suggest that the combined treatment 
compared with psychological treatment has positive effects on behaviour 7 
to 9 months after treatment according to the score of parents (1 RCT, N=34, 
Firestone 1986295) (SMD: -0.32 [95% CI: -1.02 to 0.38]).
RCT 1+
There is not suffi cient scientifi c evidence to suggest that the combined treatment 
compared with psychological treatment has positive effects on behaviour 10 
months after treatment according to the combined score of parents and teachers 
(1 RCT, N=267, Firestone 1986295) (SMD: -0.10 [95% CI: -0.34 to 0.14]).
RCT 1++
There is not suffi cient scientifi c evidence to suggest that the combined treatment 
compared with psychological treatment has positive effects on social skills 10 
months after treatment according to the combined score of parents and teachers 
(1 RCT, N=267, MTA 199939) (SMD: -0.07 [95% CI: -0.31 to 0.17]).
RCT 1++
Variable: Benefi ts 13 to 24 months after treatment
Scientifi c evidence
There is not suffi cient scientifi c evidence to suggest that the combined treatment 
compared with psychological treatment has positive effects on ADHD 
symptoms 19 to 21 months after treatment according to the score of teachers (1 
RCT, N=30, Firestone 1986295) (SMD:0.00 [95% CI: -0.88 to 0.88]).
RCT 1+
There is not suffi cient scientifi c evidence to suggest that the combined 
treatment compared with psychological treatment has positive effects on 
ADHD symptoms 19 to 21 months after treatment according to the score of 
parents (1 RCT, N=20, Brown 1985161) (SMD:0.58 [95% CI: -0.32 to 1.48]).
RCT 1+
There is not suffi cient scientifi c evidence to suggest that the combined 
treatment compared with psychological treatment has positive effects on 
ADHD symptoms 13 to 24 months after treatment according to the combined 
score of parents and teachers (1 RCT, N=242, MTA 199939) (SMD: -0.06 [95% 
CI: -0.21 to 0.09]).
RCT 1++
There is not suffi cient scientifi c evidence to suggest that the combined treatment 
compared with psychological treatment has positive effects on behaviour 22 
months after treatment according to the combined score of parents and teachers 
(1 RCT, N=243, MTA 199939) (SMD: 0.00 [95% CI: -0.25 to 0.25]).
RCT 1++
There is not suffi cient scientifi c evidence to suggest that the combined treatment 
compared with psychological treatment has positive effects on social skills 22 
months after treatment according to the combined score of parents and teachers 
(1 RCT, N=243, MTA 199939) (SMD: -0.04 [95% CI: -0.29 to 0.21]).
RCT 1++
Variable: Educational aspects at the end of the treatment
Scientifi c evidence
There is not suffi cient scientifi c evidence to suggest that the combined treatment 
compared with psychological treatment has positive effects on reading after 
treatment (5 RCT, N=397 Brown 1985161; Firestone 1981322, 1986295; Klein 
1997164; MTA 199939) (SMD:-0.10, (95% CI: -0.3’ to 0.09]).
RCT 1++
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There is not suffi cient scientifi c evidence to suggest that the combined treatment 
compared with psychological treatment has positive effects on mathematics 
after treatment (4 RCT, N=358, Brown 1985161; Firestone 1981322, Klein 
1997164; MTA 199939) (SMD:0.01 [95% CI: -0.20 to 0.22]).
RCT 1++
Variable: Educational aspects 3 to 6 months after treatment
Scientifi c evidence
There is not suffi cient scientifi c evidence to suggest that the combined treatment 
compared with psychological treatment has positive effects on reading 3 
months after treatment (1 RCT, N=20, Brown 1985161) (SMD: 0.11 [95% CI: 
-0.77 to 0.99]).
RCT 1+
There is not suffi cient scientifi c evidence to suggest that the combined treatment 
compared with psychological treatment has positive effects on mathematics 3 
months after treatment (1 RCT, N=20, Brown 1985161) (SMD: 0.57 [95% CI: 
-0.32 to 1.47]).
RCT 1+
Variable: Educational aspects 7 to 12 months after treatment
Scientifi c evidence
There is not suffi cient scientifi c evidence to suggest that the combined treatment 
compared with psychological treatment has positive effects on reading 7-10 
months after treatment (2 RCT, N=301, Firestone 1986295, MTA 199939) (SMD: 
-0.05 [95% CI: -0.27 to 0.18]).
RCT 1++
Variable: Educational aspects 13 to 24 months after treatment
Scientifi c evidence
There is not suffi cient scientifi c evidence to suggest that the combined treatment 
compared with psychological treatment has positive effects on reading 19-22 
months after treatment (2 RCT, N=260, Firestone 1986295, MTA 199939) (SMD: 
0.03 [95% CI: -0.22 to 0.27]).
RCT 1++
For the scores of parents and teachers on the nuclear symptoms of ADHD and behaviour 
problems at the end of the treatment, stimulant medication provides better results than 
psychological intervention, with effect sizes that vary from small to moderate.However, the 
benefi ts of stimulant medication on psychological therapies for nuclear symptoms of ADHD 
and behaviour problems in general are not sustained in follow-up appraisals (3-6 months, 7-12 
months and 13-24 months after the end of the treatment).The MTA study fi nds a benefi t of 
medication over the psychological intervention in the combined measurements for parents and 
teachers on nuclear symptoms of ADHD 10 months after treatment, but the effect size was small.
Stimulant medication seems to be more effective than psychological intervention in 
the improvement of social skills appraised by teachers, but this effect was small at the end 
of the treatment and not sustained in the follow-ups.It was not refl ected either in the parents’ 
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measurements of social skills, which indicates that there is no positive infl uence of the stimulant 
medication on the social skills at the end of the treatment or during follow-up.In the measurements 
of the emotional state (depression, anxiety, emotional adjustment and internalized symptoms), 
the stimulant medication was more effective than the psychological intervention at the end of 
the treatment, but the effect size was small and limited in the parents’ measurements, with no 
effect in the teachers’ measurements.
The lack of scientifi c evidence of the sustained superiority of the medication over 
psychological intervention for ADHD is diffi cult to interpret.For longer follow-ups in time, 
the results can be infl uenced by the treatment that the child has received since the end of the 
experimental intervention period.In particular, children that received psychological intervention 
and were not medicated for ADHD during the trial period were able to start to receive medication 
for ADHD later on.In the MTA study, 44% of the children of the group that only received 
psychological intervention during the study had started stimulant medication after the 10-month 
follow-up.22 months after the end of the treatment, 45% of the children had started stimulant 
medication.
Summary of the scientifi c evidence
Although there is scientifi c evidence about the superiority of the pharmacological 
intervention with respect to the psychological intervention, when stimulant 
medication is compared with complex psychological intervention (as offered 
in the MTA study), the benefi ts of the medication respect to the psychological 




Summary of the scientifi c evidence
The NICE CPG (2009)2 has reviewed the available scientifi c evidence on 
economic cost-effectiveness studies for pharmacological and psychological 
treatment and a treatment combination in children with ADHD: Lord & Paisley 
2000323, Zupancic, et al., 1998290.
The NICE economic model was also used, about the use of methylphenidate, 
atomoxetine and dexamphetamine in children with ADHD via a subanalysis 
that compared the combination of interventions with the medications evaluated 
(King, et al., 2006)201.
An economic analysis of the interventions assessed in the MTA study was 





Lord & Paisley (2000)323 performed an economic analysis that compared the 
cost-effectiveness of the combination of interventions with psychological 
therapy alone for children with ADHD in the United Kingdom, based on the 
data of the MTA study(1999)39, the results favour the combined treatment. 
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The scientifi c evidence of Zupancic, et al. (1998)290 suggests that combined and 
psychological therapy is not a cost-effective option compared with medication 
for children with ADHD. However, there are limitations in the clinical 




The review of the economic analysis of King et al.(2006)201 suggests that 
group behavioural therapy is more cost-effective than combined treatment and 
medication for children with ADHD. On the other hand, medication is more 
cost-effective than individual behavioural therapy. Combined therapy was not 




The review by Jensen et al.(2005)324 and Foster, et al. (2007)325 on the MTA 
study (MTA 1999)39 concludes that, for children with ADHD, the management 
of the medication, although not so effective as the combined therapy, is a more 
cost-effective option, above all for children with associated comorbid disorders. 
For children with comorbid ADHD with both internalizedand externalising
 disorders, they suggest that the combined treatment is relatively cost-effective.
The medication management was the most suitable option from the cost-





Different reasons why it is advisable to use multimodal treatment for 
ADHD (NICE, 2009)2
There are several reasons why non-pharmacological treatment, normally psychological treatment, 
can be combined with pharmacological treatment:
 • When psychological intervention is the option preferred by children and adolescents, 
and their families, but due to the seriousness of the symptoms, this may not be feasible 
at that time.However, the medication’s potential to provide a fast initial improvement 
over the fi rst few weeks of a combined intervention may help them benefi t from the 
psychological techniques later on.
 • In serious cases, it may be advisable to start the pharmacological treatment in order to 
offer more immediate improvement effects. This may be necessary if there is a marked 
social dysfunction, a lot of pressure from the family or companion, if the child is facing 
an impending school expulsion.
 • Behavioural learning in psychological treatment may be favoured by the combined use 
of pharmacological treatment.
 • Combining pharmacological treatment with psychological intervention may lead to a 
reduction in the drug doses and also in concerns about the use of the medication.
Recommendations
B 7.4.2.1.
In children and adolescents with moderate or serious ADHD, combined 
treatment is recommended, which includes behavioural psychological 
treatment, pharmacological treatment and psychopedagogical 
intervention at school.
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7.5. Comorbidity treatment
Questions to be answered:
7.5.1. In children and adolescents with ADHD: What must be done with comorbid epilepsy?
7.5.2. In children and adolescents with ADHD: What must be done with comorbid autism 
spectrum disorders?
7.5.3. In children and adolescents with ADHD: What must be done with comorbid mood dis-
orders?
7.5.4. In children and adolescents with ADHD: What must be done with comorbid bipolar 
disorder?
7.5.5. In children and adolescents with ADHD: What must be done with comorbid substance 
abuse?
This section describes the scientifi c evidence about the therapeutic strategy of ADHD in children 
and adolescents associated with the comorbidities that the guideline development group considers 
important, due to the possible change in treatment strategy or to doubts with respect to the 
intervention.
A description is given below of the treatment strategy for children and adolescents with 
ADHD with comorbidity:Epilepsy, autism spectrum disorders (ASD), emotional disorders and 
substance use disorder.
7.5.1. In children and adolescents with ADHD: What must be done 
with comorbid epilepsy?
The answer is based on the review by Torres, et al. (2008)326; Schubert (2005)327 and Artigas-
Pallarés (2003)328.
Summary of the scientifi c evidence
The reviews by Torres, et al. (2008)326 and Schubert (2005)327 indicate that the 
available scientifi c evidence supports the use of methylphenidate for treating 
ADHD in children with epileptic crises.
They also suggest that the treatment should be part of a biopsychosocial 
intervention.
SR of cases 
series and 
cohort studies 2+
Epilepsy is not in itself a contraindication for the use of methylphenidate if the 
crises are controlled (Artigas-Pallarés, 2003)328.
Experts’ opinion.
4
Atomoxetine does not increase the risk of epileptic crises in patients with
ADHD.
To date, there is no scientifi c evidence about the safety of atomoxetine in children 
and adolescents with ADHD and comorbid epilepsy(Schubert, 2005)327.
SR of case 
series and 
cohort studies 2+
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Recommendations
C 7.5.1.1. The use of methylphenidate is not contraindicated in children and 
adolescents with ADHD and comorbid epilepsy.
7.5.2. In children and adolescents with ADHD: What must be done 
with comorbid autism spectrum disorders?
The answer is based on the guidelines of the Autism Spectrum Disorders Study Group (Fuentes-
Biggi, et al., 2006)329. Also on the studies by Posey, et al. (2006)330 and Troost, et al. (2006)331.
Summary of the scientifi c evidence
The guideline of the ASD Study Group (Fuentes-Biggi, et al., 2006)329 indicates, 
in connection with people with ASD in whom ADHD has also been identifi ed, 
that the treatment with stimulants decreases the stereotypes and inappropriate 
language.In these cases, the drug must be used with caution as its benefi cial 
effect is less and adverse effects have been described more frequently than 
in the general population with ADHD. These effects include:withdrawal, 




No quality studies have been found in the searches made to prepare this CPG 
on the effi cacy and safety of atomoxetine for treating ADHD in children and 
adolescents, comorbid to ASD.
Two open-ended trials have been found by Posey, et al. (2006)330 and Troost, 
et al.(2006)331 performed with small samples (n=16, n=12) on children and 
adolescents with ADHD (6 to 14 years old) that assess the tolerability and 
effi cacy of atomoxetine for ADHD symptoms in children with ASD.
The authors’ conclusions suggest that atomoxetine can be an effi cient treatment 
for ADHD symptoms in children with ASD.However, they may be more 





The use of methylphenidate and atomoxetine is not contraindicated in 
children and adolescents with ADHD and comorbid autism spectrum 
disorders. However, they must be used with caution.
148  CLINICAL PRACTICE GUIDELINE ON ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) IN CHILDREN AND ADOLESCENTS
7.5.3. In children and adolescents with ADHD: What must be done 
with comorbid mood disorders?
The answer is based on the Texas Children’s Medication Algorithm Project guideline (Pliszka, et 
al., 2006)332. Also in the review by Artigas-Pallarés (2003)328.
Summary of the scientifi c evidence
The Texas Children’s Medication Algorithm Project (Pliszka, et al., 2006)332 
indicates that in the cases of children and adolescents with comorbid ADHD 
anddepressive disorder, the physician must focus, to start with, on treating the 
most intense disorder and that affects the child the most. Establishing one single 
drug is recommended for one of the disorders, the most intense one.
Experts’ 
opinion 4
The use of atomoxetine has been studied to treat patients with ADHD and 
associated anxiety (Sumner, et al., 2005)333. At the end of the treatment period, 
the atomoxetine had signifi cantly reduced the score of symptoms of ADHD and 
anxiety compared with placebo. Another study indicated that there are no data 
to show that atomoxetine is effi cient to treat major depressive disorder (Bangs, 
et al., 2005)334.
RCT1+
Despite the fact that pharmacological indication is well established for ADHD 
and depression, doubts arise about which medication is the most suitable to start 
with, methylphenidate, an SSRI or the association between both.Depending on 
the most marked symptoms, the use of the stimulant medication of the SSRI 





In children and adolescents with ADHD and comorbid mood disorders, 
it is advisable to fi rstly treat the more intense disorder and that might 
have greater repercussion on the patient.
B 7.5.3.2.
In children and adolescents with ADHD and associated anxiety, the use 
of atomoxetine is recommended as treatment of fi rst choice, as it has 
proved to be effi cient to treat both disorders.
7.5.4. In children and adolescents with ADHD: What must be done 
with comorbid bipolar disorder?
The answer is based on the AACAP guideline for bipolar disorder (2007)335. Also on the MA by 
Consoli, et al. (2007)336 and the review by Kowatch (2005)337.
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Summary of the scientifi c evidence
The practical parameters of AACAP (2007)335 for bipolar disorder indicate 
that comorbidity with ADHD predicts a worse response to the treatment. So, 
although the drugs used in adults may be useful, adolescents may be more 
diffi cult to treat, and require other interventions apart from the pharmacological 
intervention (State, et al., 2004)338.
For patients with a clear bipolar disorder, the stimulant medication may be 
useful to treat ADHD symptoms once the mood symptoms have been suitably 
controlled with other drugs.
Experts’ 
opinion 4
In the MA by Consoli, et al. (2007)336 5 open-ended trials were assessed (n=273) 
on children and adolescents with bipolar disorder, divided into two subgroups:.
with or without ADHD
The objective was to assess if the comorbid ADHD has an infl uence on the 
response to the treatment of adolescents with acute mania.
The authors’ conclusion suggests that children and adolescents with bipolar 
disorder and ADHD tend to respond less to the pharmacological treatment used 
for the acute mania. The treatment administered in the majority of the trials was 
lithium.
MA of controlled 
trials
1-
Kowatch (2005)337 indicates that the ADHD symptoms may worsen and 
complicate the treatment of the bipolar disorder, so he recommends the careful 
use of stimulants, if they are clinically indicated, only when the bipolar 
symptoms have been controlled by a mood stabiliser.Non-stimulants such as 
atomoxetine and tricyclic antidepressants may, due to their activity, induce 





In the cases of clear bipolar disorder comorbidity with ADHD in 
children and adolescents, stimulant medication may be useful to treat 
ADHD once the mood symptoms have been adequately controlled with 
other drugs.
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7.5.5. In children and adolescents with ADHD: What must be done 
with comorbid substance abuse?
The answer is based on the reviews by Kollins (2008)340, Upadhyaya (2007)341 and Wilens, et al. 
(2003, 2005)317,318.
Scientifi c evidence
Kollins (2008)340 indicates that the abuse and inadequate use of the prescription 
of stimulants are especially concerning when treating adolescents and children.
Short-term stimulants may have a greater potential for abuse or inadequate use, 
although more data are required to confi rm this observation.
Treatment with non-stimulant drugs may be considered for ADHD in patients 
with a high risk of substance abuse or improper use of stimulants.
Experts’ 
opinion 4
The review by Upadhyaya (2007)341 indicates that patients with ADHD and 
substance use disorder start to use substances at a younger age, they may take 
longer to reach remission, they have a longer course, worse results and higher 
rates of other psychiatric comorbidities.
There is scientifi c evidence of the incorrect use of stimulant medication, which 
suggests safety concerns.The pharmacological treatment studies for ADHD 
comorbid to substance abuse are limited, but they have shown that stimulant 
medication does not favour the use of substances.
Non-stimulant medication for ADHD and long-term stimulant formulas are 
available and using them incorrectly is less likely.
According to these authors, the clinical recommendations to treat this dual 
diagnosis include the use of non-stimulants or long-term formulas combined 
with psychosocial therapy to treat ADHD and substance use disorder.
Narrative 
review 3
Wilens, et al. (2005)317 performed a MA to assess the role of medication to treat 
ADHD in individuals with ADHD and substance abuse.
9 studies were included (4 of adolescents and 5 of adults, n = 222).
The authors’ conclusions suggest that the pharmacological treatment (stimulant 
or non-stimulant) in ADHD comorbid to substance use has a moderate impact 
on the result of both disorders.This improvement has not been observed in 
controlled tests with placebo.
From the safety perspective, there is no scientifi c evidence of a worsening of 





Wilens, et al. (2003)318 performed a MA with 6 long-term studies (prospective 
and retroprospective) that assessed children with ADHD (n = 1034) treated with 
and without medication to evaluate the results of substance use in adolescents 
or adults.
These authors’ conclusion suggests that stimulant therapy in childhood is 
associated with the reduction of the risk of disorders caused by the abuse of 
substances, alcohol and cigarettes, and that it has a greater protective effect 
(Wilens, 2008)342.
MA of cohort 
studies 2++
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Summary of the scientifi c evidence
The treatment with stimulants and non-stimulants in children and adolescents 
with ADHD represents a protective factor against the consumption of 
substances(Wilens, et al., 2005317; 2003318).




In the case of comorbidity of ADHD and substance use disorder in 
children and adolescents, treatment with non-stimulants or with long 
acting stimulants is indicated.
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7.6. Complementary and alternative medicine
Questions to be answered:
7.6.1. Complementary and alternative medicine: What does it consist of?
7.6.2. To treat ADHD in children and adolescents:Are complementary and alternative therapies 
effi cient?
7.6.1. Complementary and alternative medicine: What does it consist 
of?
The Cochrane Collaboration defi nes complementary and alternative medicine (CAM) as a broad 
domain of healing resources that encompasses all health systems, modalities, and practices and 
their accompanying theories and beliefs.Complementary and alternative therapies are different to 
those established by traditional health system in a culture and period (Chan, 2002)343.
The practices and products of complementary and alternative medicine are not considered to 
be an integral part of standard allopathic clinical practice. Alternative medicine refers to the use 
of treatments other than standard ones.Complementary medicine indicates the use of alternative 
treatments applied together with standard treatments (web page of the NIH, 2009)344.
Due to the exponential increase of complementary and alternative medicine or therapies 
over the last few years, health professionals are continuously receiving doubts and questions from 
their patients and carers about their use.On the other hand, many patients do not disclose their 
use to their physicians, with the possible interference in the medical treatment or adverse effects.
Due to many different causes, such as a lack of knowledge of ADHD in the general public, 
the despair of parents, social pressure, fear of medication and the broad offer that exists, there is 
a great variety of alternative treatments that lack scientifi c basis, whose effi cacy and safety has 
not been proved, and which are advertised as the panacea in ADHD (Soutullo & Diez, 2007)79.
Some of the alternative therapies for ADHD in children and adolescents include: dietetic 
treatments, optometry treatments, homeopathy, herbal medicine, auditory stimulation (Tomatis 
method) and encephalogram biofeedback (EEG-biofeedback, neurofeedback or neurotherapy), 
psychomotricity and osteopathy.
7.6.2. To treat ADHD in children and adolescents:Are complementary 
and alternative therapies effi cient?
The answer is based on the NICE (2009)2, SIGN (2005)1, AACAP (2007)72 guidelines, the 
Cochrane 1++ quality SR by Coulter & Dean (2007)345, 1+ quality RCT by Weber, et al. (2008)346 
and the RCT by Pintov, et al. (2005)347.
Dietetic treatments
It is popularly believed that many reactions to food and drink lead to hyperactive behaviour.
Dietetic treatments consist in including supplementary substances in the diet that are believed 
to be benefi cial to palliate a defi cit, or exclude substances that are believed to be harmful for the 
organism.
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Elimination interventions include those that lead to the discovery and elimination of 
substances from the individual diet of each child, for example, the elimination of tartrazine, 
artifi cial colouring agents and preserving agents. The use of fatty acids is one of the most 
outstanding supplementary interventions (NICE, 2009)2.
Summary of the scientifi c evidence
Research has encountered many diffi culties in the methodology and feasibility to 
study dietetic treatments.The quality of the scientifi c evidence is generally poor, 
refl ecting the limited amount of data.Therefore, these have been studied based 
on a narrative approach instead of a systematic approach, and no signifi cant 
conclusion has been found.The scientifi c evidence that supplementary or 
elimination diets, when compared with placebo, can reduce the symptoms of 
ADHD is not conclusive (NICE, 2009)2.
RCT1-
The SIGN guideline (2005)1 found insuffi cient scientifi c evidence to support 
the normal use of this type of interventions to treat ADHD. So diet restrictions 
or eliminations are not recommended in children with ADHD.
Experts’ 
opinion 4
The AACAP guideline (2007)72 indicates that there is not scientifi c evidence to 
support these interventions in patients with ADHD.
Experts’ 
opinion 4
The AAP guideline (2001)180 indicates that these interventions are not supported 




This consists of visual training sessions carried out by an optometrist in order to improve or 
develop visual skills or palliate defi ciencies that affect ADHD. The treatment is carried out by 
way of visual exercises and the use of coloured lenses, personalised glasses, fi lters, prisms and 
light.
No quality studies have been found in the searches made to prepare this CPG on the effi cacy of 
optometry treatments for treating ADHD in children and adolescents.
Homeopathy
Over the last few years, homeopathy has gained in importance as an alternative therapy. It is 
a therapeutic system founded by Samuel Hahnemann (1755-1843), based on the principle of 
similarity where “similars are cured by similars”.The diseases are treated by highly diluted 
substances that, in healthy people, cause the symptoms of the disease to be treated.The dilutions 
are repeated as many times as there is less than one molecule per dose and it is suggested that 
the benefi t comes from the vital energy force of the original substance. Homeopathy focuses on 
the unique traits of each patient, their experience and symptoms, and it uses this information to 
determine the prescription for each patient (Coulter & Dean, 2007)345.
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Summary of the scientifi c evidence
The Cochrane review by Coulter & Dean (2007)345 assesses the scientifi c 
evidence of the effi cacy, effectiveness and safety/tolerability of homeopathy as 
an intervention for ADHD. 4 studies were included: Jacobs, 2005348; Lamont, 
1997349; Strauss, 2000350; Frei, 2005351. No studies were found on safety/
tolerability.
In general, the results of this review do not suggest scientifi c evidence of 
the effectiveness of homeopathy for the global symptoms of ADHD, nuclear 
symptoms or associated symptoms such as anxiety in ADHD.
The conclusions of the authors of the review suggest that there is little scientifi c 




Use of medicines derived from botanical sources, using their therapeutic properties, fl avour or 
essence. Herbal medicine products are dietetic supplements. They are sold in tablets, capsules, 
powder, infusions, extracts, and dry or fresh.However, some many cause health problems, some 
are not effective or they may interact with other medications.
Summary of the scientifi c evidence
The SIGN guideline (2005)1 did not fi nd any scientifi c evidence of an acceptable 




The AAP guideline (2001)180 indicates that these interventions are not supported 
by scientifi c evidence-based studies.
Experts’ 
opinion 4
Weber, et al. (2008)346 conducted a study on the effi cacy and safety of 
Hypericum perforatum (St. John’s Wort) in a group of children with ADHD 
(n=54, 6 to 17 years old) compared with placebo. The intervention lasted for 
8 weeks. The results of the study did not show signifi cant differences in the 
symptoms of ADHD between the intervention group and the placebo group.
The authors conclude that the administration of Hypericum perforatum does 
not have greater benefi cial effects than the placebo to treat the symptoms of 
ADHD in children and adolescents.
RCT1+
Pintov, et al. (2005)347 conducted a study on the effectiveness of Bach fl owersto 
treat a group of children with ADHD (n=40, 7 to 11 years old) compared with 
placebo. The intervention lasted for 3 weeks.
The results of the study did not show signifi cant differences in the symptoms of 
ADHD between the intervention group and the placebo group.
The authors’ conclusion is that their results do not support the hypothesis that 
Bach fl owers are associated with a greater response than the placebo.
RCT1+
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Auditory stimulation
This is based on the hypothetical benefi cial effect of different tones of music and sounds on 
children with ADHD. It is assumed that the Tomatis method, for example, produces an auditory 
re-education (Soutullo & Diez, 2007)79.
No quality studies have been found in the searches made to prepare this CPG on the effi cacy 
of auditory stimulation treatments for treating ADHD in children and adolescents.
Encephalogram biofeedback
(EEG- biofeedback, neurofeedback or neurotherapy)
In this therapy, the person uses the information from the biofeedback to voluntarily gain 
control over the process of the functions that are under the control of the autonomous system. 
It aims to treat ADHD by raising the ratio between high frequency waves with respect to low 
frequency waves in the EEG. The studies are loaded with artefacts, placebo effect and the effect 
of other treatments used (Soutullo & Diez, 2007)79.
Summary of the scientifi c evidence
The SIGN guideline (2005)1 did not fi nd any scientifi c evidence of an acceptable 




The AACAP guideline (2007)72 indicates that the effi cacy of EEG retrofeedback 
has not been established as primary treatment of ADHD or as an addition to the 
pharmacological treatment (Loo, 2003)352.
RCT1+
The AAP guideline (2001)180 indicates that these interventions are not supported 




Osteopathy is based on the belief that all the body systems work together, they are related 
and, therefore, the disorders in a system may affect the functioning of others.According to its 
principles, by manipulating the musculoskeletal system, affections of the vital organs or diseases 
can be cured.
No quality studies have been found in the searches made to prepare this CPG on the effi cacy 
of osteopathy treatments for treating ADHD in children and adolescents.
Psychomotricity
Psychomotricity is the technique or series of techniques that aim to have an infl uence on the 
intentional or signifi cant act, to stimulate it or modify it, using corporal activity and its symbolic 
expression as mediators. The objective, therefore, of psychomotricity is to increase the individual’s 
capacity to interact with the environment (Núñez & Fernández Vidal, 1994)353.
No quality studies have been found in the searches made to prepare this CPG on the effi cacy 
of psychomotricity treatments for treating ADHD in children and adolescents. 
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Recommendations
D 7.6.2.1.
The elimination of artifi cial colouring agents and additives from the 
diet is not recommended as general treatment applicable in children and 
adolescents with ADHD.
D 7.6.2.2. The supplementary diet of fatty acids is not recommended as general 
treatment applicable in children and adolescents with ADHD.
 7.6.2.3.
Treatment with optometry, auditory stimulation, osteopathy and 
psychomotricity are not recommended to treat ADHD in children and 
adolescents.
B 7.6.2.4.
Treatment with homeopathy, herbal medicine and encephalogram 
biofeedbackare not recommended to treat ADHD in children and 
adolescents.
 7.6.2.5.
Health professionals must place emphasis, as with any other child and 
adolescent, on the importance of a balanced diet and regular exercise for 
children and adolescents with ADHD.
 7.6.2.6.
Health professionals must ask the families about the use of complementary 
and alternative therapies to identify and inform about their possible risks 
or side effects to treat ADHD in children and adolescents.
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8. Prevention
Given the mainly genetically based etiology of ADHD, primary prevention, namely, actions 
aimed at the disorder not occurring, would not be feasible.
What we can do is act upon some non-genetic biological factors, such as the consumption of 
toxic products during pregnancy (tobacco and alcohol), recommending that these products should 
be avoided during pregnancy.
Another level of prevention would be the early detection of this disorder, paying special 
attention, above all, to risk populations such as children with a family background of ADHD, 
premature children, with low birthweight, intake of toxic substances during pregnancy and with 
serious craniocerebral traumas (Spencer, 200751; Mick, 2002354; Sonuga-Barke, 200577; Dopfner, 
200428).
The early detection of the disorder will help us start the right treatment as soon as possible, 
which is basic to prevent associated problems (bad school performance, diffi culties in social 
relations, behavioural disorders).In this sense, it is important to bear in mind that the majority of 
children with ADHD already show symptoms of hyperactivity and impulsivity in preschool age, 
they are usually more disobedient, they have more accidents, it is hard for them to pay attention, 
etc. (DuPaul, 200112; Sonuga-Barke, 200577; Connor, 2002197; Quintero, 2006355). Given that these 
symptoms are common in young age, the diagnosis of a possible ADHD in these children can 
be diffi cult and must be based on the intensity and persistence of the symptoms, behavioural 
problems and impacton the environment (family, school, community) (DuPaul, 200112; Sonuga-
Barke, 200577; Connor, 2002197). Therefore, the role of the primary healthcare paediatricians and 
educational professionals is very important to identify and refer these children.
Recommendations
 8.1.
It is advisable to pay special attention to the risk populations:
 • Family history of ADHD
 • Prematureinfants
 • Low birthweight
 • Toxic comsumption during pregnancy
 • Serious craniocerebral (CCT) trauma.
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9. Ethical and legal aspects
Questions to be answered:
9.1. Which ethical principles must be taken into account in relationships with minors or ado-
lescents with ADHD?
9.2. What precautions must be taken, from the ethical viewpoint, in the fi eld of ADHD diag-
nosis?
9.3. What are the correct ethical standards for the start of therapeutic intervention in ADHD?
9.4. How involved must the minor be in the decision-making in the context of the diagnosis 
and treatment of ADHD?
9.5. What are the minor’s rights in the fi eld of information and confi dentiality related to the 
diagnosis and treatment of ADHD?
9.1. Which ethical principles must be taken into account in 
relationships with minors or adolescents with ADHD?
Since the Convention on the Rights of the Child, promulgated by the UN in 1989, there has been 
a series of changes in how childhood is viewed, characterised by the recognition of the capacity to 
take part in the decision-making process on the health and disease of the actual child, which have 
endowed the healthcare of children and adolescents with peculiarities.
Children and adolescents are the age groups where the preventive model is more important, 
and the care is always modulated by the fi gure of a third party, the parents or guardians, who 
are the ones who are going to make or transmit the demand and are going to intervene in the 
diagnostic and therapeutic process together with the patient.
Our care work must be modulated based on basic principles that govern the bioethics: 
Nonmalefi cence, Justice, Benefi cence and Autonomy.These principles are considered as prima 
facie principles, in other words, morally compulsory if there is no confl ict between them, but that 
they must be hierarchised for those situations where, if they do enter into confl ict, not all of them 
can be preserved. According to this internal hierarchy, Nonmalefi cence and Justice would be the 
fi rst tier principles and they would mark the minimal ethics demandable, even defi ned by law.
Autonomy and Benefi cence are related to the vital projects of people, with their ethical maxims 
and their own value hierarchies.But, however, these principles must not be understood in an 
isolated fashion, but as being closely related to the principles of dignity, integrity and vulnerability.
Respect for the principle of autonomy inevitably requires the principles of responsibility. It is 
especially in asymmetric relationships, such as medical care, and especially in the psychiatric 
and psychological care of the child and adolescent, where the principle of autonomy must 
necessarily be interpreted within the framework of ethical responsibility, as otherwise, the health 
professional’s decision may be irresponsible and extremely harmful.
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Recommendations
 9.1.1.
In the specifi c context of this guide, the ethical principles of 
nonmalefi cence, benefi cence and justice are worth taking into account, 
in connection with aspects associated with the diagnosis and treatment 
of ADHD, distinguishing the area that refers to very young children, 
when it is the parents or guardians who must necessarily assume an 
essential and almost exclusive leading role, from the area of young 
adolescents or pre-adolescents, where patients must be involved much 
more, insofar as they are developing individuals, with certain rights that 
must be preserved.
9.2. What precautions must be taken, from the ethical 
viewpoint, in the fi eld of ADHD diagnosis?
Based on a correct application of the technical criteria contained in this guideline, making a clear 
diagnosis that adapts to the child or adolescent with possible ADHD is extremely important.
Awarding diagnoses is both a pragmatic and an ethical question.And in the case of children and 
adolescents, we can fi nd negative effects, which may range from implications that compromise 
their educational future and their learning, to effects such as stigmatisation, both at school 
and within the family, with negative repercussions on the child’s opportunities.The children’s 
perceptions with respect to stigmatising attitudes are not only normal, but also more negative than 
those that occur in adults.
Recommendations
 9.2.1.
In the diagnosis of ADHD, the professional must be cautious, always 
respecting the criterion of nonmalefi cence, in order to avoid pernicious 
effects for the child or adolescent in his or her school, social and family 
environment.
9.3. What are the correct ethical standards for the start of 
therapeutic intervention in ADHD?
Starting a therapeutic intervention in children and adolescents with ADHD must respond to the 
following three parameters for it to adapt to correct ethical standards:
 • Suitability: If it is likely to achieve the objective proposed.
 • Necessity: If it is necessary, in the sense that there is no other more moderate therapeutic 
measure to achieve this purpose with equal effi cacy.
 • Proportionality: If it is weighted and balanced, as more benefi ts or advantages are 
derived from it than harm over other assets or values in confl ict.
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In the extreme case of needing to admit the patient with ADHD, we must bear in mind the 
legal provisions applicable to the case (Spanish Civil Code, Art. 211)356: in psychic disorders 
of childrenand disabled, hospitalisation must be authorised by the judge and in a suitable mental 
health establishment for the age, following a report from the children’scare services.
Recommendations
 9.3.1.
The professional who assumes responsibility for the diagnosis and 
treatment of ADHD must act in agreement with criteria of suitability, 
necessityand proportionality, restricting those more restrictive 
interventions of the minor’s rights to what is strictly necessary.
9.4. How involved must the childbe in the decision-
making in the context of the diagnosis and treatment 
of ADHD?
Competency, in the minor, is a gradual process that covers psychological and cognitive development 
and must be evaluated in agreement with the importance and relevance of the decision that is 
going to be taken. The current legislation on the patients’ rights (Law 41/2002)357 acknowledges 
the legitimacy of mature childrento participate in their health processes, although it delegates 
the evaluation of their maturity on health professionals according to each specifi c situation and 
context, who must suitably weigh up the risks and benefi ts.However, faced with situations of lack 
of maturity or insuffi cient maturity, the law foresees the subrogation of the parents or guardians in 
the decision-making (criterion of parental authority) (Spanish Civil Code Art. 154-163)358, which 
must also be in benefi t of the child, a situation that is not free from diffi culties faced with possible 
discrepancies between the criteria of both parties.
Thus, Law 41/2002357 related to the rights of the childin the health area, establishes, on a 
general basis, and applicable, therefore, to the diagnosis and treatment of ADHD, that:
1. Between 12 and 16 years of age, the adolescent’s competency and the importance of the 
decision to be made must be evaluated, weighing up the risks and benefi ts well, in order 
to defi ne if they are able, on their own, to accept or reject the treatment and evaluate the 
involvement of the parents in the decision-making.In the case of minors with suffi cient 
maturity, their opinion must prevail in the event of a possible confl ict with their parents 
or guardians.
2. In the case of childrenunder the age of 12 or between 12 and 16 without suffi cient 
maturity, the decision about the diagnosis and treatment will correspond to the parents 
or guardians.
3. From 16 years up, the adolescentmust be considered as being of full legal age for all 
intents and purposes, with the exception of situations where their incompetence is clear, 
in which case we must resort to the subrogated decision (parents or guardians).
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Recommendations
 9.4.1.
When the parents’ consent must be given, if there is clear discrepancy 
between the two, consensus and mediation must be sought for the 
greater benefi t of the minor, after informing the two parties about the 
risks derived from taking or not taking actions for the diagnosis and 
treatment of ADHD.If it is not possible to conciliate positions, the 
professionals responsible for the diagnosis and treatment will second 
the decision of the parent that adapts to criteria of greater benefi t for 
the minor.Faced with a situation of doubt or special confl ict, it is 





In all the cases, even in a situation of subrogated decision of parents 
or guardians due to immaturity or incompetence of the child, the latter 
must be informed of the situation and possible alternatives, in the 
appropriate language and understandable by him or her, clarifying any 
doubts that might arise, in order for him or her to form a valid criterion 
and cooperate in this situation.
9.5. What are the child’s rights in the fi eld of information 
and confi dentiality related to the diagnosis and 
treatment of ADHD?
The right to intimacy and respect for their private spheres is, in general, acknowledged for 
mature children. This entails confi dentiality of their healthcare data, after weighing up the risks 
and benefi ts that this may entail, and with the exception of serious risk for them.However, this 
acknowledgement may, on occasions, enter into confl ict with the parents’ or guardians’ obligations 
and willingness to have access to this information.
As a basic criterion, it can be established that breaking the confi dentiality of the mature 
childby the professional with respect to third parties, such as parents and guardians, must be 
exceptional and be ethically and legally justifi ed, and it is not valid to apply a merely paternalist 
criterion or one of parental authority.The fi rst basic principle is respect for that confi dentiality, 







Childrenwith ADHD must always be listened to and they must 
always be informed as fully as possible in agreement with their level 
of comprehension, comparing with them the different options and 
doubts they may have, and sharing the information with the parents 
or guardians in agreement with the degree of maturity and the need to 





In the care of childrenwith ADHD, the professionals must respect 
professional secrecy and confi dentiality with respect to all the 
information referring to the context of the therapeutic relationship, 
except in the case of clear risk for the childor for third parties.





Between the ages of 12 and 16, confi dentiality of the information 
and health data about the ADHD of the mature adolescentand with 
suffi cient judgement must be respected insofar as possible, especially 
when explicitly demanded by him or her.In this process the risks and 
benefi ts of transferring or communicating that information to parents 
or guardians will be considered, as well as its possible transcendence in 
other areas of the adolescent, and it will be advised on the advisability 
of dialogue and communication with parents or guardians about his 
or her health, avoiding presenting the clinical documentation to third 
parties without his or her consent, with the exception of properly 





From 16 years up, the adolescent’s confi dentiality must be preserved, 
as if he or she were of full legal age, leaving to their personal 
criterion, the decision about communicating the information to 
parents or guardians, unless there is a situation of serious risk or clear 
incompetence.
International regulations
1. Convention on the Rights of the Child. Adopted and ratifi ed by the United Nations General 
Assembly resolution 44/25, of 20 November 1989.
2. European Charter on Children’s Rights, 1992.
3. Convention on Human Rights and Biomedicine. Oviedo, 4 April 1997.
National regulations
1. Spanish Constitution (1978).
2. General Health Law 14/1986 (BOE no. 101 and 102, 28 and 29 April 1986).
3. Spanish Civil Code.
4. Instrument of Ratifi cation of the Convention for the protection of human rights and dignity 
of the human being with respect to the applications of biology and medicine (Convention 
related to human rights and biomedicine), of the Council of Europe (BOE no. 251, 20 
October 1999).
5. Organic Law 1/1996, 15 January, on Legal Protection of the Minor (BOE no. 235-249).
6. Law 41/2002, 14 November, regulatorybasisforpatient autonomy, rights and 
obligationswith respect toclinical information and documentation (BOE no. 274, 15 
November 2002).
7. Code of Ethics and Deontology of the OMC(2003).
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10. Diagnostic and therapeutic strategies
Algorithm 1. Detection and diagnosis of ADHD in 
children and adolescents
Primary care
Send to Specialised Care
(Grade D) Assess the key points of ADHD 






Is it a crisis?
Is ADHD the primary diagnosis?
Is there any comorbidity?
(Grade D) Does it satisfy DSM-IV-TR or 
ICD-10 criteria for ADHD?
Got to treatment algorithm
Child aged 6 to 17 years: 
learning/behaviour problems 







Coordinate with indicated 
speciality
Beyond guideline 
Assessment should be 
made in greater depth.
Suspicion of ADHD in children 
and adolescents:
 • Cannot remain seated/hyper-
active
 • Lack of attention/does not 
listen/daydreams
 • Impulsive acts
 • Behaviour problems
 • Low school performance
Questions to detect ADHD in 
children and adolescents:
 • What is your child like at 
school?How does he or she 
behave?
 • Has he or she got any learning 
problems?
 • Has she or he got behaviour 
problems at home, at school 
or when playing withother 
children?
 • Has he or she got problems 
to complete homework or 
chores?
Differential diagnosis for other primary diag-
noses or comorbidities:
 • Medical conditions: Auditory/visual
 • Emotional/psychiatric problems
 • Family/psychosocial problems
 • Speech and language problems
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 • School tutoring
 • (Grade B) School adaptations
 • (Good clinical practice)
Training teachers
Group strategies focused on the 
family:
 • (Grade B) Training for par-
ents
Are they effi cient?
ADHD Diagnosis (6-18 years)
 • Grade D) Interview and clinical evaluation
 • (Grade C) Questionnaires and assessment scale 
Light MildADHD Moderate-serious ADHD
Yes No
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(comes from algorithm 2)
(Grade D)
Before starting the pharmacological treatment:
 • Conduct a physical examination including measure-
ment of blood pressure,  heart beat, weight and height.
 • Look for personal and family background of cardio-
vascular diseases, of history of syncope related to 
exercise or other cardiovascular symptoms
Atomoxetine:
(Good clinical practice) Adjust dose depending 
on response up to maximum dose of 1.8 mg/kg/
day.
Start:0.5 mg/kg/day for 7-14 days. 
Maintenance:1.2 mg/kg/day






Adapt dose in agreement with response to 
maximum tolerated dose.
Dose range:
 • Immediate release 0-5 -2 mg/kg/day 
Maximum dose 60 mg/day
 • Osmotically released methylpheni-
date:18-54 mg. Maximum dose 108 mg/
day or 2 mg/kg/day
 • Extended release with pellet technology: 
0-5 -2 mg/kg/day Maximum dose 60 mg/
day
(Good clinical practice) Control:BP, H.R., 
height, weight/3 months
(Good clinical practice)
– Divide up dose dosis
– Decrease dose dosis
– Immediate + extended 
mix – Change for another 
methylphenidate presentation
– Assess effi cacy/tolerability
(Good clinical practice)
– Divide up dose
– Reduce doe
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List of abbreviations of the algorithms
ICD-10 International Classifi cation of Diseases, tenth version
DSM –IV-TR
Diagnostic and Statistical Manual of Mental Disorders, 4th version, 
revised text





Annotations to Algorithm 3 of pharmacological treatment
1. If there is a family background of good response to a drug for ADHD, evaluate its use in the 
patient identifi ed.
2. If it is impossible for patients to swallow capsules or tablets, immediaterelease methylpheni-
date can be used. This presentation can be crushed, or the capsule of extended release pellet 
technology methylphenidate can be opened, scattering the pellets over a small portion of 
food.
3. Ifextended extended release methylphenidate is used with osmotic technology and an ad-
equate adjustment of the dose is not achieved, a dose of immediate release methylphenidate 
can be added to the treatment at breakfast and/or mid afternoon, to thus adjust the total dose 
of methylphenidate in agreement with the weight of the child or adolescent with ADHD and 
with the clinical response.
 If a 12-hour therapeutic action is required and the child or adolescent with ADHD is not 
able to swallow tablets, extended release methylphenidate can be administered with pellet 
technology in the morning (opening the capsule) and in the afternoon, after school, ad-
minister a dose of immediate release methylphenidate.This latter pattern can also be fol-
lowed if there is a rebound effect in the afternoon with extended release methylphenidate 
with pellet technology.
4. If there has been a poor response to the treatment after having carried out training programmes 
for parents and/or psychological treatment and treatment with methylphenidate and atomox-
etine in children and adolescents with ADHD, then it is advisable to re-assess the diagnosis, 
the comorbid disorders, the response to the treatment, the adverse effects, to the treatment, 
generation and use of psychological interventions by the children and their parents, the ef-
fects of the stigma to accept the treatment, concerns related to school and family, the motiva-
tion of the children and parents, and fi nally, the diet of the child or adolescent with ADHD.
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11. Dissemination and implementation
For this CPG to reach the health professionals of the SNS, it will be disseminated through the 
Catalogue of GuíaSalud (www.guiasalud.es).). As well as on the web pages of the AIAQSAIAQS 
(www.aiaqs.net) and of the Sant Joan de Deu Hospital (www.hsjdbcn.org).
Once the national dissemination plan has ended within the general framework of GuiaSalud, 
the guideline development group, together with the AIAQS, will perform those diffusion activi-
ties they consider appropriate.
The CPG has two versions for professionals, a full one and asummary, both with information 
for patients, families and educators (Appendix 3). The CPG is published in digital version (full 
and summary) and it can be accessed in principle through the web pages of GuiaSalud, of AIAQS 
and of the Sant Joan de Deu Hospital, The summarizedversion is also published in book format, 
containing the CD-ROM of all the versions, to form part of the SNS CPG Library.
The measurement of the compliance and of the implementation of the CPG recommenda-
tions by monitoring and/or audit can improve its use. The AGREE instrument manual includes 
the importance of developing indicators, where item 21 on the applicability dimension is the one 
that deals with this aspect.Consequently, a CPG must offer a list of clear and quantifi able quality 
indicators or criteria, which are derived from the key recommendations included in the guideline.
The most well-known classifi cation of indicators, used in this guideline is the Avedis Donabedian 
Foundation classifi cation, which groups them into:Structure, process and results. To know and 
evaluate compliance with the recommendations considered to be most important, the assessment 
of some process variables and most important clinical results is proposed.In the clinical evalu-
ation of ADHD, measuring the key areas related to quality is recommendable. Some indicators 
are initially proposed for this, based on their apparent validity, reliability and feasibility of use at 
the different healthcare levels (primary care and specialised care).Table 12 describes the eleven 
indicators proposed depending on the type of indicator, process or result.
It is important to bear in mind that, in practice, the available indicators are not perfect and 
are an approach to the real situation.Their objective is to provide useful information to make 
decision-making easier.They are quantitative measures that, if obtained on a regular basis, enable 
the analysis of the evolution in time (monitoring). Some indicators are common to those adopted 
in other guidelines, such as the SIGN guideline (2005)1 and the ICSI guideline (2007)179. The 
development group has also proposed others.
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Table 12. Indicators proposed
Process indicators
 • Evaluation percentage of the nuclear symptoms of ADHD
 • Percentage of use of the DMS-IV-TR and ICD-10 criteria to detect other conditions and co-
morbidities in patients recently diagnosed with ADHD.
 • Evaluation percentage of the family functioning of the patient with ADHD
 • Evaluation percentage of the psychosocial functioning of the patient with ADHD
 • Percentage of patients with ADHD who are assessed with interviews, scales and question-
naires proposed in the guideline.
 • Percentage of patients with ADHD who receive psychological treatment according to pro-
posed criteria
 • Percentage of patients with ADHD who receive psychopedagogical treatment according to 
proposed criteria
 • Percentage of patients with ADHD who receive pharmacological treatment according to pro-
posed criteria
 • Percentage of the number of different health professionals and specialities involved to treat 
ADHD and nature of the interventions carried out
Result indicators
 • Number of contacts with the primary or specialised care services.
 • Percentage of satisfaction of the patient with ADHD and family with the care received
It has not been the intention of the authors to design an exhaustive and detailed assessment 
that involves the use of all the indicators proposed. The aim is to provide stakeholders and clini-
cians with a tool that may be useful to specifi cally design the assessment of care of patients with 
ADHD.
The people responsible for assessing the impact of the CPG and of the care to patients with 
ADHD must choose the most suitable period of time that each indicator refers to.
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12. Future research recommendations
Dimension of the problem
 • Studies that defi ne the real problem dimension in Spain, both in population and clinical 
samples.
 • Epidemiological information on the prevalence of the disorder in children and adoles-
cents, by age and gender, as well as the types of treatment used.
 • Prevalence of ADHD in adolescents and adults with substance abuse, and other associ-
ated disorders.
 • Prevalence of ADHD in adolescents and adults with school dropout.
 • Groups with limited representation in the current bibliography of ADHD, such as girls, 
preschoolers, adolescents and adults.
Criteria and diagnosis assessment
 • Applicability of the diagnostic criteria of ADHD to the different age intervals and gen-
ders.As well as for children and adults outside the age range of this CPG.
 • In preschool children, the clear defi nition of the ADHD symptoms to be able to establish 
symptom onset age.
 • Validity of the ADHD subtypes.
 • Predictive value and clinical utility of the items to make a correct diagnosis.
 • Developmental course of the ADHD symptoms.
 • Infl uences that determine the impact of the symptoms on impairment and on the risk of 
future disorders, such as gender and level of development, age of detection and inter-
vention that will estimate the benefi ts and risks of early diagnosis and intervention. The 
circumstantial environmental aspects: Family environment, group of friends, social-
economic adversities.Additional research in this fi eld should examine the same relation-
ships through short-term designs that will include predictive elements.
 • Methods used to establish the diagnosis of ADHD. As well as useful diagnostic methods 
to identity relevant comorbid disorders.
 • On the adaptation and usefulness of the assessment instruments for ADHD validated in 
our medium.
 • On the adaptation of diagnostic tests in our medium that might be applied in primary 
care.
 • Development of validated clinical tools in our context to assess the degree of interfer-
ence on adaptative functioning in two or more environments.
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 • Development of standardised neuropsychological tests, with practical utility and effec-
tiveness for the diagnosis and for the psychological and psychopedagogical intervention.
 • Discordance between informers due to the use of not very reliable or valid measures, 
or if the parents and teachers have different ways of conceptualising the behaviours, or 
they refl ect the context diversity.
Neurobiological, genetic and executive functions studies
 • Genetics, neuropsychological and neuroimage studies to clarify and integrate the re-
lationships between the different theoretic models that seek to explain the origin of 
ADHD.
 • Involvement of the prefrontal cortex and its connections in the ADHD.
 • The relationship between ADHD and sleep problems.
 • Genetic etiology of ADHD and the subsequent opportunities to prevent the disorder.
 • Effect of executive functions on ADHD throughout the life cycle, bearing in mind vari-
ables such as comorbidity, sex, psychopharmacology.
Effi cacy of the treatments
 • Prescription process of an effective and comprehensive plan based on the traits of the 
child and adolescent with ADHD and the family, in terms of type, intensity and fre-
quency, in order to improve the treatment plans, to achieve optimal results (immediate 
and long-term) based on clearly defi ned clinical indicators.
 • Information about the social-demographic characteristics (age, gender) or clinical char-
acteristics (ADHD subtype) that best respond to the medication or type of behavioural 
psychological treatment.
 • About how ADHD and associated comorbid disorders interact, affecting the treatment 
and its results.
 • Long-term results of the treatment in children and adolescents with or without comorbid 
disorders via longitudinal designs that consider the changes in time of the nuclear symp-
toms of ADHD, the co-existing ones and the functional results, such as occupational 
success or long-term relationships.
 • Role of the pharmacological treatment and/or behavioural therapy in the evolution of 
the disorder.
 • Effectiveness of parent training.If the group training interventions for parents are more 
effective than the pharmacological treatment in school age of children and adolescents 
with ADHD in terms of symptoms, quality of life and cost-effectiveness.
 • Effectiveness of the environmental adaptations and out-of-school or recreational activi-
ties. Evaluate if there are benefi ts in making common sense environmental changes at 
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home, at school or in the recreational atmosphere to reduce the nuclear symptoms of 
ADHD.Which out-of-school activities help reduce the symptoms of ADHD.
 • Which are the optimal services and procedures considered for the success of ADHD 
treatment in real conditions, for example, in clinical practice and in the classroom.
 • How are the drugs prescribed and which factors affect the clinical practice.
 • To treat ADHD, which clinician is the most indicated to carry it out; the most effi cient 
follow-up calendar; the most valid, sensitive and cost-effective way of monitoring the 
treatment.
 • Assessment of the role of the education and primary care professionals in providing the 
treatment for ADHD.
 • Description of the value of the effi cacy of early intervention in childhood. Its results on 
the prevalence of ADHD, as well as the management of this type of patients.
 • Effect of training on the behavioural management of children and adolescents with 
ADHD for teachers.If the training for teachers in behavioural management for children 
and adolescents with ADHD in primary and secondary education improves the symp-
toms of ADHD and the academic performance, the stress of the teacher in the classroom, 
and the impact of ADHD on students when compared with the traditional education 
methods.
 • If the psychopedagogical interventions for primary and secondary differ in their effec-
tiveness for each subtype of ADHD in behaviour, academic performance and attitude.
 • Detection at school of children with problems related to ADHD and their referral for 
assessment.Studies on whether teachers having a knowledge of the ADHD symptoms 
leads to the detection, a better referral, diagnosis and implementation of adaptations, as 
well as to behavioural, academic and attitude improvement.
 • Effi cacy and generalisation of the psychopedagogical intervention.
 • About when to interrupt the treatment of ADHD. If there are benefi ts or disadvantages 
of the long-term use of methylphenidate compared with its interruption 18 months after 
starting the treatment at least.Effect of continuing the pharmacological treatment be-
yond the 18 months, to improve the quality of life, nuclear symptoms of ADHD, associ-
ated emotional symptoms, side effects of the continued pharmacological treatment and 
the neuropsychological function.
 • Well-designed rigorous studies on the effi cacy of complementary and alternative thera-
pies to ADHD.
 • Development and assessment of new treatments for ADHD that will have greater ef-
fi cacy in time of that have healing effects.
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Appendices
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Appendix 1: Evidence levels and recommendation degrees
Appendix 1: Evidence levels and recommendation degrees of SIGN
Level of evidence
1++
High quality meta-analysis, systematic reviews of clinical trials or high-quality clinical 
trials with a very low risk of bias.
1+
Well-conducted meta-analyses, systematic reviews of clinical trials or well-performed 
clinical trials with a low risk of bias.
1- Meta-analyses, systematic reviews of clinical trials, or clinical trials with high risk of bias.
2++
High-quality systematic reviews of case control or cohort studies. Well-conducted 
case control or cohort studies with a verylow risk of bias and a highprobability that the 
relationship is causal.
2+
Well-conducted case control or cohort studies with a low risk of bias and a moderate 
probability that the relationship is causal.
2-
Case control or chort studies with a high risk of bias and a signifi cant risk that the 
relationship is notcausal.




At least one meta-analysis, systematic review or clinical trial rated as 1++ and directly 
applicable to the target population of the guidelines; or a body of scientifi c evidence 
consisting of studies rated as 1+ and demonstrating overall consistency of results.
B
A body of evidence including studies rated as 2++, directly applicable to the target population 
of the guideline and demonstrating overall consistency of results; or extrapolated evidence 
from studies rated as 1++ or 1+.
C
A body of scientifi c evidence including studies rated as 2+, directly applicable to the 
target population of the guideline and demonstrating overall consistency of results; or 
extrapolated scientifi c evidence from studies rated as 2 ++
D Scientifi c evidence level 3 or 4; or extrapolated scientifi c evidence from studies rated as 2+.
The studies rated as 1 and 2 must not be used in the recommendations preparation process due to their 
high bias possibility.
Good clinical practice
1 Recommended practice based on the clinical experience and the consensus of the 
development group.
1At times, the development group realised that there were some important practical aspects that they wished to place 
emphasis on and for which there is probably no supporting evidence.In general these cases have to do with some 
aspects of the treatment considered as good clinical practice and that nobody would normally question.
These aspects are assessed as points of good clinical practice.These messages are not an alternative 
to the scientifi c evidence-based recommendations, but they must only be considered when there is no 
other way to highlight this aspect.
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Appendix 2. Diagnostic criteria for ADHD
Diagnostic criteria for ADHD according to DSM-IV-TR 
(APA, 2001)10:
A. Either (1) or (2)
1. Six (or more) of the following symptoms of inattention have persisted for at lest 6 months to a 
degree that is maladaptive and inconsistent with developmental level:
Inattention
a) Often fails to give close attention to details or makes careless mistakes in schoolwork, work 
or other activities.
b) Often has diffi culty sustaining attention in tasks or play activities
c) Often does not seem to listen when spoken to directly.
d) Often does not follow through on instructions and fails to fi nish school work, chores or duties 
in the workplace (not due to oppositional behaviour or failure to understand instructions).
e) Often has diffi culties organising tasks and activities.
f) Often avoids, dislikes or is reluctant to engage in tasks that require sustained mental effort 
(such as schoolwork or homework).
g) Often loses things necessary for tasks or activities (e.g. toys, school assignments, pencils, 
books or tools).
h) Is often easily distracted by extraneous stimuli.
i) Is often forgetful in daily life activities.
2. Six (or more) of the following symptoms of hyperactivity-impulsivity have persisted for at lest 
6 months to a degree that is maladaptive and inconsistent with developmental level:
Hyperactivity
a) Often fi dgets with hands or feet or squirms in seat.
b) Often leaves seat in classroom or in other situations in which remaining seated is expected.
c) Often runs about or climbs excessively in situations in which it is in appropriate to do so.
d) Often has diffi culty playing or engaging in leisure activities quietly.
e) Is often “on the go” or often acts as if “driven by a motor”.
f) Often talks excessively.
178  CLINICAL PRACTICE GUIDELINE ON ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) IN CHILDREN AND ADOLESCENTS
Impulsivity
a) Often blurts out answers before questions have been completed
b) Often has diffi culty awaiting turn.
c) Often interrupts or intrudes on others.
B. Some hyperactive-impulsive or inattentive symptoms that caused impairment were present 
before the age of 7.
C. Some impairmentfrom symptoms is present in two or more settings (e.g. at school and at 
home).
D. There must be clear evidence of clinically signifi cant impairment in social, academic or 
occupational functioning.
E. The symptoms do not occur exclusively during the course of a pervasive developmental 
disorder, schizophrenia or other psychotic disorder, and are not better accounted for by 
another mental disorder.
Diagnostic guidelines for hyperkinetic disorder according to ICD-10 (WHO, 1992)111:
Attention defi cit
1. Often fails to give close attention to details, or makes careless errors in school work, or in other 
activities.
2. Often fails to sustain attention in tasks or play activities.
3. Often appears not to listen to what is being said to him or her.
4. Persistent impossibility to follow through on school work assigned or other missions.
5. Reduction in capacity to organise tasks and activities.
6. Often avoids or strongly dislikes tasks, such as homework, that require sustained mental effort.
7. Often loses things necessary for tasks and activities, such as school material, books, etc.
8. Is often easily distracted by external stimuli.
9. Is often forgetful in the course of daily activities.
Hyperactivity
1. Often fi dgets with hands or feet or squirms in seat.
2. Leaves seat in classroom or in other situations in which remaining seated is expected.
3. Often runs about or climbs excessively in situations in which it is inappropriate.
4. Is often unduly noisy in playing or has diffi culty in engaging quietly in leisure activities.
5. Exhibits a persistent pattern of excessive motor activity that is not substantially modifi ed by 
social context or demands.
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Impulsivity
1. Often blurts out answers before questions have been completed.
2. Often fails to wait in lines or await turns in games or group situations.
3. Often interrupts or butts into others’ matters.
4. Often talks excessively without appropriate response to social constraints.
 • Onset of disorder is not later than the age of seven years.
 • The criteria should be met for more than one situation.
 • The hyperactivity, inattention and impulsivity symptoms cause clinically signifi cant distress or 
impairment in social, academic or occupational performance.
 • Does not meet the criteria for pervasivedevelopmental disorder, depressive episode or anxiety 
disorder.
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Appendix 3. Information for patients, family members and 
educators
Learning to know and manage ADHD in children and adolescents.
This guideline, aimed at patients, families and educators of children and adolescents with ADHD, 
is based on the Practical Clinical Guideline on Attention Defi cit Hyperactivity Disorder (ADHD) 
in Children and Adolescents.Its aim is to provide information so that patients and their environ-
ments can have a better knowledge of the disorder and be involved in its detection, diagnosis and 
treatment.
The document makes recommendations based on the results of existing research to date.
It contains a list of addresses and reference bibliography where more information about 
ADHD can be obtained.
1. What is ADHD? How is it expressed in children and adolescents?
Attention defi cit hyperactivity disorder (ADHD) is a neurobiological disorder that starts during 
childhood and affects between 3 and 7% of the children in school age.The main symptoms are 
hyperactivity, impulsivity and inattention.These symptoms occur with greater intensity and 
frequency than what is expected in children of their same age.
The nuclear symptoms of ADHD are the following: 
Hyperactivity
Expressed by excessive movement in situations in which it is inappropriate to do so and in dif-
ferent areas (home and school).They have diffi culty remaining quiet when situations require this, 
(they get up from the seat, touch everything, never keep still, seem driven by a motor).They talk 
too much and make too much noise during quiet activities.
Inattention
Characterised by diffi culty to sustain attention in tasks that require sustained mental effort.They 
often seem not to listen, fi nd it diffi cult to follow orders or instructions and they have diffi culties 
in organising tasks and activities, often tending to forget and lose things. They are usually easily 
distracted by irrelevant stimuli. The attention diffi culties usually appear more frequently during 
the school stage when the academic demand increases.
Impulsivity
Expressed by impatience, diffi culty to postpone answers or await their turn. They often interrupt 
and blurt out answers before the questions have been completed.In general, they are characterised 
by acting without thinking, not assessing the consequences of their behaviour.
Children and adolescents with ADHD have problems in controlling their behaviour and adapting 
to the rules, thus presenting family, school and/or social adaptation diffi culties.
Are there different types of ADHD?
The DSM-IV-TR (Diagnostic and Statistical Manual of Mental Disorders, fourth edition, revised 
text) of the American Psychiatric Association (2001) classifi es ADHD into three types:
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 • ADHD, combined type:The three main symptoms are present (inattention, hyperactivity and 
impulsivity).
 • ADHD, predominantly inattentive type:When the main symptom is inattention.
 • ADHD, predominantly hyperactive-impulsive type: The predominant behaviour is hyper-
activity and impulsivity.
Which disorders are present with ADHD?
Children with ADHD may often have other associated problems, such as behaviour disorders, 
anxiety or learning problems.
2. What causes ADHD? What factors intervene?
All the factors that intervene when ADHD appears are not known with accuracy, but it is clear that 
there is an interrelationship of multiple genetic and environmental factors.
Brain structures and circuits
There is scientifi c evidence that shows that the origin of ADHD is an alteration of the brain func-
tioning, located in the areas of the prefrontal cortex and its connections with the basal ganglia.
Different studies have found that that some of these brain areas are smaller in size in the paediatric 
population with ADHD.
Genetic component
There is scientifi c evidence about the genetic component of ADHD. Recent studies show the ge-
netic complexity of ADHD, as different chromosomes and genes have been involved.The genetic 
component is perhaps the major predisposing factor for ADHD.
Neurobiological factors
The presence of non-genetic neurobiological factors in the appearance of ADHD has been re-
ferred to in different studies: Prematurity, hypoxic-ischemic encephalopathy, low birth weight 
and consumption of tobacco, alcohol and other drugs during pregnancy. At later ages, serious 
craniocerebral traumas (CCT) in early childhood, as well as infections of the central nervous sys-
tem (CNS) have also been related to a greater risk of ADHD.These non-genetic neurobiological 
factors are generically called environmental factors.
Non-neurobiological factors
Psychosocial risk factors, which would affect the development of the emotional and cognitive 
control capacity, have also been described. Today, gene-environment interaction is accepted as 
possible, so the presence of certain genes would affect the individual sensitivity to certain envi-
ronmental factors.
Diabetic factors such as the type of food, the use of food additives, sugar and sweeteners have 
also given rise to controversy, but, for the moment, there are no conclusive studies that associate 
them with ADHD.
Are there neuropsychological dysfunctions in ADHD?
Functional neuroimage and neuropsychological studies have shown that boys and girls with 
ADHD present a cognitive alteration in the so-called executive functions: response inhibition, 
surveillance, working memory and planning.
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3. How does ADHD evolve with age?
In many children the hyperactivity symptoms tend to decrease during childhood. Inattention and 
especially impulsivity remain in adolescents and adults.
The time that children can sustain attention increases with age; however, in many children 
with the disorder, this tends to be below the expected level and the level required to carry out daily 
life demands. A high percentage of children with ADHD will continue to have symptoms dur-
ing adolescence and adult age, so they must continue with the treatment.
Although the inattention and hyperactivity symptoms may persist in many cases, it is impor-
tant to remember that many adolescents with ADHD will adapt well in adult age and be free from 
mental health problems. A good prognosis will be more likely when inattention prevails more 
than hyperactivity-impulsivity, no behavioural disorders are developed and the relationships with 
family and with other children are correct.
4. How is ADHD diagnosed and who diagnoses it?
How is ADHD diagnosed?
The diagnosis of ADHD is exclusively clinical, in other words, by information obtained from 
the children or adolescents, their parents and educators, and it must be sustained in the pres-
ence of the typical symptoms of the disorder, with clear repercussion at a family, academic and/
or social level, after having ruled out other disorders or problems that might justify the symptoms 
observed.
During the interview, information must be obtained about the child’s current problems, na-
ture of the symptoms (frequency, duration, situational variation of the symptoms), onset age and 
degree of repercussion on the different areas of the child’s life.The family background must also 
be assessed (given the genetic nature of the disorder), the family functioning and the personal 
background (pregnancy, child-birth and perinatal period, psychomotor development, pathological 
background and child’s mental health history).
A physical and a psychopathologicalexamination of the child must be carried out, collecting 
information from the school and about academic performance throughout the entire school his-
tory.
The neuropsychological and psychopedagogical examinations are not essential to diagnose 
ADHD in children and adolescents.However, the neuropsychological study is recommendable 
when the presence of a specifi c comorbid learning disorder is suspected, or it is important to 
evaluate the cognitive functioning profi le.Likewise, a psychopedagogical assessment will permit 
evaluating the style of learning and establish the objectives of the re-educational intervention.
Additional laboratory, neuroimage or neurophysiological tests are not necessary to di-
agnose ADHD in children and adolescents, unless the clinical history and the physical examina-
tion show the presence of a disorder that requires their execution.
What assessment instruments are used?
To assess ADHD, information must be obtained about ADHD symptoms from the child or adoles-
cent, from parents or carers and from the teachers.The information can be obtained by open-ended 
questions, specifi c questions, semi-structured interviews, questionnaires and scales.
The use of symptoms evaluation scales is always a complement to the clinical interview. 
Scales and questionnaires exist that are useful to evaluate the ADHD symptoms and their inten-
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sity, which are usually administered to parents or carers, and to the teachers.The use of broader 
and more general psychopathologicalscales is also frequent to detect if there are other associated 
disorders.
What is the differential diagnosis?
When examining and appraising a child with ADHD, it must be taken into account that not all 
lively and absent-minded children have ADHD.So a differential diagnosis with other diseases that 
may be confused with ADHD is necessary.
The symptoms of ADHD may appear in a wide variety of disorders:
 • mental retardation
 • learning disorders,
 • pervasive developmental disorders,
 • behavioural disorders,
 • anxiety disorder,
 • mood disorder,
 • substance abuse,
 • environmental factors,
 • medical disorders.
The majority of these disorders can be ruled out with a complete clinical history and physical 
examination.
Who diagnoses ADHD?
The diagnosis of ADHD in children and adolescents must be carried out by a health professional 
(paediatrician, psychiatrist, neuropaediatrician, clinical psychologist or neuropsychologist) with 
training and experience in the diagnosis of ADHD and its most frequent comorbidities.
5. What is the treatment for ADHD?
The treatment of ADHD in children and adolescents can be personalised, in agreement with each 
patient and his or her family.The aim is to improve the symptoms and reduce the appearance of 
other associated disorders, as for the moment there is no cure for ADHD.
In children and adolescents with ADHD with moderate or severe impairment on their daily 
lives, combined treatment is recommended. This includes behavioural psychological, pharma-
cological treatment and psychopedagogical intervention.
The combination of pharmacological and psychological treatments has the potential to exer-
cise immediate effects on the symptoms of ADHD via the use of medication, as well as long-term 
effects via the development of cognitive and behavioural skills and strategies, provided by the 
psychological treatment.
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5.1. Psychological treatment for ADHD in children and adolescents
The psychological interventions that have shown some scientifi c/positive evidence for ADHD 
treatment are based on the principles of cognitive behavioural therapy (CBT).
The types of interventions applied are described briefl y below.
Behavioural therapy
This is a psychological therapy based on a behavioural analysis. The factors that are maintaining 
the inadequate behaviour are identifi ed, the behaviours to be increased, decreased or eliminated 
are defi ned, observing and recording all of them. There are two types of techniques:
 • To increase positive behaviour: Positive reinforcement such as praise, positive attention, 
rewards and privileges
 • To reduce non-desired behaviours: Response cost, time out and extinction(not paying 
attention to the behaviour to be reduced or eliminated) are used.
Parent training
This is a behavioural treatment programme whose aim is to provide information about the dis-
order, teaching parents to modify the behaviour of their children, increasing the parents’ com-
petence, improving the parent-child relationship via better communication and attention to the 
child’s development.
Cognitive therapy
Training in self-instructions, self-control and problem-solving techniques.
Social Skills Training
Children and adolescents with ADHD often have relationship problems with the family, social 
skills defi cit and relationship problems with peers.Social skills training is usually done in small 
groups of similar ages, and CBT techniques are used.
5.2. Psychopedagogical treatment for ADHD in children and adolescents
Psychopedagogical intervention is a fundamental pillar in the combined treatment of ADHD, as 
it will range from interventions aimed at improving the academic performance of the child or 
adolescent (via psychopedagogical re-education) to those aimed at improving the school environ-
ment and, therefore, their adaptation to the school (via an intervention programme at school and 
teacher training).
Psychopedagogical re-education is personalised school tutoring that is provided after 
school hours and whose aim is to palliate the negative effects of ADHD in children or adolescents 
who suffer from it, in connection with their academic competence or learning.
Emphasis is placed on the negative repercussion of the attention defi cit, impulsivity and 
hyperactivity in the school learning process.
Psychopedagogical re-education must include actions aimed at:
 • Improving the academic performance in the different areas, instrumental areas and the 
more specifi c areas for each school year.
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 • Working on habits that foster appropriate behaviour for learning (such as managing the 
timetable and controlling the school agenda) as well as study techniques (prereading, 
careful reading, analysis and underlining, synthesis and diagrams or summaries).
 • Preparing and teaching strategies to prepare for exams.
 • Improving self-esteem with respect to the tasks and study, identifying positive skills and 
increasing motivation for achievement.
 • Teaching and promoting appropriate and facilitating behaviour for correct study and 
compliance with tasks.
 • Reducing or eliminating improper behaviour such as defi ant behaviour and bad organi-
sation habits.
 • Maintaining coordination actions with the specialist that is treating the child and with 
the school, to establish common goals and offer the teacher strategies to manage the 
child with ADHD in the classroom.
 • Intervening with parents to teach them to put into practice, monitor and foster the con-
tinued use of study organisation and management tasks at home.
Children with ADHD require a personalised intervention programme at school for each one 
of them, which will include both academic actions or instruction, and behavioural actions.These 
programmes must involve the majority of the teaching staff to facilitate their effi cacy, including:
 • Those actions that refer to the methodology (the way of giving instructions, of explain-
ing the academic contents, or the assignment of chores and tasks).
 • Those that refer to the work environment (the physical situation of the child or ado-
lescent in the classroom, structured and motivating environment or the elimination of 
distracting elements).
 • Those that refer to the improvement of the child’s or adolescent’s behaviour (constant 
supervision, personalised tutorials and the use of behavioural techniques).
Training the teachers enables them to receive psychoeducation about the disorder, modify 
ideas and opinions about children and adolescents with ADHD, to train in behavioural patterns 
and be empowered to detect ADHD alert signals, thus favouring early detection.
5.3. Pharmacological treatment for ADHD in children and adolescents
Why use drugs to treat ADHD in children and adolescents?
The benefi cial effect of drugs on hyperactive behaviour has been common knowledge for more 
than 70 years.The fi rst drugs to treat ADHD were marketed in Spain more than 25 years ago.
These drugs are among the most studied and safest of all those that are used in children and 
adolescents, and all of them are very effi cient to treat the symptoms of ADHD.Between 70 and 
80% of the patients respond favourably to the fi rst treatment used.
Therefore, due to its safety, high effi cacy and limited side effects, pharmacological treatment 
is recommended to treat these patients.
With the drugs, we reduce the ADHD symptoms, improving school performance and be-
haviour of the child as well as their relationships both at home and at school. At the same time, 
they foster the effect of psychological and psychopedagogical interventions.
186  CLINICAL PRACTICE GUIDELINE ON ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) IN CHILDREN AND ADOLESCENTS
What drugs are available in Spain?
At the present time, in our country we have two groups of medicines indicated to treat ADHD 
in children and adolescents: stimulants (methylphenidate) and non-stimulants (atomoxetine).
Methylphenidate is presented in three formats, depending on the way the drug is released:
 • Immediate release: the effect lasts for about 4 hours so 2-3 doses must be administered 
throughout the day to adequately treat the patient.
 • Extended release: this is a mixture of immediate release and extended release methyl-
phenidate in one single daily dose.The difference between the two is the amount of im-
mediate and extended action drug, and the release mechanisms used. All of this means 
that the length of the effect is different: about 12 hours for extended release methylphe-
nidate with osmotic technology and about 8 hours for extended release methylphenidate 
with pellet technology.
In other countries of our environment, stimulant drugs are presented in other different 
formats:for example, in patches, association of stimulant salts, etc., not available in Spain for the 
time being.
What drug to choose?
Pharmacological treatment must be prescribed and controlled by a physician with experience in 
ADHD and in the management of these drugs and their possible side effects.The treatment must 
be personalised, that is, adapted to the needs of each patient and each family. The choice of one 
drug or another will depend on:
 • The existence of associated problems, such as tics, epilepsy, anxiety, etc.
 • The adverse effects of the medication.
 • The existence of drug consumption in the adolescent.
 • Prior experiences of lack of effi cacy with a certain drug.
 • The preferences of the child/adolescent and his or her family
 • The administration ease.
Is it necessary to carry out tests before starting treatment with these drugs?
No additional test is required (blood analysis, electrocardiogram, etc.) unless advised by the his-
tory and/or examination of the patient.For example, in patients with a background of heart prob-
lems, a cardiological study will be necessary before starting treatment.
In the treatment control it is advisable to record the weight, height, pulse and blood pressure 
on a regular basis.
How is the pharmacological treatment started?
Once the drug has been chosen, it is started with low doses, which will then be increased every 
1 to 3 weeks depending on the patient’s response and the appearance of side effects. The physi-
cian will be responsible for assessing the effi cacy and tolerability of the drug by periodic visits, 
which will be much more frequent at the start of treatment and more spread out in time (every 3-6 
months) once the drug dose has been adequately adjusted.
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Although the treatment is personalised, the general patterns for each drug are:
 • Immediate release methylphenidate, in 2-3 doses a day.
 • Extended release methylphenidate, one dose in the morning.
 • Atomoxetine, one single dose in the morning is recommended. If there are tolerance 
problems, administer at night or split the dose between morning and night.
Sometimes, if the improvement is not suffi cient or there are other associated disorders, the 
dose will have to be increased to the maximum recommended or different types of drugs combined.
What are the most frequent side effects?
The side effects mainly occur when the treatment starts, they are not very frequent, or intense, 
they are temporary and are not very serious. In some very rare cases, the treatment has to be sus-
pended. It is important to able to ask the physician responsible for the treatment about any adverse 
effects before suspending the administration of the drug.
The most frequent side effects of stimulants (methylphenidate) are:loss of weight and ap-
petite, especially at start of treatment, diffi culty to go to sleep (conciliation insomnia); headaches 
and much more infrequently, tics and restlessness.
The most frequent side effects of non-stimulants (atomoxetine) are:loss of weight and 
appetite, above all at the start of the treatment; sleepiness, gastrointestinal symptoms, such as 
abdominal pain, nausea and vomits, dizziness and tiredness.Very infrequently, jaundice may ap-
pear (the skin turns a yellowish colour due to the increase of bilirubin), refl ecting hepatic damage 
meaning that the treatment must be ended.
How long does the pharmacological treatment last?
The duration of the treatment must be considered individually depending on the persistence of the 
symptoms and their repercussion on the life of the child or adolescent.
For patients who are taking stimulants, an accepted practice is for there to be short periods of 
time, from 1 to 2 weeks a year, without pharmacological treatment, in order to be able to evaluate 
the functioning of the child or adolescent both at home and at school.One of the best moments to 
carry out this appraisal without treatment is usually at the start of the school year.
Is it recommendable to have stimulant-free periods during the 
pharmacological treatment (“therapeutic holidays”)?
Although stimulant drugs improve the symptoms of ADHD and school performance their effects 
are not only seen at school, but also at home and in other environments.Therefore, when treat-
ing ADHD in children and adolescents, pharmacological treatment rest periods (“therapeutic 
holidays”) are not recommended as they may entail a worsening of the patient’s symptoms.In 
any case, whether there are “therapeutic holidays” or not will be decided on jointly between the 
physician, family and patient, in order to assess the need to maintain the treatment or not, and 
reduce the adverse effects.
Does the pharmacological treatment produce addiction?
There is no scientifi c evidence to show that treatment with stimulants produces addiction.
But it has been clearly demonstrated that patients with ADHD receiving pharmacological 
treatment, have signifi cantly less drug consumption problems in adolescence than patients with 
ADHD who do not receive pharmacological treatment.
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Is pharmacological treatment for ADHD related to growth retardation?
The studies available to date are not very conclusive. The latest data inform that the fi nal height 
of children treated with stimulants will be 1 to 3 cm. less than expected. The growth regtardation 
is greater during the fi rst year’s treatment but tends to even out later on.
Does the effi cacy of pharmacological treatment decrease with time?
The correct use of the drugs indicated to treat ADHD in children and adolescents administered 
in the way and dose prescribed, does not produce tolerance, continues to be effi cient and it is not 
necessary to increase the dose, save for reasons of growth (increase in height and weight).There 
is scientifi c evidence that the treatment has a long-term effect if continued.
5.4. Complementary and alternative treatment for ADHD in children and 
adolescents
Due to the exponential increase of complementary and alternative medicine or therapies over the 
last few years, health professionals are continuously receiving doubts and questions from patients 
and their families about their use.On the other hand, many patients do not disclose their use to 
their physicians, with the possible interference in the medical treatment or adverse effects. It is 
important to inform the physician responsible for the treatment if complementary or alter-
native treatments are used.
Some of the alternative therapies without a general applicable recommendation for the treat-
ment of ADHD in children and adolescents, include dietetic treatments, optometry, homeopathy, 
herbal medicine, auditory stimulation (Tomatis method) andencephalogram biofeedback(EEG-
biofeedback, neurofeedback or neurotherapy), psychomotricity and osteopathy.
6. How are disorders associated with ADHD in children and 
adolescents treated?
Psychological therapy carried out with parents (parent training) is the most effective treatment 
for behavioural disorders in children. In addition, psychological therapies with children, such as 
social skills training, may be benefi cial.
If necessary in children and adolescents with anxiety disorders and ADHD, the children’s 
and adolescents’s psychiatrist could also administer effi cient and safe medication.
Learning problems require an assessment and a long-term psychopedagogical treatment 
plan.
7. How can ADHD be prevented?
Given the mainly genetically based etiology of ADHD, primary prevention, namely, actions 
aimed at the disorder not occurring, would not be feasible.
What we can do is act upon some non-genetic biological factors, such as the consumption of toxic 
products during pregnancy (tobacco and alcohol), recommending that they should be avoided 
during pregnancy.
Another level of prevention would be the early detection of this disorder, paying special atten-
tion, above all, to risk populations such as children with a family background of ADHD, prema-
turechildren, with low birthweight, intake of toxic substances during pregnancy and with serious 
craniocerebral traumas.
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The early detection of the disorder will help us start the right treatment as soon as possible, which 
is basic to prevent associated problems (bad school performance, diffi culties in social relations, 
behavioural disorders).
8. What should be done if ADHD is suspected?
In the fi eld of public health, if ADHD is suspected, the fi rst step would be to consult the primary 
care paediatrician, who, depending on the availability of the area, may refer the child or adoles-
cent to specialist child and adolescent mental health service, a children’s psychology and psychia-
try or neuropaediatrics service.
9. What can parents do to help children or adolescents with ADHD?
 • Confi rm the ADHD diagnosis with health professionals (paediatricians, clinical psy-
chologists, child psychiatrists, neuropaediatricians, neuropsychologists), with experi-
ence and training in this disorder.
 • Search for a professional assessment and personalised treatment.
 • Start the treatment with professionals who have adequate training in ADHD.
 • Search for adequate information about the disorder, which is also practical, realistic and 
is based on scientifi c data. This could be obtained from the professionals who attend 
them or ADHD associations.
 • Get the closest family members involved in the education of ADHD.
 • Learn to manage own negative emotions (anger, blame, bitterness) and maintain a posi-
tive attitude.
 • Try to give the child immediate and frequent positive reinforcements
 • Use long-lasting and effi cient rewards.
 • Use rewards before punishments.
 • Improve the child’s or adolescent’s self-esteem, use positive messages.
 • Make thoughts and problem solution tangible.
 • Simplify the rules of the house or place where they are.
 • Help the child do things step by step.
 • Make sure their instructions are understood.
 • Teach the child or adolescent to be organised and foster their social skills.
 • Be understanding.
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10. What can be done from school to help children or adolescents with 
ADHD?
The interventions carried out at school must contemplate the following strategies:
 • Use behaviour modifi cation techniques: positive reinforcement, token economy sys-
tems, modelling, extinction, response cost, time-out technique, overcorrection, etc.
 • Teach the child or adolescent training techniques in self-control, problem-solving, social 
skills training or relaxation techniques.
 • Clearly defi ne, together with the child or adolescent, the short and long-term goals, both 
referring to curricular contents and to their behaviour at school.
 • Adapt the environment and control the level of distracting elements in the classroom, 
situating the child or adolescent in a place where they can easily be supervised and at a 
distance from any stimuli that might distract them.
 • Adapt the tasks and expectations to the child’s or adolescent’s traits,reducing or simpli-
fying the instructions given to them to carry out the tasks, using short, simple and clear 
instructions.
 • Adapt the assessment method, modifying the way of administering and assessing the 
tests and examinations.
 • Complement the oral instructions with visual instructions and reminders by the teacher.
 • Offer the child or adolescent aid system to control their tasks every day, and complete 
short and long-term work (control of agenda, reminders, etc.).
 • Achieve an adequate level of motivation in students, offering frequent feedback about 
their improvements in behaviour and effort.
11. Addresses and reference bibliography
11.1. Associations in Spain
To fi nd out the updated list of all the ADHD associations, refer to the Spanish Federation of 
Association of Aid to Attention Defi cit and Hyperactivity:
F.E.A.A.D.A.H.
President: Fulgencio Madrid Conesa.
Address: Colegio San Carlos. C/Del Romeral, 8 Tentegorra 30205 Cartagena
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Appendix 4. Glossary
AGREE: Instrument that assesses the quality of the clinical practice guidelines.
Bias: A systematic deviation or error in the results or inferences of a study.In studies on the 
effects of healthcare, biases may arise from systematic differences in the characteristics of the 
groups that are compared (selection bias), in the care given or the exposure to other factors, apart 
from the intervention of interest (execution bias), in the abandonment or exclusions of people 
initially included in the study (wear bias) or in the assessment of the outcome variables (detection 
bias).The biases do not necessarily represent an imputation of prejudice, as they could also be the 
researchers’ preferences for some specifi c results, which is different to the traditional use of this 
word to refer to a partisan point of view. Many varieties of biases have been described. See, too, 
methodological quality, validity.
Case and control study (synonyms: Case control study, case reference study):A study that 
starts by identifying the people who present the diseases or outcome of interest (cases) and an 
appropriate control group without the disease or outcome of interest (controls).The relationship 
between a factor (intervention, exposure or risk factor) and the outcome of interest is examined 
by comparing the frequency or level of this factor in the cases and in the controls. For example, to 
determine if thalidomide was the cause of birth defects, a group of children with these malforma-
tions (cases) was able to be compared with a group of children without those defects (controls). 
Then, both groups were compared with respect to the proportion of those exposed to thalidomide 
in each one of them by their mothers taking that medication.The case and control studies are ret-
rospective, as they are always developed looking backward in time.
Case series: A non-controlled observational study that includes an intervention and an out-
come for more than one person.
Case study (synonyms: anecdote, case history, information of an individual case): A 
non-controlled observational study that includes an intervention and an outcome in an individual 
person.
Clinical trial (synonyms: therapeutic trial, intervention study): A study or trial that tests 
a medicine or another intervention to evaluate its effi cacy and safety. This general term includes 
randomised controlled clinical trials and controlled clinical trials.
Clinician: Health professional.
Cohorts study (synonyms: follow-up, incidence, longitudinal study):An observational 
study where a defi ned group of people (the cohort) is followed in time and where the results or 
outcome are compared between the subgroups of the cohort that were or were not exposed (or 
exposed to different levels) to an intervention or another factor of interest.The cohorts can be 
formed at that moment and followed prospectively (a concurrent cohort study) or identifi ed based 
on historical records and followed in time forwards from that moment to now (a historical cohort 
study). As a random distribution is not used, a pairing or a statistical adjustment must be used to 
guarantee that the comparison groups are as similar as possible.
Confi dence Interval (CI): The interval in which the “true” value (e.g. the effect size of an 
intervention) is estimated may have a certain degree of certainty (e.g. 95% or 98%). Note: the 
confi dence intervals represent the probability of committing random errors, but not committing 
systematic errors (biases).
Control: In clinical trials that compare two or more interventions, a control is a person from 
the comparison group that receives a placebo, no intervention, traditional care or some other type 
of service.
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 In case and control studies, a control is a person in the comparison group without the disease 
or outcome of interest.
 In statistics, controlling means adjusting or bearing in mind the external infl uences or ob-
servations.
Controlled clinical trial: This refers to a study that compares one or more intervention 
groups with one or more comparison groups (control). Although not all the controlled studies 
have a random distribution, all the clinical trials are controlled.
Cranial MRI: This is a non-invasive method to create detailed images of the brain and the 
surrounding nervous tissues.
Unlike radiographies and computerised tomographies that use radiation, the magnetic reso-
nance uses radio waves and powerful magnets.
Cross-sectionalstudy or prevalence study: A study that examines the relationship between 
the diseases (or other health characteristics) and other variables of interest that might exist in a 
defi ned population at a specifi c moment in time:the temporary cause-effect sequence cannot nec-
essarily be established in a cross-sectionalstudy.
Double blind double masked: Neither the participants in the clinical trial nor the research-
ers (those who evaluate the outcome) are aware of which intervention has been administered to 
the participants.The purpose of “blinding” the participants (both receivers and suppliers of the 
care) is to prevent performance bias.The objective of “blinding” the researchers (the assessors of 
the outcome, who may be the suppliers of the care) is to prevent detection bias.
EEG-biofeedback: Also known as encephalogram biofeedback, neurofeedback or neuro-
therapy, it is a series of experimental procedures, whose studystarted in the 1940s in the United 
States, when an external instrument was used to provide the organisation with immediate infor-
mation about the state of biological conditions such as muscletone, skin temperature, brain waves, 
blood pressure, heart rate, etc., in order to be able to make use of this information.
Effect estimation (synonym: Therapeutic effect): In studies on the effects of the health-
care, the relationship observed between an intervention and an outcome, expressed, for example, 
as the number of patients that need to be treated (NNT), odds ratio, risk difference, relative risk, 
standardised mean difference or weighted mean difference.
Effectiveness: The extent to which a specifi c intervention, when used under normal cir-
cumstances, achieves what it is supposed to do.Clinical trials that evaluate the effectiveness are 
sometimes called management trials.
Effi cacy: The extent to which an intervention produces a benefi cial outcome under ideal 
circumstances.Clinical trials that evaluate effi cacy are sometimes called explanatory trials and 
their participation is restricted to people who cooperate fully.
Electroencephalogram (EEG): Neurophysiological examination that is based on recording 
the bioelectric brain activity in basal conditions of rest, wakefulness or sleep, and during different 
activations.
Encephalopathy: Generic term that groups together all the diseases that affect the encepha-
lon and especially the brain.
Evoked potentials: Neurophysiological examination that assesses the function of the acous-
tic, visual and somatosensory sensory system and its pathways by means of provoked responses 
to a known and normalised stimulus.
Executive functions: The concept of executive functions defi nes a series of cognitive skills 
that permit anticipating and establishing goals, forming plans and programmes, starting activities 
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and mental operations, self-regulating tasks and the skill to carry them out effi ciently.This concept 
defi nes the activity of a series of cognitive processes associated with the functioning of the front 
brain lobes of the human being.
Functional image studies: The neuroimage is a minimally invasive technique that permits 
exploring the human brain, intact, and at the same time, analyse the variations of the functional 
activity of areas of the brain in specifi c mental processes of the human being.Thus, not only are 
the brain areas involved in mental functions explored, but they can also be related to the brain ac-
tivity of the conscious individual.The end product of these techniques is a map of the brain based 
on direct or indirect data of the neuronal activity.
GuiaSalud CPG Library of the SNS: GuiaSalud, is a body pertaining to the SNS, which 
the 17 autonomous communities participate in to promote the development and use of CPGs 
and other tools, as well as scientifi c evidence-based products.Its mission is to foster the offer of 
resources, services and products based on scientifi c evidence, to support the decision-making of 
professionals and patients in the SNS, as well as to promote the creation of networks of collabora-
tors and the cooperation between entities related to the CPGs and evidence-based medicine.
Hepatotoxicity: Also called drug-induced toxic hepatic disease; it entails damage, either 
functional or anatomic, to the liver induced by the intake of chemical or organic compounds.
Institute for Clinical Systems Improvement (ICSI): This institute groups together differ-
ent health organisations and its main aim is to protect the quality of healthcare and help its mem-
bers identify and accelerate the implementation of the best clinical practices for their patients. It 
is a non-profi t and independent North American institution.
Likert type evaluation: The Likert type scale is a psychometric scale commonly used in 
questionnaires and the most widely used in surveys for research.When we respond to an element 
of a questionnaire developed with the Likert technique, we do so by specifying the level of agree-
ment or disagreement with a statement (element, item or reagent).
Medline/PubMed: Medline/Pubmed is a service of the National Library of Medici ne that 
includes quotes of biomedical articles taken from the Medline database and additional, free ac-
cess, scientifi c journals.
Meta-analysis (MA): The use of statistical techniques in a systematic review to integrate 
the outcome of the studies included.It is also used to refer to systematic reviews that use meta-
analyses.
Methodological quality (synonyms: validity, internal validity): The extent to which the 
design and development of a clinical trial have avoided probable systematic errors (bias).A vari-
ation in the quality of the studies may explain the variation of the results of the clinical trials 
included in a systematic review. The more rigorously designed clinical trials (with better quality) 
probably provide results that are closer to the “truth”. See, too: external validity, validity
National Guidelines Clearinghouse (NGC): This is a public resource on scientifi c evi-
dence-based CPGs created by the Agency for Healthcare Research and Quality (AHRQ) of the 
U.S. Department of Health and Human Services.
Neurophysiologic studies: Effective research and diagnostic means to determine the ana-
tomical and functional state of the neuromuscular apparatus.
New Zealand Guidelines Group (NZGG): This is a group that leads a movement of change 
towards quality socio-health and healthcare based on scientifi c evidence-based medicine and on 
effectiveness.
Nonmalefi cence: Intentionally abstain from carrying out actions that might cause harm.
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Observational study (synonym: non-experimental study): A study in which nature is al-
lowed to take its course. The changes or differences in a characteristic (e.g. if the population did 
or did not receive the intervention of interest) are studied in connection with the changes or differ-
ences in other(s) (e.g. if they passed away or not), without the intervention of the researcher.They 
represent a greater risk of selection bias than the experimental studies (randomised controlled 
clinical trials).
Odds Ratio (OR): The odds quotient of an episode in an experimental group (intervention 
group) and the odds of the episode in the control group.An odds ratio of 1 indicates that there is no 
difference between the comparison groups.For undesirable results, an OR of less than 1 indicates 
that the intervention is effective in reducing the risk of that outcome.When the rate of the episode 
is small, the odds ratios are very similar to the relative risks.
Open-ended clinical trial: There are three possible meanings for this term:
1. A clinical trial where the researcher and participant are aware of the intervention that will 
be used in each participant (that is, it is not double blind).Random assignment may or may not be 
used in these trials.
2. A clinical trial where the researcher decides which intervention is going to be adminis-
tered (non-random assignment).
It is also known at times as an open label (although some trials called “open labels” are 
randomised).
3. A clinical trial that uses a sequential open label.
Pellets: Granulated tablets.
PET: The positron emission tomography is a non-invasive diagnostic and imaging research 
technique that is able to measure the metabolic activity of the different tissues of the human body, 
especially of the central nervous system.
Phenotype classifi cation: Grouping of visible genetic characteristics.
Placebo: A substance or inactive procedure administered to a patient, usually to compare 
its effects with those of a real medication or with another intervention, but sometimes for the 
psychological benefi t of the patient who believes that he or she is receiving an active treatment.
Placebos are used in clinical trials to “blind” participants with respect to the assignment of the 
treatment they receive.The placebos should be indistinguishable from the active intervention in 
order to guarantee adequate blinding.
Plateau effect:The plateau effect means that the drug has reached its maximum power.
Prima facie: These principles are considered as prima facie principles, in other words, mor-
ally compulsory if there is no confl ict between them, but that they must be hierarchised for those 
situations where, because they enter into confl ict, not all of them can be preserved.
Prospective study: In the assessments of the effects of the health interventions, a study in 
which the people are divided into two groups that are or are not exposed to the intervention or 
interventions of interest before the outcome has occurred.Controlled clinical trials are always 
prospective studies and case and control studies never are.Concurrent cohort studies are prospec-
tive studies, whilst the historical cohort studies are not (see, also cohort study), despite the fact 
that in epidemiology a prospective study is sometimes used as a synonym for cohort studies. See 
retrospective study.
Randomised Control Trial (RCT) (synonym: Randomised clinical trial): An experiment 
where researchers randomly assign a randomised clinical trial to eligible people in several groups 
(e.g. treatment and control group) for them to receive or not receive one or more of the interven-
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tions that are to be compared.The results are evaluated by comparing the results in one group and 
in the other. NOTE: When MEDLINE is used, the word must be consulted spelt with an “s” and 
not a “z”, namely randomised and randomized.
Rebound effect: The rebound effect consists in a state of nervousness and irritability with 
the subsequent worsening of the behaviour, which is sometimes observed when the effect of the 
stimulant drug disappears.
Relative risk (RR) (synonym: risk quotient): The risk quotient in the intervention group 
divided by the risk in the control group.The risk (proportion, probability or rate) is the quotient of 
the number of people with a characteristic in a group divided by the total number of members in 
the group.A relative risk of one indicates that there is no difference between the groups that are 
compared. For undesirable results, a relative risk f less than 1 indicates that the intervention was 
effi cient to reduce the risk of that event.
Retrospective study: A study where the events or outcome have occurred to the participants 
before the study began.Case and control studies are always retrospective, whilst cohort studies 
sometimes are and controlled clinical trials never are. See prospective study.
Risk factor: A characteristic or lifestyle of a person, or of his or her environment, that in-
creases the probability of a disease occurring.
Scottish Intercollegiate Guidelines Network (SIGN): This is a Scottish institution whose 
aims are to improve the quality of healthcare for Scottish patients in order to reduce variability in 
normal clinical practice and in the results, based on the development and dissemination of nation-
al CPGs that contain recommendations for effective practice based on current scientifi c evidence.
Screening: Identifi cation of people within a population who have a specifi c pathology.
Sluggish Cognitive Tempo: The term sluggish cognitive tempo arose as a construct to 
group together characteristics that refl ected an irregular state of alert and orientation associated 
with some children with ADHD, such as: sluggish, forgetful, sleepy, apathetic, with tendency to 
daydream, lost in their own thoughts, unmotivated, in the clouds, confused, together with a low 
performance in some neuropsychological or visual search tests.
SPECT: This is a diagnostic technique that permits visualising the three-dimensional distri-
bution of a radioactive contrast located in a body or organ of interest, in this case the brain.With 
the brain SPECT we obtain images (“cuts or sections”), in any spatial plane, which, depending 
on the radiodrug used, represent the regional perfusion, concentration of neuroreceptors or the 
metabolic activity of a known or suspected injury.
Statistical signifi cance: An estimation of the probability that an effect, which is as broad 
as or broader than the effect observed in a study, has occurred because of chance.Normally it is 
expressed as the P value, for example a P value of 0.049 for a bias difference of 10% means that 
there is less than 1 out of 20 probabilities (0.05) that such a large or larger effect or association 
like this has occurred by chance, and therefore, it could be said that the results are statistically 
signifi cant at the level of P = 0.05. The cut-off point for statistical signifi cance usually lies at 0.05, 
but sometimes at 0.01 or 0.10. These cut-off points are arbitrary and have no specifi c importance.
Although this is often done, it is not appropriate to interpret the results of a study in a different 
way depending on the P value; if this P value is, for example 0.055 or 0.045 (which are very simi-
lar but not opposing values).
Suicidalideation: Persistent presence in the individual of thoughts or ideas aimed at com-
mitting suicide.
Systematic review (SR): A review of a clearly formulated questions, which uses systematic 
and explicit methods to identify, select and critically assess the relevant research, as well as to 
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obtain and analyse the data of the studies included in the review.Statistical methods (meta-anal-
yses) may or may not be used to analyse and sum up the results of the studies included. See also 
Cochrane review.
The Cochrane Library: A series of databases, published on fl oppy and CD-ROM and 
updated every three months, which contain the Cochrane Database of Systematic Reviews, the 
Cochrane Controlled Trials Register, the Database of Abstracts of Reviews of Effectiveness, the 
Cochrane Review Methodology Database and information about the Cochrane Collaboration.
The Health Technology Assessment (HTA) Database. The Database of Abstracts of 
Reviews of Effectiveness (DARE): These are two databases offered by the Centre for Reviews 
and Dissemination (CRD) of York University, whose mission is to provide science-based infor-
mation about the effects of the interventions used in health and social care.It contains information 
about HTA and about medical technology assessment.DARE contains systematic review abstracts 
that satisfy strict quality criteria and whose aim is to evaluate the effects of the interventions.
Therapeutic holidays: Scheduled rest periods from the pharmacological treatment.
Validity (synonym: internal validity): Validity is the extent to which a result (or a measure 
or a study) probably comes near the truth and is free from bias (systematic errors). Validity has 
some other meanings. It is normally accompanied by a word or a sentence that qualifi es it; for 
example, in the context of making a measurement, expressions such as construction validity, con-
tent validity and criterion validity are used.The expression, internal validity, is sometimes used to 
distinguish this type of validity (the degree to which the observed effects are true for the people of 
the study) from the external validity or generability (the degree to which the observed effects in 
a study really refl ect what is expected to be found in a broader target population than the people 
included in the study). See, too, methodological quality.
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Appendix 5. Abbreviations
AACAP American Academy of Child and Adolescence Psychiatry
AAP American Academy of Pediatrics
ADHD Attention defi cit hyperactivity disorder
ADHD-C: Attention defi cit hyperactivity disorder, Combined subtype
ADHD-HI Attention defi cit hyperactivity disorder, predominantly hyperactive- 
 impulsive subtype
ADHD-I Attention defi cit hyperactivity disorder, predominantly Innatentive  
 subtype
AGREE Appraisal of Guidelines Research and Evaluation
AHA American Heart Association
AHRQ Agency for Healthcare Research and Quality
AIAQS Agència d’Informació, Avaluació i Qualitat de Cataluña
AMA American Medical Association
APA American Psychiatric Association
BASC Behavior Assessment System for Children-Parent Rating Scales
BOE Offi cial State Gazette
BP Blood pressure:
BT Behavioural therapy
CAM Complementary and Alternative Medicine
CBCL Child Behavior Check-List
CBT Cognitive behaviour therapy
CCT Craniocerebral trauma
CD Conduct disorder
CDC Centers for Disease Control and Prevention
CDC Developmental coordination disorder
CHTE Study habits and techniques questionnaire
CI Confi dence Interval
CMA Infobase Canadian Medical Association
Cmax Maximum plasmatic concentration
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CNS Central Nervous System
CPG Clinical Practice Guideline
CPRS Conners Parents Rating Scale
CPT II Conners Performance Test II
Cranial MRI: Cranial magnetic resonance
CRD Centre for Reviews and Dissemination
CSAT Children Sustained Attention Task
CTRS Conners Teachers Rating Scale
D2 D2 (Attention test)
DICA-IV Diagnostic Interview for Children and Adolescents-IV
DIE Integrated study diagnosis
DISC Diagnostic Interview Schedule for Children
DSM –IV-TR Diagnostic and StatisticalManual for Mental Disorders, 4th edition,  
 revised text
DSM-II Diagnostic and StatisticalManual for Mental Disorders, 2nd edition
DSM-III Diagnostic and StatisticalManual for Mental Disorders, 3rd edition
EDAH Scales for evaluating the attention defi cit hyperactivity disorder
EEG Electroencephalogram
FDA US Food and Drug Administration
FSJD Sant Joan de Déu Foundation
H.R Heart rate
ICD-10 International Classifi cation of Diseases, 10th version
ICSI Institute for Clinical System Improvement
IHE Study habits inventory
IQ Intellectual quotient
K ABC Kaufman assessment battery for children
K BIT Kaufman brief intelligence test
kg kilograms
K-SADS Schedule for Affective Disorders and Schizophrenia in School-Age  
 Children
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MA Meta-analysis
MFF_20 Matching familiar fi gure test-20
mg milligrams
MHS Multi-Health Systems Inc.
MSCA McCarthy Scale of Children’s Abilities
MTA Study The Multimodal Treatment Study of Children with Attention Defi cit  
 Hyperactivity Disorder
NICE National Institute for Healthand Clinical Excellence
NIMH National Institute of Mental Health
NLM U.S. National Library ofMedicine
NNTB Number needed to benefi t
NNTH Number needed to harm
NZGG New Zealand Guidelines Group
ODD Oppositional defi antdisorder
OMC Collegiate Medical Organisation of Spain
PET Positron emission tomography
PICO Patient / Intervention / Comparison / Outcome or result.
PROESC Writing process assessment series
PROLEC-R Revised reading process assessment series
PROLEC-SE Reading process assessment in third cycle students of primary and  
 secondary education
RCF Complex Rey Figure
RCT Randomised controlled trial
RR Relative risk
SDQ Skills and Diffi culties Questionnaire
SIGN Scottish Intercollegiate Guidelines Network
SMD Standardised mean difference
SNRI Selective Noradrenaline Reuptake Inhibitors
SNS National Health System
SPECT Single Photon Emission Computed Tomography
CLINICAL PRACTICE GUIDELINES IN THE SPANISH NHS 201
SR Systematic review
SS Social skills
SSRI Selective Serotonin Reuptake Inhibitors
STROOP Stroop Colour and word test
SUD Substance use disorder
TAD Tricyclic antidepressants
TALE Reading and writing analysis test
TALEC Reading and writing analysis test in Catalan
TP Toulouse-Pieron
TRF Teacher Report Form
UAB Autonomous University of Barcelona
UN United Nations Organisation
WAIS-III Weschler Adult Intelligence Scale, version III
WHO World Health Organisation
WISC – IV Weschler Intelligence Scale for Children, version IV
YSR Youth Self Report Form
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Appendix 7. Description of the CPG included
Eight international CPGs on ADHD have been included. Furthermore, the CPG on ADHD has 
also drawn inspiration from fi ve guidelines on other disorders and international consensus.
The chart shows the quality according to the six dimensions of the AGREE instrument of the 
eight CPGs on ADHD assessed.









Quality according to AGREE:
SIGN 2005
Scottish Intercollegiate Guidelines Network 
August 2005
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Health Care Guideline: Diagnosis and Management of Attention Defi cit 









Quality according to AGREE:
ICSI 2007
Institute for Clinical Systems Improvement 
March 2007
Children and adolescents with ADHD
United States
Primary Care physicians, organisations that provide or 
make decisions
ICSI
Recommended with modifi cations
Clinical Practice Guideline: Diagnosis and Evaluation of the Child with Attention 
Defi cit/ Hyperactivity Disorder. Treatment of the School-Aged Child UIT 








Quality according to AGREE:
AAP 2005
American Academy of Pediatrics
June 2005





Practice Parameter for the Assessment and Treatment of Children and Adolescents 








Quality according to AGREE:
AACAP 2007
American Academy of Child and Adolescent Psychiatry
July 2007
Children and adolescents with ADHD
United States
Child psychiatrists, health professionals
AACAP
Recommended with modifi cations
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Quality according to AGREE:
CADDRA 2008
Canadian Attention Defi cit Hyperactivity Disorder 
Resource Alliance
2008





Evidence-based guidelines for management of attention defi cit hyperactivity 
disorder in adolescents in transition to adult services and in adults: 








Quality according to AGREE:
BAP 2006
British Association for Psychopharmacology 
2006














Quality according to AGREE:
UMHS 2005
University of Michigan Health System
August 2005
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Attention defi cit hyperactivity disorder. The NICE guideline on diagnosis and 








Quality according to AGREE:
NICE 2009
National Institute for Health and Clinical Excellence 
2009
Children, adolescents and adults with ADHD
Great Britain




Inspiration guidelines for specifi c sections of the CPG on 
ADHD
 • Taylor E, Dopfner M, Sergeant J, Asherson P, Banaschewski T, Buitelaar J, et al. 
European clinical guidelines for hyperkinetic disorder -fi rst upgrade 5. Eur Child 
Adolesc Psychiatry. 2004;13 Suppl 1:17-30189.
 • Fuentes-Biggi J, Ferrari-Arroyo MJ, Boada-Muñoz L, Touriño-Aguilera, Artigas Pallarés 
J, Belinchón-Carmona M, et al. Good practice guidelines for the treat ment of autistic 
spectrum disorders. Rev Neurol. 2006 Oct 1;43(7):425-38329.
 • Pliszka SR, Crismon ML, Hughes CW, Corners CK, Emslie GJ, Jensen PS, et al. The 
Texas Children’s Medication Algorithm Project: revision of the algorithm for pharmaco-
therapy of attention-defi cit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 
2006 Jun;45(6):642-57332.
 • McClellan J, Kowatch, RA, Findling, R. L. Practice Parameter for the Assessment 
and Treatment of Children and Adolescents With Bipolar Disorder. J Am Acad Child 
Adolesc Psychiatry. 2007;46(1):107-125335.
 • Kowatch RA, Fristad M, Birmaher B, Wagner KD, Findling RL, Hellander M. Treatment 
guidelines for children and adolescents with bipolar disorder. J Am Acad Child Adolesc 
Psychiatry. 2005 Mar;44(3):213-35337.
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